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vAbstract
Cancer patients, treated with systemic adjuvant chemotherapy, have described experiencing
persistent deteriorations in cognition. The nature of these effects is unclear, and although a wide
range of theories have been advanced, there is currently no treatment.
This thesis uses an animal model to investigate the effects of a commonly prescribed
chemotherapeutic agent, 5-fluorouracil (5-FU). The cognitive effects of 5-FU were examined
using two behavioural tests, the object location recognition test (OLR) and the conditioned
emotional response test (CER) both of which require input from the hippocampus, a brain region
associated with memory. Memory consolidation by the hippocampus requires the continual
production of new neurons (adult neurogenesis) from progenitor cells in the sub granular zone
(SGZ) of the dentate gyrus. As an anti mitotic agent, 5-FU could be reducing the cell
proliferation required for neurogenesis and this could be a cause of the cognitive deterioration.
This hypothesis was tested by quantifying the numbers of proliferating cells (Ki67
+
) in the SGZ in
sections together with the levels of doublecortin (DCX), a neurofilament expressed in developing
neurons and brain- derived neurotrophic factor (BDNF), a factor required for new neuron survival
and synaptic plasticity, by Western blotting.
After developing the methodology (chapter 2); adult male Lister Hooded rats were given five i.v
injections of 5-FU (25mg/kg) over a two week period and their behaviour and cellular aspects of
the hippocampus compared with saline injected controls (chapter 3). 5-FU treated animals
showed significant impairments in their performance of both the OLR and CER behavioural tests.
Animals were sacrificed after the behavioural tests were performed and analysis showed they had
significantly reduced numbers of dividing cells in the SGZ and non significant reductions in the
levels of BDNF and DCX within the hippocampus. These results demonstrate that 5-FU
treatment can produce cognitive impairments in this animal model which are similar in nature to
those described by patients after chemotherapy. These behavioural changes are correlated with a
reduction in the cell proliferation required for hippocampal neurogenesis providing support for the
hypothesis that chemotherapy drugs are affecting this aspect of hippocampal function.
In order to develop a treatment for the cognitive effects of chemotherapy the antidepressant
fluoxetine was co-administered with 5-FU (chapter 4). This approach was based on recent
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evidence that fluoxetine can increase neurogenesis and protect neurons after damage. As with the
experiment described above, performance in the CER test was impaired by five injections of 5-FU
(25 mg/kg) as compared with saline treated controls. Similarly, animals treated with six injections
of 5-FU (20mg/kg) were unable to discriminate between objects in novel and familiar locations in
the OLR task. However co-administration of fluoxetine in drinking water (10mg/kg/day) for
three weeks, starting a week before 5-FU treatment, prevented the impaired performance of this
task found in the 5-FU only group. 5-FU chemotherapy caused a significant reduction in the
number of proliferating cells in the SGZ compared to controls but this reduction was eliminated in
the group co administered with fluoxetine. Fluoxetine on its own had no effect on proliferating
cell number or behaviour. Moreover hippocampal BDNF or DCX protein levels in the co-treated
group (5-FU+fluoxetine) were significantly increased compared to the 5-FU only treated group.
These findings suggest that while 5-FU can negatively affect cell proliferation and hippocampal
dependent memory, these deficits can be reversed by co- administration of fluoxetine.
To understand the long term effects of chemotherapy, the cellular effects of 5-FU treatment were
quantified one day, 2 and 6 weeks after the end of two weeks of 5-FU (20mg/kg) treatment
(chapter 5). The results showed that 2 weeks of 5-FU treatment did not significantly reduce cell
proliferation in the SGZ when quantified one day after the end of treatment. However
proliferating cell numbers were significantly reduced compared to controls two and six weeks
after the end of treatment. This suggests that 5-FU has a delayed effect on cell proliferation with
its maximum effect two weeks after the end of treatment. Cell survival was quantified by BrdU
labelling cells immediately prior to 5-FU treatment, and quantifying the numbers of BrdU positive
cells at the different time points. BrdU
+
cell numbers were significantly reduced at the end of
treatment and continued to decline at 2 weeks but stabilised by 6 weeks. These results
demonstrate that 5-FU has prolonged effects on neurogenesis after the end of chemotherapy
treatment. The effects of 5-FU on cognition and neurogenesis are discussed and correlated with
chemotherapy treated patient reports of continued cognitive impairment for months or years after
completion of chemotherapy treatment.
1CHAPTER 1
General Introduction
1.1 Chemobrain
Epidemiological studies have shown that one in every three people will develop
cancer at some time in their life (Cancer Research UK, 2007). In most cancers,
the treatment is surgical removal of the tumour followed by adjuvant
chemotherapy or irradiation. The survival rate of cancer patients has increased
due to the significant improvements in the treatment of such patients. However
chemotherapy has a wide range of unwanted side effects which include mental
symptoms such as confusion, memory deficits and difficulties in concentration.
These finding are collectively named “Chemo-brain” or “chemo-fog” by
patients and physicians (Bender et al., 2005; Wefel et al., 2004). Not only
patients who have brain tumours suffer from these deteriorations in cognitive
functions, but also patients with tumours in other locations such as breast
cancer (Ahles and Saykin, 2002; Castellon et al., 2005). However, these
cognitive deficits often last even after the treatment period ends and sometimes
for up to 10 years after treatment (Ahles et al., 2002) in addition, these
deteriorations have been found to be chemotherapeutic dose-dependent (van
Dam, Schagen et al. 1998). In patients, major confounding variables such as
depression or anxiety caused by the disease or its treatment might be
responsible for the behavioural changes experienced and this has led some
authors to ascribe the cognitive decline to these conditions rather than the
chemotherapy itself (Jenkins, Shilling et al. 2006; Shilling, Jenkins et al. 2006).
2This line of reasoning has lead to the idea that the incidence of these cognitive
problems in women with breast cancer is unrelated to their treatment with
chemotherapy and due primarily to psychological stress and changes in their
quality of life (Shilling and Jenkins 2007). This highlights the requirement of
better controlled studies and the use of animal models.
1.2 Chemobrain in clinical studies
Since chemobrain was identified, several studies have tried to determine the
cognitive effects of the chemotherapy on patients. An early study (Peterson and
Popkin 1980) reported that the neuropsychological deficits resulting from
chemotherapy could be due to the specific chemotherapeutic agent used, the
cancer itself or other generalised toxic effects on CNS. Later authors (Wieneke
and Dienst 1995) have found that 75% of patients, 6 months after standard dose,
(5-FU, doxorubicin, cyclophosphamide) or CMF chemotherapy
(cyclophosphamide, methotrexate, 5-FU) suffered from deteriorations in
attention, concentration, verbal, visual and visuospatial memories. A similar
study (van Dam, Schagen et al. 1998) which compared the effect of a standard
dose (SD) versus a high dose (HD) of systemic chemotherapy, 2 years after the
end of treatment, showed that 17% of patients under the SD chemotherapy had
cognitive impairments compared to 32% after HD chemotherapy. These
impairments primarily affected their attention, visual memory and motor
function. Similarly (Schagen, van Dam et al. 1999) found that the possibility of
developing these cognitive impairments in breast cancer patients 1.9 years after a
SD of CMF chemotherapy was 12%.
This led further authors to continue their investigations in this field. In 2000,
(Brezden, Phillips et al. 2000) found that around 50% of breast cancer patients
3having SD chemotherapy developed similar cognitive complications found in
previous studies. A more recent study (Ahles and Saykin 2002) has also
supported the concept of chemobrain and has shown that these cognitive
impairments could last up to 10 years after the end of treatment. A recent study,
(Nelson CJ 2007) has tried to list the possible mechanisms that could contribute
to this disruption. Although this still remains largely unknown, the suggested
mechanisms by which these deteriorations occur could be due to vascular injury
and oxidative damage, inflammation, direct damage to neurons, or chemotherapy-
induced anaemia. It is important to note that patients from these studies did not
have any tumour metastases and did not have any other medical complications
that might alter their cognitive function (Schagen, Muller et al. 2002; Rugo and
Ahles 2003). Clinical, studies of patients after chemotherapy are continuing to
try to understand the mechanism by which chemotherapy produces these
cognitive deficits (Wefel, Lenzi et al. 2004; Wagner, Knaevelsrud et al. 2006;
Stewart, Collins et al. 2008). Some studies have been limited by small sample
sizes but four meta-analyses of the literature have concluded that working, visual
and verbal memory appear to be consistently affected in patients who have
completed a course of chemotherapy (Anderson-Hanley, Sherman et al. 2003;
Falleti, Sanfilippo et al. 2005; Jansen, Miaskowski et al. 2005; Stewart, Bielajew
et al. 2006). Imaging studies have also shown structural (brain region volume
and white matter pathology) and functional (blood flow) changes in the brains of
patients after chemotherapy with alterations in hippocampus, striatum and
cingulate gyrus (Yoshikawa, Matsuoka et al. 2005; Bradbury 2006; Inagaki,
Yoshikawa et al. 2007; Silverman, Dy et al. 2007). Similarly an EEG study has
4shown differences in patients after receiving chemotherapy (Kreukels,
Hamburger et al. 2008).
The duration after treatment during which deficits are manifested is of significant
importance to patients. Some studies have found that deficits can last for several
years (Schagen, Muller et al. 2002; Wefel, Lenzi et al. 2004) but a more recent
longitudinal study, where patient’s cognition was tested prior to chemotherapy, as
well as at two points after treatment concluded that deficits are present one month
after treatment but have disappeared by one year (Collins, Mackenzie et al.
2009). As indicated different studies have found differing effects and some
authors have criticised the types of psychometric tests used, the subjects chosen
as controls, the small sample sizes and confounding variables associated with
depression and disease progression (Shilling, Jenkins et al. 2006; Pedersen,
Rossen et al. 2009). Some of clinical studies on chemobrain are listed on (table
1.1).
5(Wieneke
and Dienst
1995)
6 months Published norms SD chemo:
FAC/CMF
SD Chemo: 75% Attention/concentration
Verbal memory
Visual memory
Visuospatial ability
Processing speed
Not applicable
(van Dam,
Schagen et
al. 1998)
2 years BC patients
received local
therapy
SD chemo: FEC
HD chemo:
FEC+CTC
Controls: 9%
SD: 17%
HD: 32%
Attention/ concentration
Processing speed
Visual memory
Motor function
HD and SD
groups:
Concentration
Memory
Thinking
(Schagen,
van Dam
et al.
1999)
1.9 years BC patients
received local
therapy
SD chemo: CMF Controls: 12%
SD: 28%
Attention/concentration
Mental flexibility
Processing speed
Memory
Motor function
Verbal functions
Concentration
Memory
Studies (2000-2010)
(Brezden,
Phillips et
al. 2000)
*During
Chemo
*2years
Healthy females *SD chemo:
CMF/CEF
*SD chemo:
CMF/CEF
Controls: 11%
*48%
*50%
*Memory& Language
*Language& Visual-
motor cognition
Not applicable
(Ahles and
Saykin
2002)
10 years Cancer patients
received local
therapy
SD chemo
(combinations)
Controls: 14%
SD chemo: 39%
Verbal memory
Psychomotor function
Working
memory
(Tchen,
Juffs et al.
2003)
1-2 years Healthy female
controls
*CMF
*CEF/AC(Adriam
ycin
&cyclophosphami
de)
symptoms not
related to cognitive
function
Attention& concentration
Language
Visuo-spatial
HSCS (test for
detecting subtle
Cognitive
impairment).
(Castellon,
Ganz et al.
2004)
Healthy female
controls
BC patients
received local
therapy
SD chemo
(combinations)
Not applicable Visual memory
Visuospatial memory
Verbal Learning
No correlation
between this
and
neuropsychologi
cal assessments.
(Hermelin
k,
Henschel
et al.
2008)
Before
chemo
5 month
after
chemo
1 year after
Test norms Epirupcin,
Paclitaxel/cyclo
CMF+Tamoxifen/
anastrozole or
letrozole
Intelligence
assessment and
induced
menopause
cognitive problems
Verbal memory
Verbal short-term
memory
Attention
Verbal working memory
Information processing
At the three
time points
there was fixed
positive effect
of menopause
on cognitive
parameters
(Schilder,
Eggens et
al. 2009)
2 years Healthy females AC
doxorubicin/cyclo
phosphamide
chemotherapy,
randomized to
tamoxifen or
exemestane
28%
AC/tamoxifen
29%AC/exmestane
6% controls
Verbal memory
Mental flexibility
Verbal Fluency
Information processing
speed
Motor speed
memory
concentration
thinking
language
(Collins,
Mackenzi
e et al.
2009)
1 year Hormonal
treated post-
monopausals
SD adjuvant
chemotherapy
Standererdized
Regression Based
(SRP) approach
Processing speed
Verbal memory
Not applicable
6Table 1.1 Summary of cross sectional clinical studies reporting incidence of
cognitive deficits, changes in neuropsychological domains and patient-reported
cognitive measures caused by high-dose (HD) or standard-dose (SD) chemotherapy.
BC: breast cancer; chemo: chemotherapy; FAC: 5-FU, doxorubicin,
cyclophosphamide; CMF: cyclophosphamide, methotrexate, 5-FU; FEC: 5-FU,
epirubicin, cyclophosphamide; CTC: cyclophosphamide, thiopeta,
carboplatin. Adapted from (Rugo and Ahles 2003)
71.3 Animal models of chemobrain:
Clinical studies have suffered from a variety of methodological problems making
the development of an animal model to test for the cognitive effects of
chemotherapy a useful strategy. These problems have included the inability to
randomly assign patients to experimental groups (Schagen, Muller et al. 2002).
Also, in clinical studies, it is very difficult to specify which chemotherapeutic
agent may have caused the cognitive effects because patients receive
combinations of different drugs in different doses and routes. Applying
behavioural tests to the animals is a useful, fast and efficient means to asses
cognitive changes which has been extensively used and validated (Tannock,
Ahles et al. 2004). Previous studies which have modelled the toxicity of
chemotherapy in animals have provided important information about the
neurobiological changes caused by chemotherapy (listed in table 1.2). Several of
these studies investigated the effect of a single chemotherapy agent (Lee, Longo
et al. 2006; Reiriz, Reolon et al. 2006; Seigers, Schagen et al. 2008) while others
observed the effects of a combination of two drugs (Winocur, Vardy et al. 2006;
Macleod, DeLeo et al. 2007).
Behavioural paradigms that model spatial learning as well as recognition and
spatial memory in animals were commonly used in these animal models to test
the effects of chemotherapy on cognition. For example, rats injected with
vincristine in the dorsal hippocampus showed impaired spatial learning in the
Morris water maze which was associated with a wide spread lesion in the dorsal
hippocampus (Eijkenboom and Van Der Staay 1999). In another study, rats
treated with methotrexate for 6 days showed impairments in their conditioned
avoidance and histologically, their hippocampi showed decreased noradrenaline,
8dopamine and serotonin (Madhyastha, Somayaji et al. 2002). Furthermore, mice
treated with a mixture of 5-fluorouracil and methotrexate, showed not only an
impairment in their performance in the Morris water maze but also a deficit in the
delayed non-matching to sample test (Winocur, Vardy et al. 2006). In contrast,
one study, (Lee, Longo et al. 2006), found that the performance of female mice
treated with cyclophosphamide or 5-fluorouracil improved in both the water and
T- mazes. However no explanation of this has been found. Using another
behavioural test, (Macleod, DeLeo et al. 2007) have shown that doxorubicin and
cyclophosphamide impaired a contextual conditioned emotional response (CER)
whereas the cued CER remained unaffected in ovarictomized female rats treated
with both drugs for three weeks. Recently, it has been shown that methotrexate
impaired spatial memory as tested in the Morris water maze and recognition
memory in the novel object discrimination tasks after rats were treated for 3
weeks (Seigers, Schagen et al. 2008). This study also gave strong evidence that
methotrexate caused a dose-dependent decrease in the number of proliferating
cells in the dentate gyrus within the hippocampus.
Using different behavioural tests, (Gandal, Ehrlichman et al. 2008) found that
treatment with methotrexate and 5-FU decreased the ability of mice gate
incoming auditory stimuli indicating that chemotherapy disrupted this function.
These deficits were also accompanied by increased reaction to fear conditioning
and reduced animals’ response to novel objects. The generalised neurotoxicity of
5-fluorouracil has previously been demonstrated by showing that the drug caused
a dose-dependent depression in neuronal activity as measured from hippocampal
field potentials and a wide spread cellular necrosis in the brain (Berg-Johnsen,
Heier et al. 1987; Okeda, Shibutani et al. 1990).
9Recently, we have confirmed that 5-FU treatment impaired spatial memory in a
rat model (Mustafa, Walker et al. 2008; ElBeltagy, Mustafa et al. 2010) and the
studies done in this thesis are a continuation of these results.
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Study Drug Dose Period of treatment Findings
(Phillips, Thaler et
al. 1989) MTX
250mg/kg
1000mg/kg
2500mg/kg
Intravenous cannula,
infusion over 24hrs
Lethargy, hyperirritabi
seizures, reduces gluc
metabolism reversed
high Leucovorin
(Shors, Townsend et
al. 2002)
MAM 7mg/kg Intraperitoneal daily
for 14 days
*Water maze-no affec
*CER/context altered
*trace fear conditioni
affected
* Plus maze - no affec
* Reduced BrdU labe
(Bruel-Jungerman,
Laroche et al. 2005)
MAM 5mg/kg Sub acute daily for 14
days
BrdU injection
*MAM reduces NOR
neurogenesis.
*Enrichment improve
NOR and neurogenes
*MAM+enrichement
reduces NOR and
neurogenesis
(Winocur, Vardy et
al. 2006)
*5FU
*MTX
*75mg/kg
*37.5mg/kg
3 weekly
intraperitoneal
injections
Variety of water maze
affects spatial but not
memory
(Lee, Longo et al.
2006)
*Cyclphosphamide
*5FU
*100mg/kg
*150mg/kg
Intraperitoneal 4
injections
over 18 wks
*8-10 weeks recovery
*Water maze and T
maze showed
Improvement.
* LTP
down acutely but up a
wks.
(Dietrich, Han et al.
2006)
*BCNU
*Cisplatin
*Cytarabine
*10mg/kg
*5mg/kg
*250mg/kg
Intraperitoneal 3
injections over 5 days
*TUNEL increased *B
decreased in DG and
(Macleod, DeLeo et
al. 2007)
*Doxorubicin
*Cyclophosphamide
*4mg/kg
*40mg/kg
Iv 3 injections weekly *CER/audio no effect
* CER context signifi
effect
(Seigers, Schagen et
al. 2008)
MTX 37.5-300mg/kg Iv single inject+
leucovorin
*Water maze and NO
significant effects
* Dose dependent
reduction Ki67.
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(Mustafa, Walker et
al. 2008)
5FU 25mg/kg Iv 5 injections over 12
days
*OLR sig effect,
*Reduced BDNF and
DCX
*No sig effect on Ki67
(Konat, Kraszpulski
et al. 2008)
*Doxorubicin
*Cyclphosphamide
*2.5mg/kg
*25mg/kg
4 intraperitoneal
injections weekly
Significant effect on
Passive avoidance,
restored by antioxidan
(Han, Yang et al.
2008)
5FU 40mg/kg 3 intraperitoneal
injections
every second
day
*Maximum decline B
at 14 days. *increased
TUNEL *Delayed
myelination.
(Foley, Raffa et al.
2008)
*MTX
*5FU
Single or combined
*3-32mg/kg
*3-75mg/kg
Single intraperitoneal
injection
*Reduced operant
conditioning to tone s
1 day after treatment.
*Enhanced effects wi
combined drugs.
(Bessa, Ferreira et
al. 2009)
MAM 7mg/kg Sub acute daily 2
weeks
Reduces BrdU, Ki67
60%. MAM did not b
behavioural effects of
fluoxetine in rats.
(Li, Cai et al. 2009) AZT 100mg/kg Intraperitoneally 28
days
Blocked the survival
of Fluoxetine on
hippocampal neuroge
(Ko, Jang et al. 2009) MAM 1-5mg/kg
3mg/kg for
behavioural tests
Sub acute daily 14
days
*Dose dependent dec
in BrdU
*No affect on CER
(ElBeltagy, Mustafa
et al. 2010)
5Fluorouracil 20mg/kg Intravenous Two
weeks (6 injections)
Impaired OLR ,CER
and decreased
positive cell counts
12
Table 1.2. Summary of the main studies that have examined the effect of
chemotherapy on cognitive function and neurotoxicity in the CNS of adult
rodents. Abbreviations: MTX, methotrexate; MAM, methylazoxymethanol
acetate; BCNU, carmustine; AZT, 3
0-azido-deoxythymidine; 5FU, 5-fluorouracil; OLR, object location
recognition; NOR, novel object recognition; CER, conditioned emotional
response; LTP, long-term potentiation.
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1.4 Chemotherapy:
Systemic chemotherapy normally involves administration of a cocktail of agents
making it difficult to ascribe cognitive effects to a specific drug. As previously
described, a number of patient studies have tested the suggestion that systemic
chemotherapy produces prolonged cognitive deficits independent of disease or
other factors associated with treatment (Anderson-Hanley, Sherman et al. 2003;
Castellon, Silverman et al. 2005; Falleti, Sanfilippo et al. 2005; Stewart, Bielajew
et al. 2006). Most of these studies have examined breast cancer survivors and the
majority of investigations have shown that patients who received systemic
chemotherapy experienced cognitive problems which were attributable to their
chemotherapy treatment (van Dam, Schagen et al. 1998; Schagen, van Dam et al.
1999; Brezden, Phillips et al. 2000; Ahles and Saykin 2002; Wefel, Lenzi et al.
2004; Ahles 2005; Ahles, Saykin et al. 2005; Bender, Sereika et al. 2005;
Castellon, Silverman et al. 2005). Most of these studies have observed the
association of “chemobrain” with the use of CMF chemotherapy which involves
the combined administration of cyclophosphimide, methotrexate and 5-FU. More
specifically, 5-FU has been particularly associated with patient descriptions of the
cognitive side effects of chemotherapy as it has been shown that systemic
treatment with this drug significantly increased the occurrence of cognitive
problems when compared with treatment by local chemotherapy or local
irradiation (Peterson and Popkin 1980; Hussain, Wozniak et al. 1993). Recent
animal investigations have also found that 5-FU can reduce hippocampal
neurogenesis and produce hippocampal specific behavioural deficits (van Dam,
Schagen et al. 1998; Ahles, Saykin et al. 2002; Schagen, Muller et al. 2002;
Winocur, Vardy et al. 2006; Mustafa, Walker et al. 2008). Studies in this thesis
14
are a continuation of these investigations into the effects of 5-FU on memory and
the possible correlation between the cognitive deteriorations and a reduction of
hippocampal neurogenesis.
1.5 5-FLUOROURACIL:
This section describes the commonly used chemotherapeutic drug which is used
in the treatment of many cancers, 5-fluorouracil (5-FU).
1.5.1 5-Fluorouacil mechanism of action:
5-flurouracil was developed in 1957 as a toxic analogue of the RNA
base uracil and it is widely used in cancer chemotherapy. It has previously been
shown that the route of entry of 5-FU to the brain is mainly from the blood into
the CSF (Bourke, West et al. 1973). It is a low molecular weight agent (see
diagram at the start of this section) which enters the brain by simple diffusion
through the blood brain barrier enabling it to have a direct effect on neural tissue.
Clinically, it has been found that 5-FU reaches a higher concentration in
cerebrospinal fluid than other chemotherapy agents (Grochow LB 1998). 5-FU
is applied clinically in the treatment of a wide range of cancers including breast,
ovarian, colorectal and gastro intestinal tract. It is occasionally used as a single
agent but is usually combined with other chemotherapeutics especially
cyclophosphamide and methotrexate in a triad known as CMF (Schagen, Muller
et al. 2002). 5-FU is an anti-metabolite chemotherapeutic drug; however its
major action is not on RNA, but in inhibiting the enzyme thymidilate synthetase
(TS). This enzyme produces the DNA base thymidine which is required for DNA
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synthesis during S-phase of the cell cycle (Chu, Callender et al. 2003). 5-FU is a
pro-drug that has to be metabolized to produce the active metabolite 5-fluoro-
2’deoxyuridine-5’monophosphate (FdUMP) that binds to and inhibits TS (Pinedo
and Peters 1988).
Other cytotoxic metabolites produced from 5-FU metabolism are 5-fluorouridine
5`triphosphate (FUTP) and 5-fluorouridine-5`triphosphate (FdUTP) which can
bind to DNA and also inhibit RNA synthesis. The 5-FU mechanisms of action are
reviewed as follows.
DNA synthesis target mechanism (Figure 1.1)
When (FdUMP) binds to TS, the latter is inhibited and as a result the conversion
of 2`- deoxyuridine-5`-monophosphate (dUMP) into 2`deoxythymidine-5`-
monophosphate (dTMP) is disrupted. This step is an essential step in de novo
synthesis of the DNA nucleotide base thymidine. The endogenous folate 5,10-
methylene tetrahydropholate (CH2THF) potentiates the action of TS by
facilitating the binding of dUMP to TS (Parker and Cheng 1990). Calcium folate
(leucovorin) is a formyltetrahydrofolic acid derivative. Clinically, leucovorin is
combined with 5-FU in cancer chemotherapy as it augments the binding of 5-FU
metabolites to TS and so increases the 5-FU- induced inhibition of thymidylate
synthase (Murakami, Fujii et al. 1998). Studies presented in this thesis used co-
administration of leucovorin to potentiate the cytotoxic and the neurotoxic effect
of 5-FU.
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DNA and RNA target mechanisms:
FUTP, the active metabolite of 5-FU incorporates into all types of RNA affecting
both transcription and translation processes required for protein synthesis. Also
the other main active metabolite (FdUTP) is incorporated into DNA further
disrupting its synthesis and function (Pinedo and Peters 1988; Parker and Cheng
1990; Chu, Callender et al. 2003).
The cytotoxic effect of 5-FU is not restricted to tumour cells but also targets
rapidly proliferating cells at any place where growth or regeneration is taking
place. The presence of proliferating cells in the brain is a relatively recent but now
well established neurological phenomenon (Kempermann 2006). This fact led us
to investigate the possibility that 5-FU could affect the number of the proliferating
cells in the brain and whether this contributes as a causative mechanism to the
drug’s neurotoxicity.
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Figure1.1 the DNA-mediated mechanism of action of 5-fluorouracil modified
and re-drawn from (Pinedo and Peters 1988). 2'-deoxyuridine-5'-
monophosphate (dUMP) is converted into 2'-deoxy-thymidine-5'-
monophosphate (dTMP) during the process of thymidine synthesis. This
step requires the enzyme thymidylate synthase and is enhanced by the
endogenous binding of the (CH2THF) to thymidylate synthase. In order to
be active, 5-fluorouracil has to be converted to 5-fluoro-2'deoxyuridin-
5’monophospate (FdUMP) which inhibits the enzyme thymidylate synthase,
a process is potentiated by co-treatment with leucovorin.
Thymidylate
Synthase
(CH2THF)IncreasesFdUMP Inhibits
Potentiates
dTMP
Leucovorin
(CHO-THF)
dUMP
5-Fluorouracil
Thymidine synthesis
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1.5.2 5-Fluorouracil neurotoxicity:
Reviews on the side-effects of 5-FU have described relatively rare neurotoxic
effects which have been ascribed to several mechanisms. For example, some
reviewers have shown that high doses of 5-FU are associated with the occurrence
of cerebellar syndrome and or organic brain syndrome which are reversible after
stopping treatment (Lynch, Droszcz et al. 1981; Moore, Fowler et al. 1990;
Atkins, Muss et al. 1991; Yeh and Cheng 1994). Cerebellar syndrome is
characterized by ataxia and other deficits in motor coordination whereas organic
brain syndrome mainly affects cognition and results in confusion and
disorientation (Lynch, Droszcz et al. 1981; Moore, Fowler et al. 1990; Yeh and
Cheng 1994). Another theory of 5-FU neurotoxicity relates to the ability of 5-FU
to affect the vascular system of the brain (Weh, Bittner et al. 1993). There are
also reports which believe that 5-FU neurotoxicity is due to a deficiency in the
enzyme dihydropyrimidine dehydrogenase (DPD) (Tuchman, Stoeckeler et al.
1985; Takimoto, Lu et al. 1996). This enzyme is responsible for the metabolic
degradation of 5-FU in the liver which accounts for 80% of the drug’s
metabolism (Pinedo and Peters 1988). In addition, there is also a possibility of
neuronal death due to thiamine deficiency which takes part in inhibition of the
Krebs cycle causing these neurotoxic effects (Lynch, Droszcz et al. 1981; Moore,
Fowler et al. 1990).
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1.6. Adult Neurogenesis:
The results of this thesis suggest that 5-FU chemotherapy reduces hippocampal
neurogenesis. The following section reviews hippocampal neurogenesis.
1.6.1 History and definition of adult neurogenesis:
The adult mammalian central nervous system had been classified as a non-
regenerative tissue for many decades. This was changed completely with the
discovery of adult neurogenesis 40 years ago. The term neurogenesis means
the continuous production of new, functioning, neurons which previously was
believed to occur only during embryogenesis. As with most of other tissues in
the body (e.g. the epidermis of the skin), neuronal tissue has tissue-specific
stem cells which have the ability to generate cells with tissue specific functional
capacity. This was demonstrated first by Altman and Das in 1965 when they
discovered that proliferating cells appeared to form new neurons in the adult
hippocampus of rats. Before this time it had been assumed that new neurons
could not be formed once embryogenesis had finished (Altman and Das 1965;
Kempermann 2006). Two areas of the brain have the ability to generate new
neurons, the sub-ventricular zone (SVZ) of the lateral walls of the lateral
ventricles and the sub granular zone (SGZ) of the dentate gyrus of the
hippocampus, reviewed in (Gould and Gross 2002; Kempermann 2006). It has
been proposed that the level of postnatal neurogenesis relates inversely to the
complexity of the brain as ranked from lower to higher vertebrates including
birds (Goldman SA 1983), rodent (Altman 1962) Primates (Gould, Reeves et al.
1999) and humans (Eriksson, Perfilieva et al. 1998).
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Concerning neurogenesis in the SVZ, it appears to depend on the presence of
astrocytic-like cells which have the stem cell-like properties of being able to self
renew and to produce neuroblasts which begin their journey towards the olfactory
bulb through the rostral migratory stream (Fig 1.2). During their migration, they
form chains of neuroblasts which are independent of the radial glia normally
required for guidance (Alvarez-Buylla, Garcia-Verdugo et al. 2001). After
reaching the olfactory bulb, they mature into two types of interneurons, granule
cells and periglomerular cells (Lois and Alvarez-Buylla 1994; Cameron and
McKay 2001). During their two week maturation, the granule cells extend
dendrites into the external plexiform layer of the olfactory bulb (Lledo, Alonso et
al. 2006). The periglomerular cells mature over nearly 4 weeks (van Praag,
Schinder et al. 2002).
The other neurogenic area in the brain is the SGZ of the dentate gyrus of the
hippocampus. Nearly 9000 dentate gyrus progenitor cells are generated daily in
the rat within the SGZ again from astrocytic like stem cells (Cameron and
McKay 2001). The following section will discuss hippocampal neurogenesis in
details.
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Figure 1.2. Summary of subventricular zone/rostral migratory stream
(SVZ/RMS) migration towards the olfactory bulb (OB) in the anterior
forebrain in the early postnatal animal modified from
www.scielo.br/.../bjmbr/v35n12/html/4739i01.htm. Migration in the RMS is
divided into three overlapping phases that correspond roughly to different
portions of the pathway (numbers in circles). 1) Initially cells migrate but
are still able to divide. That happens in regions of the SVZ close to the
lateral ventricles where mitosis is more frequent. 2) Cells leave the cell
cycle and continue migration towards the OB. 3) upon reaching the OB;
cells penetrate the OB parenchyma and differentiate into granular and
periglomerular cells. AOB, accessory olfactory bulb; Cx, cerebral cortex;
cc, corpus callosum; lv, lateral ventricle; MOB, main olfactory bulb; St,
striatum; Tu, olfactory tubercle.
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1.6.2 Anatomy of Human Hippocampal Neurogenesis
Figure 1.3. The Human Brain, Nolte (1993). Fig. 16-10A. p. 402.
The brain is divided into 2 hemispheres containing four lobes (parietal, frontal,
occipital and temporal). The temporal lobe is the region largely responsible for
the cognitive function of the brain such as memory and spatial learning. The
hippocampus is a horse-shoe structure which lies within the temporal lobe (Fig
1.3). It is particularly involved in the consolidation of new memories, emotions
and spatial orientation. The hippocampus is a component of the embryologicaly
oldest part of the brain. It contains the dentate gyrus which is a slender gyrus
running along the hippocampal formation. In humans, the hippocampal formation
develops in a dorsal direction and then migrates ventromedially toward the
temporal lobe.
The hippocampus starts forming at around 15-16 weeks of gestation and is fully
formed by 18-20 weeks of gestation (Duan 2002). The hippocampus is a part of
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the limbic system and consists of three main subfields: the dentate gyrus, area
CA1 and area CA3 (area CA2 is very small). The dentate gyrus is composed of 3
layers. The external molecular layer which receives afferent fibres and contains
the dendrites of the granule cells, the middle granule cell layer in the dentate
gyrus and the pyramidal layer towards the hippocampus which contains the
efferent fibres (Ming and Song 2005). The main afferents to the hippocampus
originate from the entorhinal cortex. Axons projecting from the entorhinal cortex
input into the dentate gyrus and area CA3 forming the perforant pathway. Axons
project from the dentate gyrus to area CA3 forming the mossy fibre input to the
pyramidal cells of area CA3 which in turn project to the pyramidal cells of area
CA1 to form the Schaffer-collateral pathway. Efferent fibres then connect CA1
area to the subiculum (Fig 1.4).
From the above, it is clear that the dentate gurus acts as a gateway to the
hippocampus (Kempermann 2002). Hippocampal neurogenesis is indicated by
the presence of proliferating cells in the subgranular zone (SGZ) which lies
adjacent to the granule cell layer (GCL) on the hilar side of dentate gyrus
(Abrous, Koehl et al. 2005). To become functioning neurons, the cells generated
in the SGZ, have to migrate from the SGZ into the GCL of the dentate gyrus
where they are integrated in the dentate gyrus network (Abrous, Koehl et al.
2005). The cells produced by proliferation in the SGZ can differentiate into
neurons, glia or endothelial cells but studies have shown that 70% of cells
become granule cell neurons (Duman, Nakagawa et al. 2001). Therefore, the
number of proliferating cells in the SGZ adjacent to the dentate gyrus has a strong
relationship to the number of new neurons produced in adult hippocampal
neurogenesis. The types of these cells are discussed in the following section.
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Figure 1.4. The hippocampal connections adapted from
http://www.bristol.ac.uk/synaptic/pathways/. The input to the hippocampus
comes from the entorhinal cortex (EC). Input signals travel from (EC) to the
dentate gyrus (DG) and area CA3 through the perforant path (PP). In turn,
the (PP) is divided into lateral and medial branches. Mossy fibres (MF) from
the dentate gyrus send signals to area CA3. Fibres from CA3 are connected
to area CA1 through the Schaffer collateral pathway (SC) and in addition,
connect to the area CA1 cells in the contra lateral hippocampus through the
associational commissural pathway (AC). Area CA1 sends its output to the
subiculum (Sb) which in turn gives output signals to the EC, completing the
circuit.
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1.6.3 Types of Neurogenic Cells (Fig 1.5)
Developing cells found in the adult SGZ are divided into four cell types. These
cells differ in their morphology, proliferative activity, migratory behaviour, and
expression of key marker antigens (Fig 1.5 and Fig 1.6). Type 1 cells or the
radial glia-like precursor cells, are morphologically similar to radial glia and have
astrocytic and stem cell properties (Seri, Garcia-Verdugo et al. 2001). In the
developing hippocampus, radial glia-like cells are necessary for the normal
formation of the dentate gyrus (Kempermann 2006). These cells express glial
fibrillary acetic acid (GFAP), nestin, Sox2 and brain lipid binding protein
(BLBP) which can be identified immunohistochemically (Seri, Garcia-Verdugo
et al. 2001; Kempermann 2006). The second and the third types of neurogenic
precursor cell are type 2 and type 3 cells which are also called transient
amplifying progenitors. Immunohistochemically, they are negative for
expression of GFAP but are highly proliferative cells. Some of the type 2 cells
express the immature neuronal marker DCX while some do not (Kronenberg,
Reuter et al. 2003). Type 3 cells are DCX-positive, but nestin-negative and
occasionally express polysialylated neural cell adhesion molecule (PSA-NCAM).
This type of cell is involved in migration into the granule cell layer
(Kempermann 2006). The final cell type is the maturing granule cell neurone
which extends dendrites into the molecular layer and its axon to make contact
with area CA3. It is clear that there are several markers which can be used to
detect different stages of neurogenesis and the next section will describe the
methods used in the detection of neurogenesis, particularly those used in this
thesis.
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Fig 1.5. Cell types in the neurogenesis process that are distinguished by
different markers adapted from (Kempermann, Jessberger et al. 2004). Six
stages of neuronal development in the adult hippocampus are identified
according to the cell morphology, proliferative ability, and expression of
markers such as nestin, glial fibrillary acidic protein (GFAP), doublecortin
(DCX), calretinin, calbindin and NeuN. Development originates from the
putative stem cell (T1 cell; stage 1) that has radial glia and astrocytic
properties and is identical to the astrocyte-like B-cell, Neuronal development
then progresses over three stages of putative transiently amplifying
progenitor cells (T2a, T2b and T3 cells; stages 2–4), which are determined to
the neuronal lineage. This transient early postmitotic period is characterized
by calretinin expression (stage 5).
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Figure 1.6. A diagram showing the three main cell types (left) undergoing
neurogenesis and their anatomical locations (right) in the sub-granular zone
(SGZ) of the adult rodent dentate gyrus, modified from (Doetsch 2003). B
cells are the astrocytic cells (GFAP+) that are supportive to the stem cells.
Asymmetric division of B cells gives rise to the transient amplifying
progenitor cells or the D cells which express markers for immature neurons
(DCX+ and PSA-NCAM) and will not express (GFAP+) after adopting a
neuronal phenotype. Both B and D cells are positive for (Ki67+), the
proliferative marker. G or the granule neuronal cells arise from D cells. B
cells are usually located next to the endothelium of the blood vessels (BV). D
cells arise from B cells and migrate into the granular cell layer giving rise to
G cells. Abbreviations: PSA-NCAM, polysialyl neural cell adhesion; DCX,
doublecortin; GFAP, glial fibrillary acidic protein.
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GFAP+
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1.6.4 Methods of Detecting Neurogenesis
1.6.4.1. Tritiated Thymidine and Bromodeoxyuridine
In most publications, demonstration of adult neurogenesis is based on the “birth-
marking” of cells with bromodeoxyuridine (BrdU), a thymidine analogue and an
exogenous marker which permanently labels cells which are in S-phase of the cell
cycle at the same time of injection of BrdU and not when the tissue specimen was
obtained. Labelling cells in this way is an effective way of visualizing and
tracking cells and can be used to determine their survival rates, migration and
phenotypic fate (Cameron and McKay 2001; Kee, Sivalingam et al. 2002). The
first widely used substance that allowed permanent labelling of dividing cells was
tritiated thymidine which was first used in 1956 (Friedkin and Wood 1956). All
studies of adult neurogenesis from 1962 to 1993 were based on thymidine
autography. The main disadvantage of this marker is that it is not easily
combined with other cell type-specific markers that allow the phenotype of the
labelled cells to be determined (Kempermann 2006). In 1993, Cameron and
Gould used thymidine autoradiography together with immunohistochemistry
against neuron-specific enolase (NSE) (Cameron, Woolley et al. 1993). This was
followed by Frank Corotto who first applied the BrdU method of birth marking
cells to adult neurogenesis (Corotto, Henegar et al. 1993). But the first big study
that made full use of the BrdU method was that of George Kuhn (Kuhn,
Dickinson-Anson et al. 1996) who demonstrated that the fluorescent visualization
of BrdU can be combined with two or more other markers by using confocal
microscopy. Protocols using the BrdU labelling method to study neurogenesis
involve the injection of the thymidine analogue either shortly before termination
of the study (2 to 6 hours) to observe cells proliferating at the time of death or (2
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to 3 weeks) before termination to observe survival and final phenotype (Eisch
2002).
As mentioned previously, BrdU tracking methods have revealed that one month
after labelling, 70% of precursor cells adopt a neuronal phenotype while of the
remaining 30%; most become glial and a small number develop endothelial
phenotypes, respectively (Palmer, Willhoite et al. 2000). However, one concern
with the BrdU method is that BrdU may not only label dividing cells but can also
pick up cell death, by labelling DNA fragmentation or DNA repair (Cooper-Kuhn
and Kuhn 2002; Rakic 2002). Moreover, in animal studies of neurogenesis in
which learning is being measured, BrdU administered by intraperitoneal
injections could stress these animals adding a confounding variable to these
studies (Kee, Sivalingam et al. 2002). In addition, BrdU can cause toxicity and
modify the blood-brain barrier (Gould and Gross 2002). However, for most
studies of neurogenesis that involve marking and tracking dividing cells, BrdU
remains the most frequently used method (Kee, Sivalingam et al. 2002) and
because of this, the BrdU labelling protocol in has been used in this thesis
(Chapter 5) to detect possible 5-FU chemotherapy-induced changes in the
survival of newly dividing cells in the rat dentate gyrus.
1.6.4.2. Labelling of Cell cycle-related antigens
Assessment of cell proliferation in tissues can now make use of the expression of
cell cycle-related antigens detected immunohistochemically. In conditions where
only proliferation at the time of death needs to be assessed, these cell cycle
markers can be used instead of BrdU. These markers can be combined with
detection of BrdU injected some time earlier and additionally combined with
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detection of proteins such as nestin (neural stem cell marker), GFAP (astrocytes
marker), doublecortin (DCX, expressed in differentiating/migrating and immature
neurons (Abrous, Koehl et al. 2005).
These markers have been used widely to study different stages of neurogenesis
including proliferation and differentiation. Ki67 is the name of the original
antibody clone that identifies a cell-cycle associated protein (mki67) encoded on
mouse chromosome 7 (Kempermann 2006). It appears to be essential for cell
cycle progression (Starborg, Gell et al. 1996; Endl and Gerdes 2000). Expression
of the Ki67 antigen identifies cells in late G1, S, G2, and M phase of the cell
cycle (Scholzen and Gerdes 2000). MKi67 is the broadest known cell cycle-
associated antigen. When BrdU is injected some hours before death and the
tissue stained for both BrdU and Ki67 most authors report a higher number of
Ki67 positive cells as this marker is present at all stages of the cell cycle while
BrdU only labels cells in S phase (Kee, Sivalingam et al. 2002).
In our lab, we have found that the number of proliferating cells adjacent to the
dentate gyrus of the hippocampus could be affected by the chemotherapy 5-FU
by using Ki67 as a marker for those cells (Mustafa, Walker et al. 2008).
Following this work, the studies in this thesis have also used detection of the
Ki67 protein to determine changes in precursor proliferation.
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1.6.5 Regulation of Hippocampal Neurogenesis
In the normal rodent dentate gyrus, the cell cycle takes approximately 25 hours
and proliferating neural precursor cells yield 9000 new neurons per day
(Cameron and McKay 2001). This is not a constant number and can increase or
decrease according to intrinsic and extrinsic factors. First of all, there is a natural
variation in the degree of adult hippocampal neurogenesis across different rodent
strains (Kempermann, Kuhn et al. 1997; Kempermann and Gage 2002). For
example, in rats, a comparison between two strains showed a significant
difference in adult hippocampal neurogenesis (Perfilieva, Risedal et al. 2001).
Many other parameters such as total granule cell number and hippocampal weight
show a similar variability (Wimer and Wimer 1989; Peirce, Chesler et al. 2003).
It has been shown that where a large difference (25 fold) in the rate of
neurogenesis exists between two strains of mice, this is mainly due to the
influence of their genetic background (Kempermann and Gage 2002). It is very
important also to note that the regulation of the balance between cell production
and cell death also plays a major role in the net regulation of neurogenesis,
reviewed extensively in (Kempermann 2006). The following sections review the
endogenous and external factors which regulate proliferation and
differentiation/survival in hippocampal neurogenesis.
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1.6.5.1. Intrinsic Factors
Hippocampal neurogenesis is subject to changes by extrinsic and intrinsic factors
(Lledo, Alonso et al. 2006). The intrinsic modulators of hippocampal
neurogenesis affect both the proliferation and or differentiation of cells via
changes in internal conditions such as hormones, growth factors or
neurotransmitters (Lledo, Alonso et al. 2006). These factors are summarized in
the following table.
Table 1.3 Studies identifying hormone, neurotransmitter, and growth factor regulation
of proliferation and differentiation during neurogenesis in the dentate gyrus of the
adult rodent brain, modified from (Abrous, Koehl et al. 2005). Abbreviations; EGF,
epidermal growth factor; HB-EGF, heparin-binding epidermal growth factor; IGF-1,
insulin like growth factor 1; CNTF, ciliary neurotrophic factor.
Intrinsic Factors Proliferation Differentiation Study
Hormones
Oestrogen Increase No effect (TanapatP 1999)
Corticosteroids Decrease Decrease (CameronHA 1994;
Rodriguez, Montaron
et al. 1998)
Neurotransmitters
Glutamate Decrease Decrease (CameronHA 1995)
(Nacher, Alonso-
Llosa et al. 2003)
5-HT Increase Increase (Banasr, Hery et al.
2004)
Noradrenaline Increase No effect (Kulkarni, Jha et al.
2002)
Growth Factors
BDNF Increase Increase (Lee, Duan et al.
2002)
VEGF Increase Increase (Jin, Zhu et al. 2002;
Cao, Jiao et al. 2004)
EGF No effect Decrease (Kuhn, Winkler et al.
1997)
HB-EGF Increase Not applicable (Jin, Xie et al. 2003)
IGF-1 Increase Increase (Lichtenwalner,
Forbes et al. 2001)
CNTF Increase Increase (Emsley and Hagg
2003)
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1.6.5.2. Extrinsic Factors
Extrinsic factors which affect neurogenesis are agents outside of the animal or
person which have been shown to alter cell proliferation and or differentiation
during the formation of new neurons in the dentate gyrus. These include
antidepressants, anti-psychotics, cannabinoids, opiates, alcohol and mood
stabilizers (Abrous, Koehl et al. 2005). Chemotherapy, the subject of the present
study, has also been shown to affect neurogenesis (Mustafa, Walker et al. 2008).
The interaction between depression, hippocampal neurogenesis and the mode of
action of antidepressants has been extensively studied (Duman, Nakagawa et al.
2001). These investigations have provided important results on the effects of
antidepressants, particularly fluoxetine, on memory and hippocampal
neurogenesis and as described later in this thesis, provide a means to overcome
the effects of chemotherapy. The extrinsic factors affecting neurogenesis are
summarized in the following table.
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Factors/Conditions Proliferation Differentiation Reference
Learning (Morris
water maze)
Increase Increase (Gould, Beylin et
al. 1999;
Dobrossy,
Drapeau et al.
2003)
Environmental
enrichment
No effect Increase (Nilsson,
Perfilieva et al.
1999)
Exercise Increase Increase (Uda, Ishido et al.
2006)
Dietary restriction No effect Increase (Lee, Duan et al.
2000)
Seizures Increase Increase (ParentJM 1997)
Irradiation Decrease Decrease (Monje,
Mizumatsu et al.
2002)
Chronic
antidepressants
Increase Increase (Mayberg,
Brannan et al.
2000)
Chronic stress Decrease No effect (Pham, Nacher et
al. 2003; Heine,
Zareno et al.
2005)
Ageing Decrease Decrease (Heine, Maslam
et al. 2004)
Cerebral ischemia Increase Increase (LiuJ 1998)
Depression model
(bulbectomy)
Decrease Decrease (Keilhoff, Becker
et al. 2006)
Table 1.4 showing studies which have examined the effect of extrinsic
factors and pathological conditions on proliferation and or differentiation in
hippocampal neurogenesis in the adult rodent brain, modified from (Parent
2003).
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1.6.6. Neurogenesis and memory
1.6.6.1. Types of memory (Fig 1.7)
The effect of chemotherapy on cognition appears to involve changes in memory.
It is important to differentiate types of memory. In outline, memory is divided
into three types, which are sensory memory, short-term memory and long-term
memory.
(I) Sensory memory
The sensory memories represent memories related to sensory stimuli. Each
sensation has its own type of memory for example, echoic, iconic and haptic
memories for aural, visual and touch stimuli respectively. If of interest,
information will be transferred from sensory memory into short term memory
(Neath, Gordon et al. 2005).
(II) Short-term memory
Short-term memory also called working memory is the ability to recall needed
information temporarily. Short term memory stays for a very short time (around
200 ms). It involves a collection of structures and processes in the frontal cortex.
The information is processed and subsequently can be transferred to long term
memory by transformation of memories into a stable form. If this fails to occur,
the information will be lost. Recalling of information can lead to an increase in
the short term memory capacity. If this process is interrupted, the retention of
information in short –term memory will be disturbed. In order for this not to
happen, the person tries to finish the act in the short term memory very rapidly.
Working memory is essential for the intelligence of humans (Smith, Jonides et al.
1996).
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(III) Long-term memory
Long-term memory has a larger capacity than short-term memory and is designed
to store information for a longer time. In order not to forget the information in the
working memory, it tends to travel to the long term memory very rapidly. There
are two types of long-term memory which are the episodic and semantic
memories. Episodic memories represent our daily events and the experience
gained from one’s life. Semantic memory, on the other hand, is the type of
memory related to the person behaviour and skills. In order to work effectively,
information stored as semantic memories should be in a direct contact with
episodic memory, in another words; the person should learn the things or adapt
his behaviour according to his previously gained experience. There are three
functions of long term memory: storage, deletion and retrieval. Short-term
memory is converted to long-term memory through rehearsal
(www.cc.gatech.edu/classes/cs6751_97_winter/Topics/human-cap/memory).
This occurs by repeated exposure to the stimulus of interest. Furthermore, the
time during which we gain this information is vital in this process. Deletion
occurs by decay or interference of a memory. It is also worth mentioning that
emotional factors are involved in remembering and forgetting things. Retrieval,
on the other hand requires recall or recognition of information (Smith, Jonides et
al. 1996; Neath, Gordon et al. 2005). These different types of memory involve
different processing mechanisms by inducing changes in both physiological
(synaptic processing) e.g. long term potentiation and depression in the
hippocampus (LTP and LTD respectively) (Bliss and Collingridge 1993) and
longer term changes in synaptic proteins (e.g. synaptogenesis) which is related to
the spatial learning function of the hippocampus (Ramirez-Amaya, Balderas et al.
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2001; Shors 2004). Furthermore, the types of memory involve different brain
structures and regional interactions. The following section will discuss the
function of hippocampal neurogenesis in memory processing
Figure 1.7 an outline of the types of human memory adapted from
( www.cc.gatech.edu/classes/cs6751_97_winter/Topics/human-cap/memory).
Incoming information is passed first to the sensory memory and is then
stored in short -term (working memory) by attention. Short term memory is
converted into long term memory by rehearsal. Information is then encoded
in long -term memory. Retrieval of information from the long-term memory
occurs through recall and recognition processes. If the process is
interrupted at any stage, forgetting occurs (down arrows).
Rehearsal
EncodingAttention
Sensory
memoryInformation
Long term
memory
Working
memory
Forgetting Forgetting
Retrieval
Forgetting
If not
attended
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1.6.6.2. Role of Hippocampal neurogenesis in memory and learning
Procedural learning, a type of instinctive learning requires the acquisition of
motor skills and does not depend on the hippocampus. However, one type of
learning that requires the hippocampus is the learning of declarative memories
(Kempermann 2006). Learning in the hippocampus is believed to use the
process of long-term potentiation or depression by which conductance at
particular synapses within the hippocampus is made either stronger or weaker
(Duan 2002). This is believed to be responsible not only for the consolidation of
memories by the hippocampus but also the recall of stored information
(Kempermann 2006). Another type of learning which is believed to be largely a
function of the hippocampus is spatial learning. In patients with Alzheimer’s
disease, the hippocampus is affected from the onset of the disease and spatial
memory impairment and disorientation are early symptoms (Kempermann 2006).
One of the most widely used tests of spatial memory, especially in rodents, is the
Morris water maze (Morris 1984).
A number of studies have demonstrated that learning increases hippocampal
neurogenesis. For example, in the study of Gould (Gould, Beylin et al. 1999),
adult rats which were trained for 1 week to acquire the location of the platform in
the Morris water maze or trained for one week in the conditioned eye blink
response (a measurement of associative learning). The number of proliferating
cells in the SGZ as demonstrated by BrdU labelling, increased significantly. In
contrast the training of animals on a non-hippocampal dependent task did not
alter cell proliferation indicating the effect of certain types of learning on
hippocampal neurogenesis (Gould, Beylin et al. 1999).
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While learning increases neurogenesis, blocking of neurogenesis impairs
memory. For example, in their study, (Snyder, Hong et al. 2005), prevented
neurogenesis by irradiation of the hippocampus which caused rats to become
significantly impaired in acquiring long term spatial memory in the Morris water
maze. Irradiation also impaired performance in the contextual conditioned fear
response task which is hippocampal dependent (Winocur, Wojtowicz et al. 2006).
Similarly administration of the proliferative cell toxin methylazoxymethanol
acetate (MAM) impaired performance in two hippocampal dependent tasks, the
object recognition memory test (Bruel-Jungerman, Laroche et al. 2005) and trace
memories for a conditioned emotional response in a trace paradigm (Shors,
Townsend et al. 2002). These animal models have demonstrated that
hippocampal neurogenesis is playing an important role in mediating memory and
learning. In humans, the hippocampus is believed to be involved in verbal,
spatial and recognition memories (Reed and Squire 1997; Carrozzo, Koch et al.
2005; Grunwald and Kurthen 2006). It is very important to note that
chemotherapy negatively affects verbal, visual and working memory in cancer
patients (van Dam, Schagen et al. 1998; Ahles and Saykin 2002; Castellon, Ganz
et al. 2004). Thus there is a strong relationship between hippocampal function
and the types of memory which are affected by chemotherapy. This evidence
directed the present investigation of the effect of chemotherapy on the types of
memory mediated by the hippocampus and in turn the relationship between the
cognitive impairments produced by chemotherapy and hippocampal
neurogenesis.
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1.7. Behavioural testing
In order to establish a suitable animal model of chemobrain, it was necessary to
choose a proper test to assess hippocampal memory function. Animal
behavioural testing has been extensively used in memory and neurogenesis
studies as it provides a good parameter to detect intact hippocampal function. In
humans, the hippocampus is clearly important in mediating certain types of
memories. This was evidenced by (Scoville and Milner 2000) who reported
severe declarative memory loss in an epileptic patient after bilateral hippocampal
removal in order to alleviate his symptoms. From this, there is a strong
hypothesis that the cognitive deficits seen after or during chemotherapy treatment
are caused by targeting a specific anatomical locus in the brain which is the
hippocampus. Moreover, the recognition that neurogenesis and continuous
neuronal regeneration are occurring in the human hippocampus (Eriksson,
Perfilieva et al. 1998), made it fundamental to test our animal models for their
memory function after their treatment with chemotherapy and the possible
correlation between this and the chemotherapy-induced reduction in hippocampal
neurogenesis. For this reason we chose two different behavioural parameters to
assess two different types of hippocampal memories. These were the object
location recognition test (OLR) to test for animals’ spatial working memory and
the conditioned emotional response (CER) to test for the animals contextual fear
conditioning. The following sections review these tests.
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1.7.1. Object Location Recognition Test
Spatial working memory is a part of hippocampal function (Ennaceur and
Meliani 1992; Dix and Aggleton 1999; Ennaceur, Michalikova et al. 2005).
Human studies have revealed that hippocampal lesions reduce patient ability to
spatially remember objects (Nunn, Graydon et al. 1999). Animal studies that
tend to test spatial working memory have extensively used the Morris water maze
and they have shown that this task is specific for assessing an intact hippocampal
spatial working memory function. Moreover, it was found that hippocampal
damage impaired rat performance in the water maze task (Morris, Garrud et al.
1982; Sutherland, Whishaw et al. 1982). However, this test has the disadvantage
of a lengthy training protocol which may induce stress in rats (Ennaceur and
Delacour 1988; Ennaceur and Meliani 1992). Another test which has been shown
to accurately assess the spatial orientation memory of rats without primary
reinforcement (e.g. electric shock) or long pertaining period is the object location
recognition (OLR) task. For this reason, we chose the OLR as a test for spatial
working memory of our rats. In this test, two identical objects are presented for
rats to explore in the familiarization trial for three minutes. After 5 minutes
inter- trial interval, one object is moved to a new location (choice or test trial) and
rats are allowed to explore both objects for 3 minutes again (Ennaceur, Neave et
al. 1997; Dix and Aggleton 1999). This test has been previously used in our lab
to test rats’ spatial working memory and showed that rats treated with 5-
fluorouracil had a chemotherapy-induced memory impairment compared to
controls (Mustafa, Walker et al. 2008). Rats usually tend to explore the new
location of an object more that the old one (Mumby, Gaskin et al. 2002; Dere,
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Huston et al. 2007) which highlights the ability of rats to remember the general
architecture of an abject in a certain spatial location.
Rats’ exploration of novelty is displayed usually by approaching, inspecting,
sniffing and manipulating the object with their paws (Dere, Huston et al. 2007).
It has been shown that hippocampal lesioning impairs performance in the OLR
task (Mumby, Gaskin et al. 2002; Dere, Huston et al. 2007). Furthermore, (Lee,
Hunsaker et al. 2005) reported that dentate gyrus lesions reduce rats exploration
for new locations of objects. This adds further evidence to the theory that
hippocampal neurogenesis (which is occurring mainly in the dentate gyrus) is
linked to memory and that the chemotherapy induced memory impairments could
be related to the reduction of hippocampal neurogenesis.
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1.7.2. Conditioned Emotional Response Test
Conditioned emotional response is an emotional response that is acquired by
conditioning. The mechanism by which this conditioning happens is the
occurrence of fear which is a protective behavioural response for both human and
animals against dangerous or unpleasant stimuli. A well known example of
conditioned response is the “Pavlovian” example in which the dog salivates on
hearing the bell ringing as food is always offered after the sound of the bell.
Conditioning or extinction means the reduction in the response to an unpleasant
stimulus with time (Barad 2005). Extinction requires a certain type of learning
which is different from ordinary learning theories. In other words, it is a type of
inhibitory learning (in which the response to a stimulus is reduced). On the other
hand, excitatory learning occurs where there is an increased response to a
stimulus (Barad 2005). As it is learning dependent, extinction requires functional
long term potentiation in the brain (LTP). The molecular mechanism essential
for this process to occur depends on the NMDA type of receptors (N-methyl-D-
aspartate) which are activated by calcium influx (Falls, Miserendino et al. 1992;
Lin, Yeh et al. 2003).
It is crucial to differentiate between contextual conditioning which is occurring
due to pairing of a stimulus (e.g. foot shock) to the context (background stimuli
present in the test chamber) and the cue-specific conditioning which occurs due
to pairing of a tone to a foot shock (Fendt and Fanselow 1999; Fanselow 2000).
There is increasing evidence that contextual conditioning is a part of hippocampal
functions whereas the cue-specific conditioning requires both an intact amygdala
and hippocampus (Phillips and LeDoux 1992; Fanselow 2000).
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Moreover, it was reported that amygdaloidal lesions interfere with both
contextual fear and the cue-specific conditioning whereas hippocampal lesions
interfere only with contextual fear conditioning sparing the cue-specific
conditioning (Kim and Fanselow 1992; Phillips and LeDoux 1992; Fanselow
2000). Fear associated tachycardia, analgesia, freezing, startle vocalization and
increased levels of several hormones especially corticosteroids are detected in
animals in fear conditioning states (Fendt and Fanselow 1999). Freezing which is
defined as absence of all movement of the animal except that for respiration
along with hunched posture and piloerection, has been used as an index to
measure the conditioned fear of the animal during the CER test (Fendt and
Fanselow 1999; Fanselow 2000).
The above review has evidenced that the CER test is recognized as a behavioural
model for testing hippocampal dependent memory and learning. For this reason
we tended to use the CER to assess another aspect of hippocampal function. The
CER test which was performed in this thesis to assess an intact hippocampal
function was adapted from (Resstel, Joca et al. 2006) in which animals were
habituated in the first day followed by application of 10 foot shocks (0.4 Ma
each). Moreover, there is evidence that X ray-induced disruption of hippocampal
neurogenesis impaired animals contextual conditioning to fear (Saxe, Battaglia et
al. 2006). Because our project aimed to investigate the effect of 5-FU
chemotherapy on hippocampal memory and neurogenesis, it was necessary to
assess the effect of the drug on animal performance in the CER test as well as its
effect on hippocampal neurogenesis and the possible correlation between both in
our developed animal model of chemotherapy.
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1.8. Antidepressants
Antidepressants were first introduced at a similar time to antibiotics,
antihypertensives, and a range of other drugs. The following section reviews the
different types of antidepressant and their more recent relationship with
neurogenesis.
1.8.1. Types and mechanisms of action of Antidepressants
1.8.1.1. Tricyclic antidepressants (TCA):
The tricyclic antidepressants are frequently used in the treatment of depression.
They were designed and developed to block the reuptake pumps for both
serotonin and noradrenaline (and to a lesser extent, dopamine). In addition, TCAs
block the muscarinic cholinergic receptors, H1-histamine receptors, and alpha-1
adenoreceptors. Some TCAs also block 5-HT2 receptors, which may contribute
to the therapeutic action of these agents. Antidepressants bind to an allosteric site
close to the neurotransmitter uptake site on nerve terminal and block its synaptic
reuptake thereby increasing neurotransmitter concentration in the synaptic cleft
(Carlsson 1984; Range 1996; Gareri, Falconi et al. 2000; Range 2007).
1.8.1.2. Monoamine oxidase inhibitors (MAOIs)
Drugs classed as MAOIs were amongst the first clinically used antidepressants.
However, the side effects of MAOIs and the discovery of other more efficient
categories of antidepressants decrease their clinical applicability. The main
action of MAOIs is the irreversible inhibition of the enzyme monoamine oxidase.
MAO exists in two subtypes, A and B. The MAO- A form acts mainly on the
neurotransmitter most closely linked to depression (serotonin and noradrenaline).
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Moreover, it acts on the amine which controls blood pressure (noradrenaline).
Thus, MAO- A inhibition is associated with antidepressant action and the
hypertensive side effects of MAOIs (Carlsson 1984; Range 1996; Range 2007).
1.8.1.3. Selective serotonin reuptake inhibitors (SSRIs), the drug of choice
Selective serotonin reuptake inhibitors (SSRIs) are widely used for the treatment
of moderate to severe depression. Their effectiveness has been assessed
clinically and shows a similar response rate to tricyclic antidepressants. SSRIs
are powerful antidepressants that are used to treat many psychological disorders
such as anxiety, aggression, obsessive compulsive disorders and post traumatic
stress disorder. These psychiatric conditions are all associated with serotonin
dysfunction which reflects the primary role of serotonin in the regulation of these
disorders (Wong, Bymaster et al. 1995; Mancini and Ameringen 1996). The
major differences between various SSRIs are in their abilities to inhibit the
reuptake of serotonin. The serotonin transporter is a molecular complex that has
an enzyme binding site (energy producing Na+/ -K ATPase) and other binding
sites (e.g. serotonin, sodium ion, SSRI) (Frazer 2001). When sodium binds to its
location on the molecule, it increases the transporter affinity for serotonin,
permitting serotonin binding with its transporter (Stahl 1999). In contrast, when
an SSRI binds to its site on the molecule, this decreases the affinity for the
serotonin transporter, resulting in an inhibition of serotonin binding to the
transporter. Several drugs within the SSRI class have been introduced recently,
including fluoxetine. Clinically, fluoxetine is currently the most prescribed
antidepressant. This may be because it has a higher selectivity to 5-HT re- uptake
compared to noradrenalin re- uptake and because it has fewer side effects
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compared with TCAs. As with other antidepressants it usually requires 2-4
weeks of treatment before a therapeutic effect is produced (Range 1996; Range
2007). Fluoxetine has been shown to improve cognition in a variety of situations
involving memory impairment (Cassano, Puca et al. 2002; Horsfield, Rosse et al.
2002; Blaney, Berg et al. 2004; Mowla, Mosavinasab et al. 2007).
The actions of fluoxetine on the hippocampus include an increase in
neurogenesis, a phenomenon known to be associated with improved memory
(Levkovitz, Caftori et al. 2002; Vermetten, Vythilingam et al. 2003; Chen,
Pandey et al. 2006; Hitoshi, Maruta et al. 2007; Mowla, Mosavinasab et al. 2007;
Marcussen, Flagstad et al. 2008; Monleon, Vinader-Caerols et al. 2008). One of
the studies presented in this thesis, shows that co-administration of fluoxetine
with 5-FU chemotherapy helped to prevent the cognitive deficits and decreased
neurogenesis found after chemotherapy in a rat model (ElBeltagy, Mustafa et al.
2010).
1.8.1.4. Others
A newly discovered class of antidepressants known as, serotonin antagonists
reuptake inhibitors (SARIs). They are powerful antagonists of serotonin
receptors with a weaker blocking of 5-HT reuptake (Stahl 1998; Gareri, Falconi
et al. 2000). Noradrenergic and specific serotonergic antidepressant (NASSA)
is another category of antidepressants which act by antagonising alpha-2
adenoreceptors and increase of 5-HT receptors and cause postsynaptic blocking
of 5-HT2 and 5-HT3 receptors. This mechanism provides an effective way to
control depression with fewer side effects than those produced by SSRIs
(Stimmel, Dopheide et al. 1997). However, Electroconvulsive therapy (ECT) is
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the most reliable treatment in cases of psychotic and treatment-resistant
depressions as it has the advantage of a faster action than drug therapy However,
The major side effects of ECT are those related to cognition e.g., confusion and
memory impairments (Range 1996; Range 2007).
1.8.2. Antidepressants and neurogenesis
It has been suggested that the formation of new memories is a function of the
hippocampus (McClelland, McNaughton et al. 1995). Recent theories have
suggested that the reduction in hippocampal neurogenesis produced by stress
could lead to a disruption of adaptive behaviour and thus potentiate depression.
Evidence for this has come from observations that stress- exposed animals have a
much lower rate of neurogenesis in the hippocampus (Gould, Tanapat et al. 1998;
Tanapat, Galea et al. 1998; Gould and Tanapat 1999). Cell proliferation in the
SGZ is affected by both chronic and acute stress (GouldE 1997). In addition,
stress has been reported to produce atrophy of the pyramidal cells of the dentate
gyrus and CA3 as well as decreasing the formation of granule cells in the dentate
gyrus which results in a decrease in hippocampal volume, a feature also observed
in chronic depression (Sapolsky 1996; Sheline 1996; Duman, Malberg et al.
1999). These stress-induced changes as well as the use of antidepressants to treat
depression are very important modulators of the course of depression. These
findings have been shown in both preclinical studies where atrophy and death of
stress-exposed neurons in the hippocampus has occurred (Sheline, Wang et al.
1996; Shah, Ebmeier et al. 1998; Bremner, Narayan et al. 2000) and also in post-
mortem studies where atrophy and cell death occurred in the hippocampus and
the prefrontal cortex (Kumar, Schweizer et al. 1997; Kumar, Jin et al. 1998;
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Narayan, Bremner et al. 1999). As mentioned above, several studies have shown
that antidepressants increase neurogenesis (Levkovitz, Caftori et al. 2002;
Vermetten, Vythilingam et al. 2003; Chen, Pandey et al. 2006; Hitoshi, Maruta et
al. 2007; Mowla, Mosavinasab et al. 2007; Marcussen, Flagstad et al. 2008;
Monleon, Vinader-Caerols et al. 2008).
In their study, (Manev, Uz et al. 2001) showed that S100ß, a neurotrophic
regulatory factor, was increased by the selective serotonin reuptake inhibitor,
fluoxetine and its immunoreactivety was reduced with the reduction in serotonin
synthesis. It is clear that treatment with antidepressants increases neurogenesis.
Furthermore, it is hypothesized that one mechanism by which antidepressants act
via up regulation of neurogenesis. In addition, the time required by
antidepressant treatments to produce a behavioural effect (i.e. chronic not short-
term course of treatment), may be due to the time required for the increased
numbers of new neurons to become integrated into the dentate gyrus. It is also
important to note that recovery from depressive behaviour extensively depends
on different mechanisms of treatment (Duman, Heninger et al. 1997).
`
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1.9. HYPOTHESIS
1.9.1. Chemotherapy induces cognitive deficits
Our hypothesis is that 5-FU easily crosses the blood brain barrier due to its low
molecular weight, producing cognitive impairment symptoms such as confusion,
memory deteriorations and attention and concentration disruption. These
symptoms which have been claimed by patients undergoing 5-FU chemotherapy
treatment have been investigated in a rat model by testing their behavioural
response in two hippocampal specific behavioural tasks, the object location
recognition and the conditioned emotional response which showed memory
impairments in 5-FU chemotherapy-treated rats.
1.9.2. Chemotherapy reduces neurogenesis in the hippocampus
According to the literature reviewed earlier in this chapter, our hypothesis is that
cytotoxic drugs, particularly those with high blood-brain barrier permeability
which includes 5-FU, are targeting the proliferation and survival of dividing cells
in the SGZ of the dentate gyrus. This was tested by quantifying the numbers of
proliferating cells in the SGZ in control and 5-FU treated animals. Dividing cells
were identified by immunohistochemical staining for the endogenous
proliferative marker Ki67 as described in (Mustafa, Walker et al. 2008), on one
half of each brain obtained from animals after behavioural testing. Cell survival
was tested (Chapter 5), by injecting BrdU immediately prior to drug
administration and quantifying BrdU positive cell numbers, by
immunohistochemistry, at different time points after drug treatment. Cell
proliferation, at the time of death, was also quantified in these experiments, by
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staining for Ki67, to determine if drug treatment has a prolonged effect on cell
proliferation in the SGZ.
Contralateral half brains were processed for Western blotting to quantify DCX
and BDNF proteins (Chapters 3 and 4). DCX is transiently expressed in new
born neurons and levels in the hippocampus and frontal cortex give a measure of
the rate of neurogenesis. Changes in BDNF protein levels in the hippocampus
were also quantified to determine the effect of 5-FU treatment on neurotrophic
factor levels. These are believed to be important in cell survival and maturation
during neurogenesis. Measures of Ki67, BrdU, DCX and BDNF aimed to
determine the proliferation, differentiation and survival aspects of neurogenesis in
the present animal model of chemobrain.
1.9.3. A reduction in hippocampal neurogenesis will correlate with and may be
the cause of the cognitive impairment found after chemotherapy treatment.
Our hypothesis is that the disruption of hippocampal neurogenesis, as a result of
chemotherapy treatment, will cause deficits in memory processes mediated by it.
In the animal model used in this thesis, rats were tested using two behavioural
tasks that require hippocampal-mediated memory. These were the object location
recognition (OLR) and the conditioned emotional response (CER) tests. The
OLR test depends on the inherent ability of rats to explore the new location of the
object in the presence of familiar stimuli (Mustafa, Walker et al. 2008). The CER
test is testing the contextual fear conditioning of the rats which was shown to be a
hippocampal specific task (Resstel, Joca et al. 2006).The advantages of these tests
is that they do not require long training and learning protocols as in Morris water
maze. Adult male rats were used and behavioural testing was carried out
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immediately after the period of animal treatments with the cytotoxic drug 5-FU.
The details of these tests are described in (Chapter 2, Materials and Methods).
1.9.4. Treatment with antidepressants will prevent the deficits in both
neurogenesis and cognition found after chemotherapy.
In addition to determining the cognitive and cellular changes brought about by
chemotherapy, one study in this thesis also examined the effect of chronic
treatment with the antidepressant fluoxetine co administered with 5-FU (Chapter
4). This was done to test the ability of chronic treatment with antidepressants to
improve the disrupted picture of neurogenesis and memory induced by
chemotherapy.
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5-fluorouracil and or fluoxetine treatment
Behavioural testing
OLR and CER tests
Study termination
Brain tissue preparation
Figure 1.8. Outline of the methods used to test the effect of 5-fluorouracil
and or fluoxetine treatment on hippocampal specific memory and
neurogenesis in a rat model in this thesis. Hippocampal recognition memory
was tested using the (OLR) test. The contextual conditioning of rats was
measured by carrying out the (CER) test. At the end of the study, one
cerebral hemisphere of brain tissue was processed for Western
immunoblotting to quantify brain derived neurotrophic factor (BDNF) and
doublecortin (DCX) protein levels in the hippocampus and frontal cortex.
The other cerebral hemisphere was processed for immunohistochemical
staining for the proliferative markers (Ki67 and BrdU).
Memory
Frontal and Hippocampal
samples preparation
Sectioning brain tissue
Western blot for DCX and BDNF
proteins
Immunohistochemistry for Ki67
and BrdU
Proliferation and SurvivalDifferentiation
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1.10 AIMS AND OBJECTIVES
The objectives of these studies were as follows:
1- To study the behavioural effects of 5-FU chemotherapy in two behavioural
paradigms (OLR and CER) both of which require hippocampal memory.
2- To study the effect of 5-FU chemotherapy on hippocampal neurogenesis by
measuring cellular proliferation and differentiation in the dentate gyrus of the
hippocampus. At the same time to quantify the effect of 5-FU on the
neurotrophic factor BDNF and the neuronal differentiation marker doublecortin
(DCX).
3- To study the long term effects of 5-FU treatment on the survival of new born
cells in the dentate gyrus and the rate of cell proliferation at different time points
after the end of drug treatment.
4 - To study the effect of the anti-depressant fluoxetine, on both memory and
neurogenesis when given during 5-FU treatment.
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CHAPTER 2
Preliminary Studies to evaluate:
1- 5-Flurouracil toxicity (pilot study)
2- The parameters for behavioural testing
2.1.1. INTRODUCTION
As 5-FU is a toxic drug, it was necessary to establish a suitable dosage and
regime of administration which produced limited morbidity and after which the
animals would be capable of performing the proposed behavioural tests. 5-FU is
known to cause weight loss and, if this is too pronounced acutely or caused a
cumulative weight reduction of more than 20%, Home Office licensing
regulations would require termination of the experiment. From the literature a
wide range of doses from 20 – 150 mg/kg have been administered to rodents
with a variety of acute and chronic dosing regimens (Migone et al. 2006; Lee et al
2006; Mustafa et al. 2008; Foley et al 2008; Han et al. 2008). Studies using a
chronic dosing regimen to reduce tumour load have commonly used 25-30mg/kg
which is believed to be within the human dose range used in treatment of breast
and other cancers (Au et al 1983; Watson et al 1998; Reagan et al. 2008).
However previous studies in this laboratory, using 25mg/kg in a series of
injections over two weeks, had caused some morbidity, with one animal out of
ten having to be put down (Mustafa et al. 2008).
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As the dose of 25mg/kg has been used previously in chronic studies it was
decided to try to use this dose again in combination with the same concentration
of leucovorin while paying particular attention to daily body weight changes.
At the end of chemotherapy administration it is important that animals are
capable of performing the proposed behavioural tests. General activity
behaviour can be assessed by videotaping locomotor activity and using the Etho
Vision tracking software (Noldus Information Technology UK) to measure
movement. Comparison of activity of control and treated animals enables the
measurement of any drug effect on activity which might alter normal exploratory
behaviour.
A wide variety of objects and box sizes have been used in different studies of
object recognition and object location behavioural studies. Discussions with
investigators familiar with these types of test indicated that these parameters
could have a significant effect on the ability of animals to perform the tests (K.
Fone personal communication). It was decided to try 2 different objects in the
novel object location test (OLR) to find the most appropriate ones to use.
The CER behavioural test requires animals to remember the context of an
unpleasant stimulus (electrical shock) over 24 hours. Memory is assessed by
measuring the freezing behaviour when the animal is returned to the original
context (CER box). It is important to establish that untreated animals, which
have not experienced unpleasant stimuli, do not freeze on being returned to the
CER box and that animals which have been shocked are able to remember the
experience after 24 hours and show a behavioural change.
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The studies reported in this section establish a suitable drug dosage which should
enable animals to perform the behavioural tests and also carry out the controls
necessary to establish the validity of the CER test.
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Experiment1: (5-FU toxicity): Effect of 5-Fluorouracil on
Hippocampal Recognition Memory, and Fear Conditioning of
Rats
2.1.2. MATERIALS AND METHODS
2.1.2.1. Animals
All animals in this and future studies were Lister Hooded male rats obtained from
Charles River Laboratories. Animals were delivered at between 2-3 months and
270-300gms, housed in the Bio-Medical school Service Unit (BMSU) and
allowed to acclimatize for 5 days prior to any procedures. All procedures were
conducted in accordance with Home Office guidelines and local ethical approval
and carried out under a Home Office personal licence (40/8761) and project
licence (40/3283). For this experiment animals were randomly divided into
control (saline-injected, n=5) and treated (5-FU-injected, n=5) groups and housed
5 per cage under standard conditions (12hr light / dark cycle and free access to
water and food).
2.1.2.2. 5-FU Chemotherapy Treatment
All rats received 5 intra-tail vein (i.v.) bolus injections, under general anaesthesia
(hypnorm), over the course of 10 days (every other day). Animals were warmed
in a heated box and the tails thoroughly cleaned with surgical scrub prior to
injection. Treated animals received 5-FU (25mg/kg) and leucovorin (25mg/kg)
both from (Mayne Pharma, UK) in the same injection (Au, Walker et al. 1983).
The control group received 0.9% sterile saline injections in the same volume as
the treated group. Weights were monitored daily during treatment.
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2.1.2.3. Behavioural Testing
Behavioural testing to all animals was carried out before and after drug injection.
The locomotor test was done during the habituation for the OLR test. Animals
were videoed during one hour of habituation and their distance and velocity
analysed using the Ethovision software.
Rats were tested for their ability to perform the two behavioural tests (OLR and
CER) both before and after treatment, to make sure that rats were able to perform
these tasks and to determine the effect of drug treatment.
Table 2.1.1. A protocol table of the study. Rats were habituated for 5 days
in BMSU. Over 10 days, rats were injected by sterile saline or 5-FU+LCV
every other day (5 injections). Rats were tested for their performance in the
OLR and CER tests before and after treatment respectively. Rats were killed
on the following day of the CER test.
Day 1-5 Day 6 – 10 Day 11 -20 Day 21 - 25 Day 26
Weighing
and
habituation
OLR then CER
behavioural tests
5-FU+LCV or saline
intravenous
injections
OLR then CER
behavioural tests
Killing of animals
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2.1.2.3.1. The Object Location Recognition Test
The OLR test was modified from the method of Dix and Aggleton, 1999.
Equipment consisted of two large opaque plastic boxes (66cm length, 41cm width
and 40 cm in height) set up in a well aired room at a temperature of 22
0
C with
maximal lighting. These boxes (Arenas) were labelled as Arena1 and Arena 2
and were kept with the same label until the end of this test. Both boxes were in
the same room but an opaque divider prevented animals seeing the other arena.
Animal activity was remotely monitored by a ceiling mounted video camera
which relayed images to an adjacent room. This test was done over two days; on
the 1
st
day animals were put into an arena for one hour to habituate before
returning to their home cages. Arenas were cleaned and swabbed with Alcosan,
water and 20% ethanol between all trials.
The second day of the test involved the familiarization trial (sample trial), the
inter trial-interval (ITI) and the choice trial. For the sample trial, two identical
objects (either weighted striped plastic bottles or toy penguins) were placed in
each arena at specific locations. The rats were introduced into their arenas and
left for 3 minutes. Animal behaviour was displayed and recorded in the adjacent
room.
After 3 minutes, the rats were removed from the arenas and returned back into
their home cages for the inter-trial interval time (ITI) which lasted for 5 minutes.
For the choice trial, the objects were placed back into the arenas, but, one object
in was placed in a different location. Rats were left to explore the objects for
another 3 minutes (Fig 2.1). Exploration of the object was defined as when the
animal sniffed, licked, chewed or directed its nose at a distance  1cm from the
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object (King, Sleight et al. 2004). Exploration time was obtained from the
recorded video tapes.
Figure 2.1.2 Schematic representation of the object location recognition
(OLR) task. Animals habituate for 1 hr on day one and on day two they
complete the familiarisation, inter-trial interval and choice trials.
2.1.2.3.2. The Conditioned Emotional Response Test
The CER test was carried out in a protocol modified from Resstel et.al, 2006. On
the first day (the shock day), each animal was put individually into the CER box,
which is a metal box (25 cm height, 24 cm width and 25 cm length) with a metal
grid floor connected to a shock generator to give a 0.4ma electric shock. Shocks
were monitored using an oscilloscope. 10 shocks, one every minute lasting for
one second, were given to the rat in over a period of ten minutes (total 10
shocks). The box was cleaned between trials with 20% alcohol to avoid olfactory
cues.
On the following day, each animal was returned to the same box in the same
conditions for ten minutes without shocking. The duration of freezing behaviour
as defined as the absence of all movement with the exception of respiration, was
measured from the videos using a stop watch.
ITI
24 hours
Habituation Familiarization Choice
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Figure 2.1.3. A picture modified from pnf.ruhosting.nl/Skinner.htm showing the
conditioned emotional response apparatus (the modified Skinner box) used
in the CER test.
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2.1.2.4. Statistical analysis
All statistical parameters were calculated using GraphPad Prism 4.0 software.
Weight data were analysed using repeated measures two-way ANOVA followed
by the Bonferroni post-test. Locomotor activity parameters (distance and
velocity) were analysed by using one way ANOVA. For behavioural testing
before and after treatment, the Student’s t-test was used. Within treatment group
comparisons (e.g. comparison of drug-treated group exploration of object RT
versus object LT) were analysed using a paired t-test expressed as Mean±S.E.M.
Between groups comparisons (e.g. drug-treated group versus vehicle-treated
group) were analysed using the unpaired version of the t-test. For analysis of
results from the CER test an unpaired t- test was used to compare between
controls and treated animals.
For all tests, a significance level less than 0.05 was used (P<0.05).
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2.1.3. RESULTS
2.1.3.1. Weight changes during treatment.
The body weight of rats was monitored daily throughout the experiment. Rats
receiving 5-FU chemotherapy exhibited a significant decrease in the amount of
weight gained during the treatment period compared to their controls
(P**=0.005) and appeared to transiently lose weight on most days following
injections (Fig.2.1.4).
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Figure 2.1.4. Body weights (Mean±S.E.M) of saline and 5-FU+LCV treated
groups (n=5 each) recorded daily during the study. Injections were
administered as indicated on the graph by arrows.
5-FU+LCV injections significantly decreased weight gain compared to saline
(P**=0.005) over the time period (P***<0.0001). The interaction between
time and treatment factors was also significant (p***<0.0001); repeated
measures two-way ANOVA with Bonferroni post-hoc test).
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2.1.3.2. Locomotor activity (distance and velocity) measurement.
Locomotor activity was measured in saline and drug treated groups during the
habituation period prior to the OLR test both before and after treatment. There
was no significant difference between groups in the mean velocity (cm/sec) or in
the total distance (cm) moved by the animals (P=0.3) (one-way ANOVA), Fig
2.1.5. A and B. This indicates that drug treatment (5-FU+LCV), did not alter
these aspects of locomotion and that any differences in the behavioural tests were
not due to the treated animals being unable to perform these tests.
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Figure 2.1.5. (A) The total distance and (B), the mean velocity of animals
(Mean±S.E.M) in each group (n=5) during the habituation period (1 hour) of
the OLR test before and after treatment. There was no significant difference
between any groups in both parameters (P=0.3; One-way ANOVA).
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2.1.3.3. Object Location Recognition before Treatment
The OLR test was performed for all animals before treatment to test whether all
animals were able to perform the task before starting the treatment. In this
experiment striped water bottles and penguin toys were used. As shown in Fig
2.1.6. Both controls and the group to be treated with 5-FU+LCV explored both
objects in the sample trial equally (P>0.05). After changing the one location of
one object in the choice trial, neither controls nor the group to be treated with 5-
FU+LCV exhibited any significant difference in exploratory time between
objects in the novel or familiar location (P=0.6 and 0.2 respectively).
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Fig 2.1.6.A and B Exploration time (Mean±S.E.M) of rats performing OLR
task before treatment in the two groups (n=5 each). In the sample trial
(white shaded), objects were placed in either RT (right) or LT (left)
locations. In the choice trial (dark shaded). Replicas of the same object used
in the sample trial were placed in either locations (OLD or NEW) (designed
the old location (OLD) or a novel location (NEW). There was no significant
difference in the exploration time spent by animals in either sample or choice
trials (P<0.05; paired Student’s t-test).
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2.1.3.4. The CER results before treatment
The (CER) test was performed for all animals before treatment to ensure that all
animals were able to perform the task before starting the treatment. As shown in
Fig 2.1.7. There was no statistically significant difference in the amount of
freezing between control and the group to be treated with 5-FU+LCV (P=0.7).
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Fig 2.1.7. The freezing times (Mean±S.E.M) exhibited by the rats in each
group before treatment (n=5). There was no statistically significant
difference in the measured freezing time between the control and the group
will be treated with 5-FU+LCV (P=0.7; paired Student’s t-test).
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2.1.3.5. Object Location Recognition after drug treatment.
Both saline and 5-FU-treated rats displayed similar amounts of exploration time
for both objects and locations in the sample trial indicating that rats did not have
a preference for either of the objects or their locations in the box. In the choice
trial, after the 5 minute inter-trial interval, there was no difference between the
exploration time of the familiar (Old) and novel (New) locations in both saline
and 5-FU+LCV treated groups (P=0.5 and 0.7 respectively) as shown by a paired
Student’s t-test Fig 2.1.8 [A and B]). Indicating that even the saline treated
animals were not able to differentiate between familiar and novel locations in this
task.
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Fig 2.1.8. A and B, Exploration time (Mean±S.E.M) of rats in OLR task after
treatment (n=5 in each group). In the sample trial (white shaded), objects
were placed in either RT (right) or LT (left) locations. In the choice trial
(dark shaded). Replicas of the same object used in the sample trial were
placed in either locations (OLD or NEW) designed the old location (OLD) or
a novel location (NEW). There was no significant difference in the
exploration time spent by all animals in either sample or choice trials
(p<0.05; paired Student’s t-test).
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2.1.3.6. The CER test results after treatment
For the CER test, freezing behaviour was recorded 24 hours after conditioning
when animals were returned to the test box. Vehicle-treated animals spent an
average of 132 seconds in this behaviour. In contrast 5-FU-treated animals spent
an average of only 94 seconds exhibiting this type of behaviour, which was not
significantly less than controls (P=0.07; unpaired Student’s t-test; Fig 2.1.9).
CER results after treatment
saline 5FU +LCV
0
50
100
150
Fr
ee
zi
n
g
tim
e(s
ec
)
Fig 2.1.9. Freezing time (Mean±S.E.M) exhibited by the rats in each group
after treatment (n=5). There 5-FU+LCV measured freezing time, although
less, but was not significantly different from the measured freezing time in
the saline treated rats (p=0.07; unpaired Student’s t-test).
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Experiment 2: Optimization of the parameters for behavioural
testing
2.2.1 INTRODUCTION
As shown in the first experiment, control rats were not able to perform the object
location recognition task. In the conditioned emotional response test, there was a
tendency towards a decrease in the measured freezing time of the 5-FU+LCV
treated animals compared to the saline- treated animals. These results could be
attributed to the small sample number (5 animals per group) which made it
difficult to reach a statistically different conclusion. Another factor which could
affect the accuracy of the result obtained from the object location recognition task
was the unintended variation of the objects used during both sample and choice
trials (a toy penguin and a stripped water bottle). It has been noticed from the
replayed videotapes which recorded the behaviour of the animals during the
object location recognition task, that the rats were so much interested in exploring
the toy penguins much more than exploring the stripped water bottles. For these
reasons, it was necessary to design a new experiment (without treatment) with
bigger sample number which avoids these confounding variables to test whether
Lister Hooded rats are able to perform the OLR and the CER behavioural tasks or
not before establishing these two tests in future studies. To optimize the object
location recognition test, decorated water bottles were used either in the
familiarization or the choice trials and the test was run as usual. For the
conditioned emotional response test, half of the rats was shocked and the other
were not and their freezing behaviour was recorded.
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2.2.2 MATERIALS AND METHODS
2.2.2.1. Animals and Housing
For this project 20 adult Lister Hooded rats were obtained from BMSU,
University of Nottingham. Rats weighed approximately between 220-255g when
they arrived. Animals spent one week acclimatizing the new environment in
BMSU .They were housed in four cages 5 animals each and weighted daily. This
assignment was done randomly. The rats were housed in appropriate conditions
according to BMSU standard procedures. Their diets consisted of water and dry
rat chow which were readily available at all times for both cages.
2.2.2.2. Behavioural Testing (modified object location recognition and
conditioned emotional response tests):
Object location recognition testing was done for all animals as described in
(Experiment 1, Chapter 2) with the previously described considerations (using the
decorated water bottle in all test trials). Animals then were divided randomly into
two groups (10 rats each) for the CER test. The first 10 rats were put individually
in the CER box for 10 minutes without interference and the freezing behaviour
was recorded for each animal separately. The second ten rats were tested for
their conditioned emotional response as described in (Experiment 1, Chapter 2).
On the last day of the CER test, animals were killed. Their termination involved
stunning, followed by dislocation of the cervical spine in the neck using a blunt
instrument. Animal bodies were disposed of in the -80ºc freezer of the BMSU.
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Table 2.2.1. A protocol table of the study is presented above. On arrival,
rats were left to habituate the new condition of the BMSU for one week then
on days 8 and 9 rats were tested for their performance in the OLR and on
days 10 and 11, half of the rats were tested for their response in the CER
tests. At the end of the third week all rats were killed.
2.2.2.3. Statistical Analysis
All statistical parameters were calculated using GraphPad Prism 4.0 software. .
For the OLR behavioural, paired Student’s t-test was used expressed as
Mean±S.E.M. For CER analysis, Student’s unpaired t- test was used to compare
between shocked and non-shocked animals freezing time.
For all tests, a significance level less than 0.05 was chosen (P<0.05).
Day 1 to day 5 Days 8 and 9 Days 10 and 11 Day 12
Habituation in
BMSU
Object location
recognition test for all
animals
Conditioned emotional
response test for half of the
rats
Putting down
of all animals
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2.2.3. RESULTS
2.2.3.1. Object Location Recognition
Animals displayed similar amounts of exploration time for both objects in the
sample trial (exploring objects in RT and LT) locations indicating that rats did
not have a preference for either of the objects or their locations in the box. After
the 5 minute inter-trial interval in the choice trial, animals spent significantly
more time exploring the object in the novel location compared to that in the
familiar location (P***<0.0001; Fig 2.2.2).
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Figure 2.2.2. Exploration time (Mean±S.E.M) of rats performing the object
location recognition (OLR) task. In the sample trials (white shaded), (LT
and RT) locations, all rats (n=20) spent the same amount of time exploring
replicas of an object in both locations (RT and LT)) (p=0.9). In the choice
trials (dark shaded), replicas of the same object used in the sample trial were
placed in either locations (OLD or NEW). All rats explored the NEW
location significantly more than the OLD location (p***<0.0001). All
comparisons were calculated using paired Student’s t-test.
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2.2.3.2. Conditioned Emotional Response Test
For the shocked animals, freezing behaviour was recorded 24 hours after
conditioning when animals were returned to the test box (during 10 minutes).
The freezing behaviour of the non-shocked animals was recorded during the 10
minutes of their testing. Shocked animals spent an average of 154 seconds in this
behaviour. In contrast the non-shocked animals spent an average of only 10
seconds exhibiting this type of behaviour, which was significantly much less than
in shocked animals (P***=0.0001; unpaired Student’s t-test; Fig 2.2.3). This
confirms that this is a good test for memory and those animals were able to
perform this task.
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Figure 2.2.3. The freezing times (Mean±S.E.M) exhibited by the rats in each
group (n=10). The shocked animals freezing time was significantly greater
than the non-shocked animals freezing time (P***=0.0001). The analysis
was done by using unpaired Student’s t-test.
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2.2.4. DISCUSSION
The aim of this pilot study was to establish suitable parameter for an animal
model to study effects of the anticancer drug 5-FU on the behaviour of Lister
Hooded rats. In particular it was necessary to ascertain that the drug dose
(25mg/kg) was suitable and that two behavioural tests chosen could be used to
test cognition under these conditions.
2.2.4.1. 5-FU significantly reduced weight gain
Previous studies have shown that 5-FU exerts cytotoxic effects on the
proliferating cells of the intestinal wall reducing nutrient absorption (Houghton,
Houghton et al. 1979; Huang, Kemp et al. 2002). In the present experiments, 5-
FU+LCV treated rats (n=5) showed a significant reduction in their body weights
compared to the saline treated animals (Fig 2.1.4). The oscillating pattern in the
weight of 5-FU treated animals indicates the possible transient effect on feeding
from which the animals recovered on the following day. Although weight gain
was transiently affected by the injection protocol, overall morbidity was low and
the dose used appeared to be suitable for use in further studies. This conclusion
was reinforced by the locomotor data (distance and velocity) which showed that
drug- treated animals showed no difference from saline treated animals (Fig
2.1.5. [A&B]).
2.2.4.2. OLR test.
In Experiment 1, we found that none of the groups of animals could discriminate
between objects in novel and familiar locations in the choice trial, either before or
after drug treatment (Fig 2.1.6 [A&B] and 2.1.8 [A&B] respectively). A
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possible cause was the low number of animals per group (n=5) compared to other
studies that have used a minimum of 6 animals per group. The other factor which
might explain these results was the type of object used during these trials as it
was noticed that animals seemed more interested in exploring the toy penguins
rather than the water bottles.
On the basis of this, objects were replaced by decorated water bottles which when
combined with an increased sample size, showed that the Lister Hooded rats
(Experiment, 2) were capable of performing this test and showed significantly
increased preference for the object in the novel location.
2.2.4.3. CER test.
In Experiment1, when drug treated animals were compared with a saline-
treated group, a non -significant difference in freezing time was found between
the two groups (Fig 2.1.9). The difference in freezing behaviour was seen
particularly in the first three minutes of the test but declined after this (data not
shown). Although this result was not significant, it is likely that a larger sample
size (10 rather than 5) wouldshow a significant result and this was confirmed in
subsequent experiments. In Experiment 2, CER test where unshocked animals
were compared with those who received shocks during their first period in the
CER box, the shocked animals showed significantly more freezing time than
the non- shocked group (Fig2.2.3) Indicating that memory of the context in
which the shocks were experienced is maintained for 24 hours and showing that
this is an appropriate test of contextual memory (Frankland, Josselyn et al.
2004).
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2.2.5. CONCLUSION
These preliminary experiments have demonstrated that the dose of 5-FU+LCV of
25mg/kg is suitable for future studies and does not cause excessive morbidity.
This was confirmed by the locomotor data which showed that the activity of
drug-treated animals was not different to controls and that they should be able to
perform the behavioural tests after treatment. It was found that n=5 was too small
a sample size and that appropriate objects must be used for these animals to be
able to perform the OLR test. The CER test appears to be a useful test of
memory over 24 hours. It clearly differentiates between animals experiencing an
adverse stimulus in a particular context from those that have not experienced this
stimulus, but have been in the same context. Although not reaching significance
in these experiments, larger sample sizes should be able show differences
between drug and saline- treated animals. Further experiments detailed in the rest
of this thesis make use of these preliminary results which give greater confidence
in the results obtained.
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CHAPTER 3
Effect of 5-FU on memory and neurogenesis in the adult male rat
hippocampus
3.1 INTRODUCTION
In the preliminary study (Chapter 2); adult L.H male rats were given 5 tail vein
injections of either saline or 5-FU at a dose of 25 mg/kg in combination with
leucovorin (25 mg/kg) in the same syringe. This did not cause significant
morbidity and these preliminary findings form the basis for the present study in
which a larger number of rats were treated with the same 5-FU+LCV protocol.
This study looks at the effect of 5-FU chemotherapy on three aspects of
neurobiology. First, the effect of drug treatment on cognitive behaviour as
measured in the OLR and CER tests; second on the number of proliferating cells
in SGZ of the dentate gyrus as a measure of this aspect of hippocampal
neurogenesis and third on the levels of doublecortin (DCX), a marker of newly
formed neurons and brain derived neurotrophic factor (BDNF) were measured by
Western blotting, in the hippocampus and frontal cortex. DCX is a microtubule-
associated protein which is transiently expressed in developing neurons in which
it is required for their migration (Friocourt, Koulakoff et al. 2003; Couillard-
Despres, Winner et al. 2005; Plumpe, Ehninger et al. 2006). In the adult brain
this protein is only expressed in neurogenic areas such as the dentate gyrus of the
hippocampus and the rostral migratory stream within the frontal lobe (Nacher,
Crespo et al. 2001; Kempermann 2006; Gage, Kempermann et al. 2008). DCX is
expressed by dentate gyrus granule cell precursors for between three days and
several weeks during their final rounds of cell division and as they migrate into
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the dentate gyrus and start making connections (Brown, Couillard-Despres et al.
2003; Plumpe, Ehninger et al. 2006).
Due to its restricted expression pattern, the quantification of DCX - positive cells
has been suggested as a measure of adult hippocampal neurogenesis (Couillard-
Despres, Winner et al. 2005). In the present study, DCX protein was quantified
by Western blotting to see if 5-FU chemotherapy affected the levels of this
protein. Protein levels were measured in both hippocampus and frontal cortex to
see if the effects of chemotherapy were region specific.
BDNF is a key component in both the formation of memories and hippocampal
neurogenesis. This secreted neurotrophic factor is produced by both neurons and
endothelial cells and produces its effects by binding to the TrkB receptor
(tyrosine receptor kinase B) on target cells (Leventhal, Rafii et al. 1999). During
the process of learning, BDNF expression is up-regulated and plays a key role in
both early and late phase long-term potentiation (LTP) (Lu, Christian et al. 2008;
Waterhouse and Xu 2009).
BDNF levels in the hippocampus increase with antidepressant treatment and
exercise, both of which cause an increase in hippocampal neurogenesis (Sairanen,
Lucas et al. 2005). Conversely BDNF levels and neurogenesis decrease with lack
of exercise and stress (Yasuhara, Hara et al. 2007). The exact role of BDNF in
hippocampal neurogenesis is still not clear but both mature dentate gyrus granule
cells and neural progenitors in the SGZ express both BDNF and the TrkB
receptor (Li, Luikart et al. 2008). Expression of TrkB, however, increases as the
neural progenitors in the SGZ mature (Donovan, Yamaguchi et al. 2008). If the
BDNF / TrkB signalling pathway is blocked, both progenitor cell proliferation
(Lee, Duan et al. 2002; Li, Luikart et al. 2008) and the survival of newly born
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granule cells is reduced (Lee, Duan et al. 2002; Sairanen, Lucas et al. 2005) while
infusion of BDNF into the hippocampus increases neurogenesis (Scharfman,
Goodman et al. 2005). Interestingly, genetic ablation of either TrkB or BDNF
reduces the neurogenic and behavioural response to antidepressants (Sairanen,
Lucas et al. 2005; Li, Luikart et al. 2008).
The first step of neurogenesis is the division of neural stem and progenitor cells.
In this chapter, this was quantified by counting the number of Ki-67 positive cells
in the SGZ of the dentate gyrus (Kee, Sivalingam et al. 2002).
By combining investigations of these parameters it was hoped to determine if 5-
FU chemotherapy affects cognitive behaviour and to provide a cellular
mechanism for this effect.
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3.2 MATERIALS AND METHODS
3.2.1. Animals
20 male Lister Hooded rats, 2-3months age and their weights between 200-250
grams, were bought from Charles River (UK) and left to habituate to the new
environment of the Biomedical Services Unit (BMSU), University of Nottingham
for one week. Rats were housed in groups of 5 under standard laboratory
conditions with free access to food and water all the time and weighted daily.
Rats were randomly assigned to vehicle (n=10) or 5-FU+LCV chemotherapy
(n=10) groups.
3.2.2. 5-FU chemotherapy treatment
Over the course of 2 weeks (every other day excluding weekends) rats received 5
i.v. injections into the tail vein of 5-FU (Mayne Pharma, PLC) and leucovorin
(LCV, Teva, UK LTD) at a dose of 25 mg/kg in the same syringe while under
(0.2 ml intraperitoneal) hypnorm general anaesthesia. The vehicle group
received 0.9% sterile saline at an equivalent injection volume equivalent to drug
treated animals. Two animals from the chemotherapy- treated group died in this
experiment, one failed to recover from the anaesthetic and the other died after 2
days for unknown reasons. Animals were weighed daily during the treatment
period.
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Table 3.1. A protocol table of the study. Rats were tested in the OLR and
the CER tests respectively prior to treatment to ensure that they were able to
perform the tasks. Rats then received 5 intravenous injections of 5-FU+LCV
(25mg/kg) as shown in the table. Animals then were tested for their
performance in the OLR then the CER tasks. On day 26 of the experiment,
all animals were sacrificed.
3.2.3. Behavioural Testing
The OLR and the CER tests were carried out and analysed as described in
(Chapter 2, section 2.1.2.3.1 and 2.1.2.3.2). Animals in the object location
recognition test that did not explore in behavioural testing sample or choice trials
(i.e. combined exploratory time of 0 seconds for both object/objects locations)
were excluded.
3.2.5. Brain Tissue Preparation
Two days after performing the CER test, (Fig 3.1) rats were killed by rapid
stunning and decapitation. Whole brains were dissected from the skull and
divided into two along the longitudinal fissure. One half was used for histology
and the other for Western blot analysis.
Days 1-7 Days8&9 Days10&11 Days 12-20 Days 21& 22 Days 23 & 24 Day 26
Habituation
in the
BMSU
OLR test CER test 5-FU+LCV or
saline,
every other
day
OLR test CER test Sacrifice
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3.2.6. Preparation of half brain for histology.
Half brains were cryoprotected in 30% sucrose for 2 hours before being frozen in
isopentane cooled in liquid nitrogen. Tissue was stored at -80
0
C before being
warmed to -20
0
C in a cryostat (Microm), embedded in OCT compound (VWR
International Ltd.) and serially sectioned at 20Pm. Sections were thaw mounted
onto APES coated slides (aminopropyltriethoxysilane) and air dried before being
stored at -20
0
C. The hippocampus was identified from Toluidine blue- stained
sections using information from a rat brain atlas (Paxinos, Watson et al. 1985).
3.2.7. Immunohistochemistry for Ki67
Sections for immunostaining were selected from the whole length of the
hippocampus using a systematic random sampling procedure (Mayhew and
Burton 1988). Slides were defrosted at RT and sections ringed with a PAP pen
(Vector Laboratories). All washes were carried out in PBS and all procedures
were at RT.
Sections were washed 3 times with phosphate buffered saline to remove OCT
compound, fixed in 0.5% paraformaldehyde (PFA) for 3 minutes and washed
again 3 times.
Primary antibody (anti Ki-67 Rabbit Polyclonal Vector Laboratories) diluted
1: 250 in PBS was applied for one hour.
Sections were washed and secondary antibody (Alexa 488; goat anti- rabbit,
Molecular Probes) diluted 1: 250 applied for one hour.
Sections were washed, counter- stained with the red nuclear dye, propidium
iodide (Molecular Probes; 1:3000 in PBS), mounted in glycerol and viewed under
fluorescence illumination on a Nikon Optiphot-2 microscope. Images were
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captured using a Spot Insight QE camera and Spot Advanced software (Image
Solutions Ltd.). All counting was done blind to whether the material was from
control or drug- treated animals.
3.2.8. Western Immunoblotting
3.2.8.1. Sample preparation and protein quantification using Lowry assay
Hippocampal and frontal cortex tissue samples were homogenized at 4°C to
produce a 100mg/ml solution in lysis buffer. An equal volume of x2
solubilisation buffer was added to the homogenized sample to solubilise the
protein. The Lowry assay was used to determine the protein concentration within
the tissue samples before protein separation and immunoblotting. 20µl of the
homogenized and solubilised samples was diluted (1:10) in distilled water to a
total volume of 200 µl. A standard curve of bovine serum albumin (BSA)
dilutions (in distilled water, total volume of 200 µl) (which protein concentrations
of the tissue samples will be compared with) was prepared within the
concentration range of 0 to 0.4 mg/ml. 1 ml of Lowry AB solution was added to
all diluted tissue and BSA samples and left to incubate at room temperature for
10 minutes. Folin reagent (Sigma) was diluted 1:1 using distilled water and
added at 100 µl per tissue and BSA samples. Tissue and BSA samples were then
transferred onto a 96 well plate at 200 µl per well and allowed 45 minutes at
room temperature for the Folin reagent to react with Lowry AB solution until
development of the characteristic blue colour of samples. The colour density
depends on the protein concentration present in the sample. The 96 well plate
was loaded onto a Dynex MRX Model 96 well plate reader (MTX Lab Systems
Inc., USA) which was used to colorimetrically detect the protein concentration
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within the samples. Revelation software (MTX Lab Systems Inc., USA) was
used to analyze the colorimetric reading and provided the protein concentration
value for each sample. Details of solutions used in sample preparation and
protein quantification are described in Appendix I.
3.2.8.2. Protein separation
The solubilised samples were warmed on a heating block at 95°C for 5 minutes,
vortexed (5 min), centrifuged (1300 rpm, 1 min) and loaded onto a 16% SDS-
polyacrylamide gel. Samples were run in parallel to 15µl of a molecular weight
marker (PageRuler plus Prestained protein ladder manufactured by Fermentas
UAB, Lithuania). Proteins were separated for 45 minutes (200 V at room
temperature) with SDS-gels immersed in electrophoresis buffer. The protein
separation was followed by transfer of proteins from the gel onto a nitrocellulose
membrane for 90 minutes (200V at 4°C) in transfer buffer. Ponceau solution
(Sigma, UK) was used to confirm successful transfer of protein to the
nitrocellulose membrane. Details of solutions used in this step are described in
Appendix I.
3.2.8.3. Protein transfer and band detection
Nitrocellulose membranes were blocked with a 5% milk solution (dried milk
powder dissolved in Tris-buffered saline-Tween 20 (TBST) while shaking (1
hour at room temperature). All primary and secondary antibody dilutions were
prepared in 5% milk solution. Membranes were incubated for 60 minutes on a
constant shaker at room temperature with the following primary antibodies:
polyclonal rabbit doublecortin (DCX) (1:1000; Cell Signalling Technology,
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USA) and polyclonal rabbit BDNF N-20 (BDNF) (1:500; Santa Cruz, USA).
Membranes were washed 3 times for 5 minutes each using TBST. Afterwards, all
membranes were incubated with different secondary antibodies according to the
method used for detecting protein bands. For visualization using the Odyssey
system, membranes were incubated with fluorescent ®-conjugated secondary
antibody, polyclonal goat anti-rabbit IgG (LICOR Bioscience, UK; 1:10000
dilution of 1 mg/ml stock in 10 ml of antibody dilution buffer with gentle shaking
for 1 hour at room temperature).
Membranes were washed again in the same way following primary antibody
incubation and rinsed with distilled water to prepare them for protein detection.
Membranes were drained of excess fluid and allowed to dry just before scanning.
Membranes were scanned using the infra-red Odyssey imaging system (LICOR
Bioscience, UK).
For protein bands detection with the ordinary ECL (enhanced
chemiluminescence) detection method, membranes were incubated with
polyclonal goat anti-rabbit horse radish peroxidase (HRP)-conjugated secondary
antibody (1:2000; DAKO Cytomation, Denmark) on a shaker for one hour at
room temperature. Membranes were then washed in a similar way as after
primary antibodies and rinsed with distilled water in preparation for band
detection. Solutions from the chemiluminescence’s kit (Amershham, GE
Healthcare, UK) were applied onto the membranes for one minute then dried with
filter paper. Membranes then were sealed in developing cassettes with
photographic film (Kodak) in a dark room. After 10 minutes, the film was
developed, rinsed with distilled water, fixed and left to dry.
3.2.8.4. The control protein
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Glyceraldehyde 3- phosphate dehydrogenase (GAPDH; 37 kiloDaltons), a
constitutively expressed housekeeping gene, was used as a loading control
against which values of BDNF (15 kiloDaltons) and DCX (47 kiloDaltons)
protein bands were normalized. GAPDH was immunoblotted on BDNF/DCX-
containing membranes by incubating them with mouse GAPDH primary antibody
(Abcam, UK). For the Odyssey method, secondary antibody was then incubated
(IRD 700 ®-conjugated secondary antibody polyclonal goat anti-mouse IgG
(LICOR Bioscience, UK; 1:10000) and the same protocol as described above was
continued. For the ECL detection method, secondary antibody was polyclonal
rabbit anti-mouse HRP-conjugated secondary antibody (1:2000; DAKO
Cytomation, Denmark) then the same protocol was continued.
3.2.8.5. Quantification and data analysis
18 hippocampal or frontal cortex tissue samples from both vehicle and
5-FU+LCV chemotherapy group (10 controls and 8 5-FU) were run on one gel
and the assay was repeated 3 times. Quantitative measurement of protein level
was performed using (LI-COR Bioscience, USA) software specialized for the
Odyssey infrared viewing images by measuring the infrared wave length of the
protein band against the black background of the scanned area (700 nm wave
length florescence is shown in red channel and 800 nm fluorescence wave length
is shown in green channel). For ECL detection method, quantitative measurement
of protein level was performed using the Quantity One 1-D analysis software
(BioRad Laboratories, USA) by measuring the optical density (OD) of the protein
band against the light coloured background of the photographic film. The values
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for BDNF and DCX for each sample were divided by their corresponding
GAPDH value which was run on the same gel and the product was then
multiplied by 100. The percentage values of each experimental group were
averaged from the 3 trials and presented as the mean expression of BDNF and
DCX proteins as a percentage of GAPDH expression.
3.2.9. Statistical Analysis
All statistical analyses were performed using Prism Version 4.0 (GraphPad
Software Inc., USA). Weight data were analysed using repeated measures of
two-ways ANOVA with Bonferroni post-hoc test. Within-group analysis of OLR
task was done using the paired Student’s t-test to compare the mean exploratory
times of objects in the sample and choice trials. Unpaired Student’s t-test was
used for between-group analysis comparing the mean exploratory time values of
vehicle and 5-FU treated rats. OLR data were converted to percentages to
compare for the preference index (PI) between groups was analyzed by using
unpaired Student‘s t-test. Data for CER test, proliferating cell counts and
Western immunoblotting were analyzed by unpaired Student‘s t-test. P-values
less than 0.05 were considered significant (P<0.05).
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3.3 RESULTS
3.3.1. Weight
The body weight of control and drug treated rats was monitored daily throughout
the study. Rats receiving 5-FU+LCV chemotherapy exhibited a significant
decrease in weight gain during the treatment period compared to their controls
(P**=0.006), (repeated measures Two-ways ANOVA with Bonferroni post-hoc
test, Fig.3.2), although they rapidly increased in weight after the last injection.
Animals on 5-FU+LCV treatment showed a 24 hr drop in weight after each
injection which recovered during the following day.
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Figure 3.2. Body weight (Mean±S.E.M) of saline and 5-FU+LCV-treated
groups on each day (n=10 and 8 respectively). The injections are labelled on
the graph by arrows. There was a significant decrease in the amount of
weight gained by rats treated with 5-FU+LCV when compared to their
controls (p**=0.006) over the time (p**= 0.001). The interaction between the
time and the treatment factors was significant (p***<0.0001; repeated
measures two-way ANOVA with Bonferroni post-hoc test.
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3.3.2. Object location recognition test before treatment
The OLR test was carried out on all animals before treatment to ensure that they
were capable of performing the task. As shown in Fig 3.3. both groups explored
the objects in the two locations equally in the sample trial (P>0.05). After
changing one location of one object in the choice trials both groups spent
significantly more time exploring the object in the (NEW) location compared to
the object in the (OLD) location (P***=0.0001 and ***0.0006 respectively).
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Fig 3.3.A and B Exploration time (Mean±S.E.M) of rats performing the
OLR task before treatment (n=10 each). In the sample trial (un shaded), (RT
and LT locations), both controls and the group to be treated with 5-FU+LCV
spent the same amount of time exploring both locations of the objects
(RT&LT) (P>0.05). In the choice trial (dark shaded), replicas of the same
object used in the sample trial were placed in either locations (OLD or
NEW) designed the old location (OLD) or a novel location (NEW). Vehicle
treated rats or the group to be treated with 5-FU+LCV spent a significantly
more time exploring the object in the (NEW) location compared to the
(OLD) location (P***=0.0001) and (P***=0.0006) respectively. All
comparisons were calculated using paired Student’s t-test.
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3.3.3. CER test before treatment
The (CER) test was performed before treatment to ensure that all animals were
able to perform this task before starting the experiment. As shown in Fig 3.4.
There was no statistically significant difference in the amount of freezing
between control and the group to be treated with 5-FU+LCV (P>0.05).
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Fig 3.4. Freezing times (Mean±S.E.M) exhibited by the rats in each group
before treatment (n=10). There was no statistically significant difference in
the freezing times between the control and the group to be treated with 5-
FU+LCV (p>0.05; paired Student’s t-test).
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3.3.4. Locomotor activity (total distance and Mean velocity) after treatment
Locomotor activity was measured during the habituation period prior to the OLR
test after treatment. There was no significant difference in the mean velocity
(cm/sec) or in the total distance (cm) performed by the animals (P=0.3) unpaired
Student’s t-test, Fig 2.1.5. A and B) which means that 5-FU+LCV did not alter
animals’ movement during the habituation phase of the OLR test suggesting that
the changes measured during the test trials were due to true changes in behaviour
of the animals not due to restriction of their movements.
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Figure 3.5. (A) The total distance and the mean velocity (B) (Mean±S.E.M)
performed by saline and 5-FU+LCV-treated groups (n=10 and 8
respectively) during the habituation period (1 hour) of the OLR test after
treatment. There was no difference between groups in the mean velocity or
the total distance after treatment during the habituation period of the object
location recognition test (p=0.3 in both; unpaired Student’s t-test).
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3.3.5. The object location recognition test after treatment
After 5-FU+LCV treatment, animals’ spatial working memory was again tested
using the OLR test. Both saline and 5-FU+LCV- treated rats displayed similar
amounts of exploration time for both objects in the sample trial (exploring objects
in RT and LT locations indicating that the rats had no preference for either of the
objects or their locations in the box. In the choice trial, after the 5 minutes inter-
trial interval, saline- treated animals proceeded to explore the object in the new
location significantly more than the object which remained unmoved (P*=0.014,
paired Student’s t-test), Fig.3.6. However, 5-FU+LCV-treated rats showed no
significant difference in the mean exploration time between objects in the new
and old locations (P>0.05, Fig 3.6). These results indicate that animals in the
control group retained the ability to discriminate between objects that had
remained unmoved and those in a novel location but that the 5-FU+LCV
chemotherapy treatment had caused a deficit in the spatial recognition memory of
these rats. Object exploratory times in the choice trial were converted into a
preference index (PI) to allow for the between-experimental-group comparison.
The preference index of the 5-FU+LCV treated groups was significantly lower
than the preference index of the saline treated rats (as shown in Fig. 3.7 ;
P**=0.001) confirming the memory deficits caused by 5-FU+LCV chemotherapy
in those animals.
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Fig 3.6. A and B, Exploration time (Mean±S.E.M) of saline and 5-FU+LCV
treated groups in the (OLR) task after treatment (n=10 and 8 respectively).
In the sample trial (white bars), LT and RT locations, both saline and 5-
FU+LCV-treated rats spent the same amount of time exploring replicas of
an object in both locations (RT and LT) (P>0.05). In the choice trial (dark
shaded), replicas of the same object used in the sample trial were placed in
either locations (OLD or NEW). Saline-treated rats spent a significantly
greater time exploring the object in the new location (NEW) compared to the
old location (OLD) (P*=0.014).
There was no significant difference in the time spent exploring the object in
the new location compared to the old location by rats treated with 25 mg/kg
of 5-FU+LCV (P>0.05; paired Student’s t-test).
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Fig 3.7. The preference index (PI) (Mean±S.E.M) of saline and 5-FU+LCV
chemotherapy-treated rats performing the object location recognition task
(n=10 and 8 respectively). The 5-FU+LCV (25 mg/kg)-treated group had a
significantly lower PI than the saline treated (p**=0.001; unpaired Student’s
t-test).
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3.3.6. The CER test after treatment
For the CER test, freezing behaviour was recorded 24 hours after conditioning
when the animals were returned to the test box. Vehicle-treated animals spent an
average of 148 seconds in this behaviour. In contrast 5-FU+LCV treated animals
spent an average of only 70 seconds exhibiting this type of behaviour, which was
significantly less than controls; Fig 3.8, (P*=0.01; unpaired Student’s t-test).
These results indicate that the 5-FU-treated animals had poorer recognition of the
context of the unpleasant stimuli compared to control animals.
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Fig 3.8. Freezing time (Mean±S.E.M) exhibited by the rats in saline and 5-
FU+LCV-treated groups after treatment (n=10 and 8 respectively.
The 5-FU+LCV freezing time was significantly less than the freezing time for
the saline-treated rats (P*=0.01; unpaired Student’s t-test).
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3.3.7. Proliferating cell counts
Five brains from each group were analysed and 12 sections, distributed along the
length of the hippocampus, were stained from each brain. Ki67-positive cells
were easily identified in the SGZ adjacent to the dentate gyrus. Figure 3.9 (A; B;
C) displays representative images of Ki67-positive cells in sections counter-
stained with the nuclear dye PI. Only cells which had both a red PI stained
nucleus and nuclear Ki67 staining were counted. 5-FU+LCV-treated rats had a
significantly lower number of positive Ki67 proliferating cells within the SGZ
compared to the saline-treated group (P*=0.03, unpaired Student’s t-test,
Fig.3.10), indicating that the number of proliferating cells in the SGZ is reduced
after 5-FU+LCV chemotherapy.
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Figure 3.9. Representative images of rat dentate gyrus by fluorescent
microscopy (A) Ki67- positive cells (circled) on the edge of the dentate gyrus.
(B) Propidium Iodide (PI) nuclear staining showing all nuclei. (C) Merged
image of A and B. Regions of the DG are highlighted: granule cell layer
(GCL); sub-granular zone (SGZ) and the hilus (HILUS). All images were
taken at x40 magnification.
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Figure 3.10. Ki67-positive cell counts in the dentate gyrus (Mean±S.E.M) of
the saline and 5-FU+LCV-treated rats (n=5 each). There was a significant
decrease in the mean numbers of Ki67-positive cells in the 5-FU+LCV-
treated rats compared to the saline-treated rats (p*=0.03; unpaired
Student’s t-test).
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3.3.8. Western blot results
Levels of DCX and BDNF proteins were measured in the hippocampus and
frontal cortex to determine whether the 5-FU+LCV-induced memory deficits
could be attributed to changes in a measure of neurogenesis (DCX) or in the
levels of a neurotrophic factor (BDNF) known to be involved in memory and
neurogenesis.
3.38.1 Levels of DCX and BDNF proteins in the hippocampus.
5-FU+LCV treatment produced a trend (non-significant) towards a reduction in
DCX levels in the hippocampus (P=0.1, unpaired Student’s t-test, Fig 3.11.A).
The same treatment also produced a non-significant decrease in the level of
BDNF protein as compared to the saline-treated animals (P*=0.09; unpaired
Student’s t-test, Fig 3.11.B).
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Figure 3.10. A, B, C and D. Representative Western immunoblots of rat
hippocampal tissue. (B) Protein bands at the molecular weight
corresponding to doublecortin (DCX) protein are indicated at 47 kiloDaltons
(kDa) using the Odyssey system. On the same blot, corresponding levels of
GAPDH protein from same samples using Odyssey system are shown (A).
(D) Representative Western immunoblot of hippocampal BDNF protein
bands are indicated at 15 KiloDalton (KDa) using the ELC developing
system. On the same blot, corresponding levels of GAPDH protein from
same samples using ELC method were shown (C). GAPDH was used as a
loading control to ensure that equal amounts of proteins were loaded in each
well (n=8-10).
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Figure 3.11. A and B. Graphs represent levels of DCX and BDNF
respectively in the hippocampus (Mean±S.E.M; n= 10-12). There was no
significant difference in the levels of DCX protein in the hippocampus
between the saline-treated and the 5-FU+LCV-treated groups (P=0.1;
unpaired Student’s t-test). BDNF protein levels in the 5-FU+LCV treated
group was not significantly decreased compared to the saline-treated group
(P=0.09; unpaired Student’s t-test). Data are the mean intensity/OD of either
DCX or BDNF protein bands displayed as a percentage of the corresponding
value of the GAPDH loading protein.
(B) Hippocampal BDNF protein
(A) Hippocampal DCX protein
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3.3.8.2. Levels of DCX and BDNF proteins in the frontal cortex
In the frontal cortex, DCX levels were not significantly decreased by 5-FU+ICV
chemotherapy when compared to saline-treated animals (P=0.2, unpaired
Student’s t-test, Fig 3.12 (A). However, frontal cortex tissue levels of BDNF
were significantly decreased due to 5-FU+LCV chemotherapy compared to the
saline treated rats (P**=0.005, unpaired Student’s t-test, Fig 3.12. (B)
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Figure 3.12 (A) Graph represents levels of the DCX protein in the frontal
cortex (Mean ±S.E.M; n= 10-15). Although decreased, there was no
significant difference in the levels of DCX protein between the saline treated
and the 5-FU+LCV treated groups (P=0.2; unpaired Student’s t-test).
(B) Graph represents BDNF levels in the frontal cortex which were
decreased significantly by 5-FU+LCV treatment (P**=0.005; unpaired
Student’s t-test) compared to the saline-treated rats. Data are the mean
intensities/OD of DCX and BDNF protein bands displayed as a percentage of
the corresponding wave length of the GAPDH loading protein.
(B) BDNF levels in the frontal cortex
(A) DCX levels in the frontal cortex
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3.4. DISCUSSION
The reported incidence of cognitive problems associated with chemotherapy is
very high (Moleski 2000; Wefel, Lenzi et al. 2004; Shilling, Jenkins et al. 2005).
These cognitive deficits, as described by patients, mostly affect their memory,
attention and information processing abilities. The verbal, spatial working and
the recognition aspects of memory, which are mediated by the hippocampus, are
considered the most vulnerable parameters in chemobrain sufferers (Reed and
Squire 1997; Carrozzo, Koch et al. 2005; Grunwald and Kurthen 2006). The
present study aimed to use an animal model to investigate the effect of
systemically administered 5-FU chemotherapy on hippocampal memory tasks
and to correlate these with changes in DCX and BDNF protein levels in the
hippocampus and with different measures of hippocampal neurogenesis.
Treatment involved two weeks of 5-FU+LV injections (5 injections; 25mg/kg)
into the tail vein followed by behavioural testing which started one day after the
final injection.
3.4.1. 5-FU chemotherapy decreased weight gain but did not affect locomotor
activity.
There was a significant decrease in the amount of weight gained by rats treated
with 5-FU+LCV during the treatment period when compared to the saline treated
rats (Fig.3.2). This is a common observed effect of systemically administered 5-
FU (Lee, Kim et al. 2006) and is attributed to the cytotoxic effect of the 5-FU on
the proliferating cells of the gastrointestinal tract lining which reduces its ability
to absorb nutrients (Huang, Kemp et al. 2002). Animals rapidly gained weight
after the end of the treatment.
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The measurement of the mean velocity and the total distance travelled by the 5-
FU+LCV-treated rats (locomotor activity parameters, Fig 3.5.A and B) over the
course of 1 hour prior to behavioural testing, did not show any difference from
the same parameters measured in the saline-treated group. This indicates that the
deficits which occurred in the performance of the behavioural tests in the 5-
FU+LCV-treated rats were not attributed to a reduction in their locomotor
activity compared to the saline treated rats. This is important as behavioural
changes produced by the anti-mitotic drug methylazoxymethanol acetate (MAM)
have been suggested to be due to reduced movement (Dupret, Montaron et al.
2005).
3.4.2. 5-FU altered the spatial memory of the rats
Hippocampal memory function was initially measured by testing the rats using
the OLR behavioural test. The OLR test is a non-stressing spatial recognition
memory testing for rats (Mustafa, Walker et al. 2008) which uses the
hippocampus and requires an intact dentate gyrus of the rat to be able to perform
this task (Lee, Hunsaker et al. 2005). Both control and drug-treated groups could
successfully perform this test prior to the start of treatment. 5-FU+LCV
treatment however significantly impaired the ability of animals to remember the
locations of objects as shown by their failure to spend more time on the object in
the novel location (Fig.3.6). This impairment in spatial memory was further
analysed by conversion of the exploratory activity data into preference indices
which also showed a significant difference between treated and control groups
(Fig.3.7).
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Apart from an earlier paper from our research group, the OLR test has not been
used to examine the effects of chemotherapy on cognition (Mustafa, Walker et al.
2008). Several groups have used a related test, the object recognition test (ORT),
which tests the ability of rats to recognise that the appearance of an object has
changed without any change in its location (Ennaceur and Delacour 1988).
Treatment of rats with the chemotherapeutic drug methotrexate (Seigers, Schagen
et al. 2008) or the anti proliferative and cytotoxic drug MAM (Bruel-Jungerman,
Laroche et al. 2005), produced a deficit in the ORT task. Both tests (ORT and
OLR) require an intact hippocampus but the OLR has been shown to specifically
require the dentate gyrus (Lee, Hunsaker et al. 2005). The OLR results presented
here are in line with earlier work from our group which showed that a lower dose
of 5-FU+LCV (20mg/kg) caused significant deficits in the performance of this
task (Mustafa, Walker et al. 2008) and suggest that a general effect of anti-
proliferative drugs may be to produce deficits in this type of memory task. The
specificity in the requirement of the OLR test for an intact dentate gyrus strongly
suggests that this part of the hippocampus is at least one of the brain regions
adversely affected by 5-FU.
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3.4.3. 5-FU impaired the contextual fear conditioning of the rats
The CER test as carried out here, measures recall of the context of an unpleasant
stimulus after a 24 hour interval. Memory is quantified by the amount of freezing
behaviour exhibited by the animal on being returned to the same arena (context)
as the delivery of the unpleasant stimulus. Our results showed that treatment with
5-FU+LCV significantly reduced the amount of time animals spent in a freezing
posture when returned to the arena compared to saline treated animals, indicating
a failure in the recall of the context of this experience. (Fig.3.8). Performance of
the CER behavioural test, where the stimulus is paired to a context, is impaired
by hippocampal lesions (Matus-Amat, Higgins et al. 2004) but is also thought to
involve input and modulation from other brain structures, notably the amygdala
and anterior cingulate gyrus, which are involved in the emotional and nociceptive
aspects of the test (Huff and Rudy 2004; McGaugh 2004; Malin and McGaugh
2006). If the unpleasant stimulus is paired with a tone (cued fear conditioning),
hippocampal lesions have much less effect on performance indicating that the cue
specific response is largely mediated only by the amygdala (Kim and Fanselow
1992; LeDoux 2000). Clinically it has been shown that sustained contextual
anxiety is associated with an increase in cerebral blood flow in the right
hippocampus (Hasler, Fromm et al. 2007) and the CER rodent test as performed
here is a good measure of human hippocampal-dependent declarative memory
(Maren, Aharonov et al. 1997; Rudy, Huff et al. 2004). From the above, it is
clear that the CER test, although not as specific to the dentate gyrus as the OLR
test, is still testing hippocampal function.
The CER test has been used more frequently than the OLR test in examining the
cognitive effects of chemotherapy or other mitotic inhibiting drugs; MAM (Ko,
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Jang et al. 2009); MTX and 5-FU (Gandal et al 2008); cyclophosphimide and
doxorubicin (Macleod et al. 2007); cyclophosphimide (Reiriz et al 2006).
Although doses and administration vary significantly between studies, only two
of these investigations found that drug treatment caused a deficit in the
performance of the CER test (Macleod et al. 2007; Reiriz et al. 2006).
The present investigation is the first to demonstrate that 5-FU+LCV treatment
can impair performance in this test and together with the OLR test, supports the
idea that drug treatment is affecting the hippocampus. The CER result from this
chapter has recently been published (ElBeltagy, Mustafa et al. 2010).
3.4.4. 5-FU decreased proliferating cell counts in the hippocampus
One of the hypotheses of this investigation was that chemotherapy might be
reducing the levels of cell proliferation in the SGZ of the dentate gyrus and in this
way affect the formation of hippocampal dependent memories (Madsen,
Kristjansen et al. 2003) . Because changes in human neurogenesis are not
detectable clinically, it was important to use an animal models to test this. In the
present study, 5-FU chemotherapy significantly reduced the number of
proliferating (Ki67 positive) cells in the dentate gyrus of the hippocampus of
adult rat brains compared to the saline treated rat brains (Fig.3.10). This result
provides significant support for this hypothesis and a mechanism which may be
contributing to the cognitive deficits experienced by patients. Proliferating cells
in the SGZ can be either dividing stem cells or transit amplifying cells (Fig.3.9.A
and C). Neural stem cells are slow dividing cells and most dividing cells in the
SGZ are rapidly dividing transit amplifying cells which are often found in small
clusters as shown in (Fig 3.9 A and C) (Kempermann, 2006). It is likely that
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most of the reduction in dividing cells seen is due to a reduction in proliferating
transit amplifying cells.
An earlier study from our group (Mustafa et al. 2008) found a non-significant
reduction in Ki67 positive cell numbers in the SGZ after a lower dose of
5-FU+LCV (20mg/kg). Together with the present results this shows that the
reduction in cell proliferation is dose-dependent.
Several other investigators have looked at the effects of antimitotic drugs on cell
proliferation in the SGZ. These have included the cytotoxic drug MAM (Ko,
Jang et al. 2009); which produced significant reductions in cell proliferation.
Chemotherapeutic drugs, e.g MTX (Seigers et al. 2008); BCNU, cisplatin and
cytarabine (Dietrich et al. 2006); thioTEPA (Migone and Weber 2006) and 5-FU
(Han et al. 2008) have also been investigated in this way. All of these drugs
caused a reduction in cell proliferation but only (Seigers et al. 2008) have
previously correlated this change with changes in cognitive behaviour. As well as
showing a dose-dependent effect of MTX on cell proliferation. These authors
found that high doses of this drug impaired the performance of rats in the Morris
water maze test.
A post-mortem study which was done by (Monje, Vogel et al. 2007) has provided
evidence that patients undergoing chemotherapy treatment for tumours in their
CNS show reduced hippocampal neurogenesis, particularly a dramatic reduction
in the immature neurons suggesting that neurogenesis is severely affected. We
have shown that treated rats with 5-FU+LCV chemotherapy displayed
significantly reduced numbers of proliferating cells in the dentate gyrus of the
hippocampus by using the proliferative marker Ki67 (ElBeltagy, Mustafa et al.
2010) . Furthermore, it has been reported that adult neurogenesis is the most
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likely target of 5-FU chemotherapy (Mustafa, Walker et al. 2008). These findings
are in line with the current results obtained from this study which strengthen the
idea of the possible association between the memory impairments and the 5-FU
induced reduction in hippocampal neurogenesis.
3.4.5. 5-FU chemotherapy reduced BDNF levels in frontal cortex not in the
hippocampus
In the present study, although there was a tendency towards reduction of the
BDNF levels in the hippocampus of the 5-FU+LCV treated rats compared to the
saline treated ones, this reduction was not significant (Fig.3.11.B). The effect of
5-FU chemotherapy on BDNF levels seems to be regionally specific as the frontal
cortex BDNF levels were significantly reduced (Fig.3.12.B). Previously, it was
reported that BDNF levels in the frontal cortex of dopamine transporter knockout
mice were reduced as brain plasticity (which depends on the brain dopaminergic
system) also requires BDNF (Fumagalli, Racagni et al. 2003). Moreover, it was
found that there is a strong relationship between the deteriorated memory and
reduced levels of frontal cortex BDNF in mice tested for their performance in the
water radial-arm maze (Bimonte-Nelson, Hunter et al. 2003). It is possibly that
5-FU chemotherapy targets neurons within the dentate gyrus because BDNF
mRNA expression is prevalent in the granular cell layer of the dentate gyrus
(Wetmore, Ernfors et al. 1990; Conner, Lauterborn et al. 1997). However, it was
reported that there might be different roles of endogenous BDNF splice variants
in protecting neuroblastoma cells from death induced by chemotherapy (Baj and
Tongiorgi 2009) which might give a reason why BDNF level was reduced in
frontal cortex but not in the hippocampus of 5-FU treated rats. Furthermore, it
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was found that BDNF neurotrophic activation of TrkB protects neuroblastomas
cell from chemotherapy-induced cell death via the phosphatidylinositol 3'-kinase
pathway (Jaboin, Kim et al. 2002) and because there are many other suggested
pathways by which BDNF might be involved in brain response to chemotherapy,
it is possibly that the effect of 5-FU chemotherapy on BDNF protein level is
regionally specific.
Another issue was raised in this study, which was the use of the CER as a test for
contextual conditioning of rats as there is strong relationship between stress and
elevated corticosteroid levels in the brain (de Kloet, Oitzl et al. 1999). The
pairing of foot shocks with the context is stressful for animals which leads to
elevated levels of corticosteroids (Davis 1997; Korte 2001). It has been proposed
that BDNF levels did not change in rat hippocampus with elevated corticosteroid
levels (Schaaf, De Kloet et al. 2000). Moreover, it has been found that
eosinophils BDNF levels were not dramatically reduced by dexamethasone
treatment in asthmatic patients (Noga, Hanf et al. 2005). From these findings, we
decided not to test rats for the CER test in future experiments especially that it
has been reported that stress could affect the level of hippocampal neurogenesis,
our main target in future experiments (Lee, Kim et al. 2006).
3.4.6. 5-FU chemotherapy did not change DCX levels in the hippocampus or
frontal cortex.
In the present study, 5-FU+LCV+LCV chemotherapy didn’t change the DCX
levels in the hippocampus (Fig.3.11.A) or in frontal cortex (Fig.3.12.A). DCX is
detected early in embryonic life and further expressed at high levels in most cells
of the developing brain. Although expressed during neuronal development, DCX
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is no longer expressed after neuronal maturation is completed. However, in the
adult mammalian nervous system, its expression does still continue in restricted
areas such as the dentate gyrus of the hippocampus and the lateral wall of the
olfactory bulb axis which illustrates the continuous neurogenesis in the adult
brain in these areas (Brown, Couillard-Despres et al. 2003; Couillard-Despres,
Winner et al. 2005). DCX expression in neurons is transient and present
throughout stages of final mitosis of neurogenic precursors and their
differentiation while Ki67 is an endogenously expressed proliferative marker
expressed in all stages of the cell cycle except G0 phase (Kempermann 2006).
Therefore, the lack of DCX changes in the present study may suggest that 5-FU
chemotherapy targets late stages of proliferation especially since there was a gap
between the last 5-FU+LCV treatment and termination of the study (the period of
behavioural testing). This possibility was consistent with the studies of Chapter 4
and 5 which showed that 5-FU neurotoxicity requires at least 2 weeks to occur
(ElBeltagy, Mustafa et al. 2010). As discussed above, the unchanged levels of
BDNF protein between controls and 5-FU+LCV treated animals could be
attributed to the stress to which animals were exposed during the CER test. The
same reason could be addressed for the unaffected DCX levels in either
hippocampus or frontal cortex. There is evidence that chronic mild stress or the
stress caused by transient ischemia in the brain elevate numbers of DCX
immunoreactive cells in the dentate gyrus of the hippocampus of rats which
highlights that stress could modulate DCX in the hippocampus even in the
opposite way to chemotherapy (Nakatomi, Kuriu et al. 2002; Tanaka, Yamashiro
et al. 2004).
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3.5. CONCLUSION
The results from this study indicated that 5-FU+LCV chemotherapy produces
deficits in memory tasks dependent on the hippocampus of adult rats as measured
by the OLR and CER tests. These deteriorations were strongly related to the
reduction in the amount of neurogenesis of the 5-FU-treated rats compared to the
saline-treated ones. However, this study failed to resolve the effect of
chemotherapy on the neurotrophic factor, BDNF or the immature neuronal
marker, DCX in regulating neurogenesis. The next chapter shows the effects of
the antidepressants, namely fluoxetine, on memory and neurogenesis of the adult
male hippocampus which will help in establishing the possible protective role of
antidepressants against chemotherapeutic-induced deficits in a rat model.
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CHAPTER 4
Fluoxetine reverses the memory deficits caused by the
chemotherapy agent 5-Fluorouracil
4.1 INTRODUCTION
Systemic adjuvant chemotherapy is used in the treatment of many cancers
including breast cancer. For some time breast cancer patients have reported that
chemotherapy can have negative effects on cognition, a phenomenon which has
led to the use of the terms “chemobrain” or “chemofog” (Anderson-Hanley,
Sherman et al. 2003; Myers 2009). This together with the realisation that many
chemotherapy agents can cross the blood brain barrier has led to cross sectional
and longitudinal studies of patient cognition during and after chemotherapy has
been carried out. The majority of these studies have shown mild to moderate
cognitive deficits as reviewed in (Collins, Mackenzie et al. 2009). In particular
four meta-analyses of the literature have concluded that working, visual and
verbal memory appear to be consistently affected in patients who have completed
a course of chemotherapy (Anderson-Hanley, Sherman et al. 2003; Falleti,
Sanfilippo et al. 2005; Jansen, Miaskowski et al. 2005; Stewart, Bielajew et al.
2006).
A treatment for “chemobrain” would provide significant benefits to the large
number of cancer survivors who have had chemotherapy. Development of such a
treatment would be helped, if it was understood what the underlying causes were
and why the condition persists after the end of chemotherapy. This question has
attracted numerous suggestions reviewed in the following literatures (Barton and
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Loprinzi 2002; Saykin, Ahles et al. 2003; Verstappen, Heimans et al. 2003;
Jansen, Miaskowski et al. 2005; Ahles and Saykin 2007; Taillibert, Voillery et al.
2007; Dietrich, Monje et al. 2008; Wefel, Witgert et al. 2008; Soussain, Ricard et
al. 2009; Chamberlain 2010).
No agreement has however been reached on the cause of chemobrain leading
Saykin et al. to state “the greatest gap in our knowledge regarding chemotherapy-
related cognitive changes is a lack of understanding of the mechanism or
mechanisms that account for the observed changes” (Saykin, Ahles et al. 2003).
Numerous suggestions that have been put forward from both human and animal
studies and these have included the following:
Inhibition of hippocampal neurogenesis: (Dietrich, Han et al. 2006; Han, Yang
et al. 2008; Mustafa, Walker et al. 2008; Seigers, Schagen et al. 2009);
neuroinflammation: (Hook, Kimmel et al. 1992; Chen, Hinton et al. 1994;
Cleeland, Bennett et al. 2003; Tangpong, Cole et al. 2007; Han, Yang et al. 2008;
Seigers, Timmermans et al. 2010); damage to the brain micro vasculature:
(Merkle, Moore et al. 2000; Dietrich, Marienhagen et al. 2004; Rzeski, Pruskil et
al. 2004; Moore, Merkle et al. 2006); anaemia: (Cunningham 2003); damage to
white matter tracks (leukencephalopathy) including demylination and death
of oligodendrocytes and their precursors: (Akiba, Okeda et al. 1996; Brown,
Stemmer et al. 1998; Choi, Lee et al. 2001; Moore, Somers et al. 2002; Cho, Choi
et al. 2004; Yamashita, Yada et al. 2004; Dietrich, Han et al. 2006; Inagaki,
Yoshikawa et al. 2007; Abraham, Haut et al. 2008; Baehring and Fulbright 2008;
Han, Yang et al. 2008); induced menopause or hormonal changes: (Bender,
Paraska et al. 2001; Shilling, Jenkins et al. 2003; Tchen, Juffs et al. 2003; Fan,
Houede-Tchen et al. 2005; Bender, Sereika et al. 2007; Hermelink, Henschel et
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al. 2008); metabolic changes including glucose metabolism and oxidative
stress: (Silverman, Dy et al. 2007; Joshi, Aluise et al. 2010).
Reflecting the uncertainty in the cause of chemotherapy induced cognitive
deteriorations, a wide range of possible treatments have been suggested, reviewed
in (Gehring, Sitskoorn et al. 2008). These have included cognitive behavioural
or psychological therapies (Cimprich and Ronis 2003; Biegler, Chaoul et al.
2009; Poppelreuter, Weis et al. 2009), acupuncture (Johnston, Yang et al. 2007),
pharmaceutical interventions including erythropoietin (O'Shaughnessy 2003;
Chang, Couture et al. 2004; Fan, Park et al. 2009), pychostimulants such as
methylphenidate and mondafinil (Rozans, Dreisbach et al. 2002; Mar Fan,
Clemons et al. 2008; Kohli, Fisher et al. 2009); glutamate receptor antagonists
(Rzeski, Pruskil et al. 2004), and stem cell treatment (Noble and Dietrich 2002).
Results from these interventions have been variable, where patient trials have
been carried out, some are open label and may suffer from placebo or practice
effects and none appears to have been taken up in general clinical practice.
In this thesis, the hypothesis is that the cognitive deficits produced by
chemotherapy are, at least in part, caused by a reduction in hippocampal
neurogenesis. With this in mind, an intervention which would increase
hippocampal neurogenesis and cognition was sought. There is good evidence
that antidepressants can fulfil these criteria especially the selective serotonin
reuptake inhibitors (SSRIs) such as fluoxetine (Malberg, Eisch et al. 2000;
Herrera-Guzman, Gudayol-Ferre et al. 2009). Fluoxetine is one of the most
commonly prescribed antidepressants which inhibit serotonin reuptake from the
synaptic cleft (Wong, Bymaster et al. 1995). Moreover, a number of human
studies have found that treatment with fluoxetine, can improve cognition and
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memory in patients suffering from mild to moderate cognitive impairment
(Cassano, Puca et al. 2002; Horsfield, Rosse et al. 2002; Levkovitz, Caftori et al.
2002; Mowla, Mosavinasab et al. 2007). The improvement in memory appears to
be independent of depressive symptoms and the original causes of cognitive
decline. One study of human post-mortem material has also shown that
antidepressants including, fluoxetine, increase hippocampal cell proliferation in
the SGZ of the dentate gyrus (Boldrini, Underwood et al. 2009). Similarly,
animal studies have shown that chronic but not acute treatment with fluoxetine
improves cognition and increases neurogenesis in the SGZ (Kodama, Fujioka et
al. 2004; Chen, Pandey et al. 2006; Marcussen, Flagstad et al. 2008; Monleon,
Vinader-Caerols et al. 2008).
The present chapter investigates whether treatment with fluoxetine can prevent
the cognitive and cellular changes produced by 5-FU treatment. As shown in
Chapter 3, in the present study we further demonstrate that 5-FU causes
impairments in spatial memory as demonstrated by the OLR behavioural test, and
reduces the number of the proliferating cells in the SGZ. Co-administration of
fluoxetine, however reduced the impact of these cognitive deficits and prevented
the decrease in cell proliferation in the SGZ. As BDNF is implicated in the
neuroprotective and neurogenesis-promoting effects of antidepressants (Duman,
Nakagawa et al. 2001), BDNF levels in the hippocampus were measured to test
the effect of chronic 5-FU+LCV chemotherapy and fluoxetine on this growth
factor. Also it has been reported that antidepressant treatment increases
expression of phosphorylated cyclic-AMP response element binding protein
(pCREB) and PSA-NCAM in the hippocampus both of which proteins are
expressed in newborn neurons (Sairanen, O'Leary et al. 2007). In the present
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study, the effect of fluoxetine and 5-FU+LCV chemotherapy on hippocampal
levels of DCX, another protein expressed by newborn neurons, was also
determined. Both chemotherapy and antidepressants may be altering
hippocampal function and an understanding of this may provide a mechanism for
improving cognition during cancer treatment. Results from this chapter have
recently been published (ElBeltagy, Mustafa et al. 2010).
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4.2 MATERIALS AND METHODS
4.2.1. Animals, drug administration.
Adult male Lister Hooded rats (Charles River UK) of 150-170gms at the start of
experiments were maintained in the BMSU and weighed daily. Animals were
allowed to habituate for 2 weeks before treatment and housed in groups of 4
under standard conditions of 12-h light – 12-h dark cycle (From 8.30am to 8.30
pm) with free access to food and water. Behavioural testing of all animals was
performed one day after the end of drug treatment between (8.30am and 2pm).
Doses given of 5-FU are the standard doses used to investigate the effects of
5-FU and are within the range which reduces tumour load in rats (Au et al 83;
Watson et al 98) and are equivalent to the human dose range (Reagan, Nihal et al.
2008).
45 rats were randomly assigned to 4 groups (saline (n=12), 5-FU+LCV (n=12),
fluoxetine (n=11) and combined 5-FU and fluoxetine treated (n=10). 5-FU+LCV-
treated animals received 6 intravenous (i.v) bolus injections of 5-FU
20mg/kg/day (MAYNE Pharma PLC) together with leucovorin, 20mg/kg/day
(TEVA UK LTD) i.v. under isoflurane anaesthesia every other day over two
weeks. Saline-treated control animals (n=12) or fluoxetine treated (n=11)
received an identical sequence of normal saline (0.9%) injections. Animals
receiving fluoxetine (PINEWOOD Healthcare Colonel, Ireland) were given the
drug in the drinking water with a dose of 10mg/kg/day over 3 weeks (started one
week before 5-FU+LCV injection) being calculated from the amount of daily
water intake (Yau, Hibberd et al. 2002). The concentration of fluoxetine given in
drinking water was calculated to give the animals 25mg/5mls of water consumed.
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Water intake decreases with fluoxetine treatment but dosages were recalculated
every other day depending on water consumption and animal weights.
Drinking water containing fluoxetine was freely available to the animals. The
solution of fluoxetine was changed every other day.
Table 4.1. A protocol table of the study is presented above. A chronic
period of treatment lasted 21 days during which rats received injections of
5–FU+LCV chemotherapy 20mg/kg (short dotted bar, 2 weeks) and
antidepressant fluoxetine 10mg/kg/day (long dotted line, three weeks) in
drinking water. After drug treatment rats were tested for their performance
in the OLR test. One day after the OLR test, animals were killed.
Two weeks of 5-FU+LCV injections or
saline injections (days21-34)
Three weeks of Fluoxetine in drinking water
(days 15-34)
OLR Test for all animals
(days 35-48)
*Sacrifice
(days 49&50)
*Immuno-
Histochemistry
*Western blot
Habituation
days (1-14)
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4.2.2. Behavioural testing, object location recognition task
This was modified from a previous protocol (Dix and Aggleton 1999) and was
recorded by video camcorder as done previously in our laboratory (Mustafa,
Walker et al. 2008). The locomotor activity (the distance and velocity of rats) was
measured throughout the habituation period of the test. Exploratory activity of the
object was measured as described earlier (Chapter 2, section 2.1.2.3.1).
Behavioural data analysis was done as previously described (Chapter 2, section
2.1.2.6).
4.2.3. Brain tissue preparation
On the day following the OLR test, rats were killed by rapid stunning followed
by decapitation. 29 Brains from all groups were randomly chosen from animals
undergoing behavioural testing. These brains were prepared for
immunohistochemistry as previously described (Chapter 3, section 3.2.6).
A systemic random sampling technique (Mayhew and Burton 1988) was used to
choose every 21st section throughout the length of the dentate gyrus (overall 10
sections).
4.2.4. Ki67 Immunohistochemistry
Immunohistochemistry for Ki67 protein, along with sterology and microscopy for
Ki67 were carried out as described previously (Chapter 3 section 3.2.7).
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4.2.5. Western Immunoblotting of BDNF and DCX proteins
Hippocampus and frontal cortex sample preparation and determination of sample
protein concentration using Lowry assay were carried out as detailed previously
(section 3.2.7.1., Chapter 3). In the present study, a new system was used for
Western blotting to optimize the protein band signal strengths and to shorten the
time needed to obtain the final results.
This new system is the SNAP i.d, protein detection system and blotting
membranes (Millipore, UK) which unlike conventional Western blotting, where
diffusion is the primary means of reagent transport, the SNAP i.d. system applies
a vacuum to actively drive reagents through the nitrocellulose membrane.
After protein separation was done as previously described (section 3.2.7.2.,
Chapter 3), nitrocellulose membranes were placed directly in the SNAP i.d.
champers and blocked in 0.5% Fish Gelatine Buffer (NBS, Biologicals, Ltd, UK)
for 20 seconds. All primary and secondary antibody dilutions were made in the
same blocking solution. Primary antibodies (polyclonal rabbit doublecortin
(DCX) (1:1000; Cell Signalling Technology, USA) and polyclonal rabbit BDNF
N-20 (BDNF) (1:500; Santa Cruz, USA). were then poured over the
nitrocellulose membranes into two different chambers for each antibody for 10
minutes. Membranes then washed with Tris-buffered saline-Tween 20 [TBST]
(Appendix I) 3 times 20 seconds each. After this, membranes were incubated
with secondary antibodies (fluorescently -conjugated secondary antibody,
polyclonal goat anti-rabbit IgG [LICOR Bioscience, UK; 1:10000 dilution of 1
mg/ml stock in 5 ml of antibody dilution buffer (fish gelatine buffer) at room
temperature] in the same chambers for 10 minutes while keeping the chambers in
an aluminium foil wrapped box to protect the nitrocellulose membranes from
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light which could interfere with the infra-red detection method used to visualise
the protein bands. Secondary antibodies were removed by washing using Tris-
buffered saline-Tween 20 [TBST] 3 times 20 seconds each. The control protein
was used as described previously (section 3.2.7.4, Chapter 3) and was incubated
with each nitrocellulose membrane separately in each chamber of the SNAP i.d.
system to avoid cross reaction between antibodies. Finally, membranes were
drained of excess fluid and allowed to dry just before scanning. Membranes
were scanned using an appropriate filter on the infra- red Odyssey imaging
system (LICOR Bioscience, UK). Quantification and data analysis were carried
out similar to that in chapter 3 section 2.7.5 except that 12 hippocampal (3 from
each group) or 8 frontal cortex tissue samples (2 from each group) were run on
one gel and the experiment was repeated 3 times.
4.2.6. Statistical Analysis
All statistical parameters were calculated using Graph pad Prism 4.0 software,
USA. Paired student t- test (two-tailed) and repeated- measures of ANOVA were
used to analyse data of the OLR task. Weight and water intake data were
analysed using repeated measures Two-way ANOVA.
One- way ANOVA with Bonferroni post-hoc test was used to analyse data of the
proliferating cell count, the preference index, Western immunoblotting data, the
mean velocity and the total distance moved by the animals. A probability level
of P<0.05 was considered statistically significant
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4.3 RESULTS
4.3.1. Body weight of rats
Animals were weighed daily. Animals on 5-FU+LCV showed a weight loss
during drug administration and, although they showed improved weight gain after
the end of drug treatment (data not shown), they were still significantly below
control weights (P**=0.007, repeated measures of Two-way ANOVA, Fig.4.2).
Animals on fluoxetine or fluoxetine and 5-FU+LCV were significantly lighter
than controls during drug administration but recovered to control weights by the
end of the experiment. Animals on 5-FU+LCV showed a 24 hr drop in weight
after each injection which recovered in the following day. Animals treated with
fluoxetine also put on less weight than controls.
136
fluoxetine 21 End (34)
300
350
400
450
500
550
Saline 5FU+LCV
5FU+LCV&fluoxetine
fuoxetine
injections
Days
B
o
dy
w
ei
gh
ts
(g
)
Figure 4.2. Body weight for each experimental group (Mean±S.E.M; n=10-
12) were measured daily throughout the course of treatment (fluoxetine and
5-FU+LCV). There was a significant difference across all groups due to
treatment (P**=0.007) over the period of time (p***<0.0001). Also the
interaction between time and treatment was highly significant (p***<0.0001;
repeated measures Two-way ANOVA with Bonferroni post-hoc test). There
was significant reduction in the mean body weight of fluoxetine, 5-FU+LCV
or fluoxetine&5-FU+LCV-treated groups compared to the saline-treated
group during the treatment period. On the graph, injections (arrows) are
indicated and on the X axis, the start of fluoxetine and the end of drug
treatment are indicated.
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4.3.2. Water intake
Water bottles of each cage were weighed daily during the period of fluoxetine
treatment (3 weeks) and the amount of water intake was calculated and averaged
for each experimental group. Fluoxetine was changed in the water bottle every
other day with recalculation of the dose to keep it unchanged over the chronic
course of treatment (10mg/kg/day). Fluoxetine alone or combined with 5-
FU+LCV significantly decreased the amount of water intake by the animals
compared to the saline treated animals on the following day after fluoxetine
administration (P**<0.001, repeated measures Two-way ANOVA, Bonferroni
post test, Fig. 4.3). There was no significant difference in the amount of water
intake between saline and 5-FU+LCV-treated groups (P>0.05) during the
5-FU+LCV injection period. Again there was no significant difference between
the 5-FU+LCV combined with fluoxetine and the 5-FU treated groups in the
amount of water intake during the drug treatment period (P>0.05).
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Figure 4.3. Volume of water intake for each experimental group (Mean
while S.E.M was removed for clarity; n=10-12) were observed daily
throughout the course of drug treatment (fluoxetine and 5-FU+LCV). There
was a significant difference across all groups over the chronic period of time
(P***<0.0001, repeated measures Two-way ANOVA with Bonferroni post-
hoc test). T-here was a significant reduction in the mean volume of water
intake in both fluoxetine and fluoxetine and 5-FU+LCV treated groups
compared to the saline treated group (P**<0.001) on the following day of
fluoxetine treatment. There was no significant difference in the mean volume
of water intake between saline and 5-FU+LCV treated groups (P>0.05)
during the treatment period. Also there was no significant difference
between fluoxetine only and 5-FU+LCV and fluoxetine treated groups
(P>0.05) during the treatment period. The interaction was not significant.
On the X axis, the start of fluoxetine and the end of drug treatment are
labelled. On the graph, injections (arrows) are indicated.
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4.3.3. Velocity and Distance (Locomotor activity)
Locomotor activity was measured during the habituation period prior to the OLR
test. There was no significant difference in the mean velocity (cm/sec) or in the
total distance (cm) performed by the animals (P=0.1 and 0.6 respectively, one-
way ANOVA, Fig 4.4 A and B) which means that fluoxetine on its own or
combined with 5-FU+LCV did not alter animals movement during the
habituation phase of the OLR test suggesting that the changes measured during
the test trials are due to true changes in behaviour of the animals not due to
restriction of their movements.
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Figure 4.4. (A) Mean velocity and total distance (B) (Mean±S.E.M) moved by
saline and 5-FU+LCV-treated groups (n=10-12) during the habituation
period (1 hour) of the OLR test after treatment. There was no difference
between all groups in the mean velocity or the total distance after treatment
during the habituation period of the object location recognition test (P=0.1
and 0.6 respectively; one way ANOVA with Bonferroni post-hoc test.
A
B
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4.3.4. Object Location Recognition
The OLR test measures interactions with objects either in familiar or novel
locations within a test arena. During the familiarization trial, when animals
explore two identical objects, both vehicle and drug treated groups showed no
preference for either object or the total exploration time (data not shown).
Following a 5 min inter-trial interval, one object is moved to a new location
(choice trial) and object preference is recorded. Saline-injected controls and
animals receiving fluoxetine in their drinking water both explored the novel
object location significantly more than the familiar location (P=0.01 and 0.02
respectively) (Fig.4.5). However, animals treated with 5-FU+LCV by iv
injection failed to show discrimination between objects in familiar and novel
locations (P=0.06). Surprisingly 5-FU+LCV-treated animals spent more time
examining the familiar object although this was not significantly different from
the time spent on the novel object.
Animals which had received fluoxetine in their drinking water throughout the
experiment as well as i.v injections of 5-FU+LCV spent more time exploring the
novel object but this was not significantly different from the time spent exploring
the familiar object. Further analysis using the PI was done to compare between
the four groups, see (Fig 4.6).
Comparing the PI between the control and the 5-FU+LCV-treated group
demonstrated a significant preference decrease after treatment with the
chemotherapy drug (P*<0.01). Similarly fluoxetine on its own showed a
significantly higher preference index to 5-FU+LCV treated animals (P*<0.05).
Comparing the preference index (PI) of animals treated with 5-FU+LCV on its
own and that of animals simultaneously given fluoxetine and 5-FU+LCV showed
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that co- administration of fluoxetine significantly improved preference compared
with animals on 5-FU+LCV alone (P*<0.05). These findings indicate that
animals receiving 5-FU+LCV show deficits in spatial memory which are
improved by simultaneous administration of fluoxetine.
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Figure 4.5. Exploration time (Mean±S.E.M) of groups (n=10-12) for
replicates of an object viewed in the new and the old locations. The figure
shows that the saline treated animals explored the new location (dark
shaded) significantly more than the old location (un-shaded) (p*=0.01).
Whereas the 5-FU+LCV treated animals failed to discriminate between the
new and the old objects (P=0.06). There was a non-significant increase in the
exploration time of the new object than the old one in the combined (5-
FU+LCV and fluoxetine) group (p=0.1). Concerning fluoxetine-treated rats,
their exploration of the new location was significantly greater than the old
location (p*= 0.02). The analysis was done using paired T test (two tailed) to
compare between the mean exploration time of the old and the new location
in the choice trial after treatment within each group.
*
*
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Figure 4.6. Exploration time was converted into mean preference index (PI)
(Mean±S.E.M) for each experimental group in the OLR task. The
preference index is defined as the calculated exploration time of the new
location, represented as a percentage of the combined exploration time of
both novel and familiar locations of an object. The preference index showed
a significant decrease in the 5-FU+LCV treated rats in comparison to the
other three groups (P=0.001; one way ANOVA with Bonferroni post-hoc
test.
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4.3.5. Proliferating Cell Counts
As shown in Fig 4.7. A there was a significant reduction in the total number of
Ki67-positive cells of the 5-FU+LCV-treated group compared to saline-treated
rats (P*<0.05). This difference was abolished by co-treatment with fluoxetine
(P>0.05) while fluoxetine alone did not have any effect on the total number of
Ki67-positive cells compared to controls (P>0.05). Fig 4.7. B shows a
representative image of Ki67-positive proliferating cells within the dentate gyrus
displayed with PI nuclear counterstaining. Although 5-FU+LCV affected
behaviour and reduced cell proliferation across the groups, there was no direct
correlation between proliferating cell number and performance in the behavioural
test for individual animals (data not shown).
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Figure 4.7. Ki67 Proliferating cell counts (Mean±S.E.M) in the sub-granular
zone (SGZ) of the dentate gyrus (7-8). (A)There was a significant reduction
of the number of Ki67 positive cells of the 5-FU+LCV-treated group
compared to controls (p*<0.05) which was abolished after co-treatment
(fluoxetine and 5-FU) (p>0.05). There was no difference in the proliferating
cell count between controls and fluoxetine only-treated group (p>0.05; one
way ANOVA with Bonferroni post-hoc test. (B) Representative image of rat
DG by fluorescent microscopy. Proliferating cells in cluster (circled) within
the dentate gyrus (DG) are immunostained for Ki67 (green) and
counterstained with propidium iodine nuclear strain (red). Regions of the
DG are highlighted: granular cell layer (GCL) ; subgranular zone (SGZ)
and the hilus (HILUS).
SGZ GCLHILUS
10µm
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4.3.6. Hippocampal BDNF and DCX Levels
The effect of 5-FU+LCV chemotherapy and fluoxetine on levels of BDNF
neurotrophic factor and DCX neurogenic protein was measured in the
hippocampus and the frontal cortex. BDNF levels in the hippocampus differed
significantly between the 5-FU+LCV and the combined 5-FU+LCV&fluoxetine-
treated groups (P*=0.02, one way ANOVA. Fig.4.10 [A]). There was no
difference in the level of hippocampal BDNF protein between the 5-FU+LCV
and the saline-treated groups (P>0.05). Moreover there was no significant
difference in the same protein levels between the saline and fluoxetine only-
treated groups (P>0.05, one way ANOVA. Fig.4.10 [A]). Hippocampal DCX
levels showed a marginally non-significant difference between groups (P=0.053,
one way ANOVA. Fig.4.10 [B]). Fontal cortex BDNF protein level showed a
marked significant difference between groups (P**=0.008, one way ANOVA.
Fig.4.11 [A]). There was a significant increase in the level of frontal cortex
BDNF protein in the fluoxetine-treated group compared to the saline-treated
(P*<0.05) while there was no change in the level of frontal cortex BDNF between
the 5-FU+LCV and the combined 5-FU+LCV & fluoxetine-treated groups
(P>0.05, one way ANOVA. Fig.4.11 [A]). Also co-treatment with fluoxetine did
not alter the same protein level in the same tissue (P>0.05). On the other hand,
levels of frontal cortex DCX differed significantly between groups (P=0.019, one
way ANOVA. Fig.4.11 [B]). Bonferroni post-hoc test revealed a significant
difference in the protein level between the 5-FU+LCV and the combined 5-
FU+LCV&fluoxetine treated groups (P*<0.05). Also the level of frontal cortex
DCX protein in the fluoxetine only-treated group was significantly higher than
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the same protein levels in the 5-FU+LCV treated group (P*<0.05, one way
ANOVA. Fig.4.11 [B]).
Figure 4.8. Representative Western immunoblots of hippocampal tissue are
displayed. In the top box, protein bands at the molecular weight
corresponding to (DCX) protein are indicated at 47 kiloDaltons (kDa). On
the same immunoblots, corresponding GAPDH protein bands detected in the
same samples from which DCX was detected at 37 kDa. The bottom box
displays protein bands at the molecular weight corresponding to (BDNF)
protein as indicated at 15 kDa. Corresponding GAPDH protein bands were
observed on the same immunoblots as BDNF bands. GAPDH was used as a
loading control to ensure that equal amounts of protein were loaded into
each well. From each experimental group 3 tissue samples were
immunoblotted for both BDNF and DCX except for fluoxetine samples in the
lower box whereas 2 samples only were loaded for BDNF protein
fluoxetine
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4.3.7. Frontal Cortex BDNF and DCX Levels
Figure 4.9. Representative Western immunoblots of frontal cortex tissue are
displayed. The middle blot displays protein bands at the molecular weight
corresponding to (DCX) protein are indicated at 47 kiloDaltons (kDa). The
bottom blot displays protein bands at the molecular weight corresponding to
(BDNF) protein as indicated at 15 kDa. On the same immunoblots,
corresponding GAPDH protein bands detected in the same samples from
which DCX and BDNF were detected are observed at 37 kDa. (top blot).
GAPDH was used as a loading control to ensure that equal amounts of
protein were loaded into each well. From each experimental group 2 tissue
samples were immunoblotted for BDNF and DCX where 1 labels (saline
treated samples), 2 labels (5-FU+LCV treated samples), 3 labels (5-
FU+LCV&fluoxetine treated samples) and 4 labels (fluoxetine treated
samples).
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Figure 4.10. Graphic representation of levels of brain-derived neurotrophic
factor (BDNF) and doublecortin (DCX) proteins in the hippocampus
(Mean±S.E.M; n= 7-9). Graphs represent the mean amplitude of the wave
lengths emitted from the protein bands relative to that of GAPDH protein
that was blotted on the same gel. (A) BDNF levels in the hippocampus
differed significantly between groups (p*=0.02, one way ANOVA with
Bonferroni post-hoc test). There was a significant difference only between
the5-FU+LCV and the combined 5-FU+LCV&fluoxetine-treated groups
(P*<0.05). (B) DCX levels in the hippocampus were marginally different
between groups (p=0.053, one way ANOVA with Bonferroni post-hoc test).
There was no significant difference between group pairs (p>0.05).
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Figure 4.11. Graphic representation of levels of brain-derived neurotrophic
factor (BDNF) and doublecortin (DCX) proteins in frontal cortex
(Mean±S.E.M; n= 6-9). Graphs represent the mean amplitude of the wave
lengths emitted from the protein bands relative to that of GAPDH protein
that was blotted on the same gel. (A) BDNF levels in the frontal cortex
differed significantly between groups (p*=0.019, one way ANOVA with
Bonferroni post-hoc test). There was a significant difference only between
the saline and the fluoxetine treated groups. (B) DCX levels in the frontal
cortex differed significantly between groups (p**=0.008, one way ANOVA
with Bonferroni post test). There was a significant difference between the
5-FU+LCV and the 5-FU+LCV&fluoxetine-treated groups (P*<0.05). Also
there was a significant difference in the level of DCX protein between the
5-FU+LCV and fluoxetine- treated groups (p*<0.05).
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4.4 DISCUSSION
Reports by patients undertaking chemotherapy have indicated that systemic
chemotherapy can produce a wide range of cognitive symptoms including
difficulties in concentration, attention and memory which have become
collectively known as “chemobrain” (Wefel, Lenzi et al. 2004). These effects
can have a significant impact on patient quality of life and in their ability to
return to work (Ahles, Saykin et al. 2005; Scherwath, Mehnert et al. 2006).
Psychometric testing of patients during and after systemic chemotherapy has
confirmed patient reports and indicates that chemotherapy can produce a range of
mild to moderate cognitive deficits which are dose dependent and can last for
several years after the cessation of treatment (van Dam, Schagen et al. 1998;
Anderson-Hanley, Sherman et al. 2003; Castellon, Silverman et al. 2005; Falleti,
Sanfilippo et al. 2005). The symptoms described by patients after chemotherapy
treatment almost always include deficits in declarative memory. These involve
difficulties in the recall of both semantic (factual) and episodic (temporal) aspects
of memory for which the hippocampal formation is known to be required
(Eichenbaum, Yonelinas et al. 2007). Clinically, it has been reported that
antidepressants can improve memory function in patients suffering from a variety
of conditions (Horsfield, Rosse et al. 2002; Levkovitz, Caftori et al. 2002;
Vermetten, Vythilingam et al. 2003). Similarly, in animal models, SSRI
antidepressants have been reported to improve cognition after stroke or stress
(Ramanathan, Kumar et al. 2003; Song, Che et al. 2006; Li, Cai et al. 2009) but
not in normal animals (Stewart and Reid 2000; Yau, Hibberd et al. 2002). In the
present study, chronic treatment with the SSRI fluoxetine was integrated with 5-
FU+LCV chemotherapy to determine whether fluoxetine could alter the cognitive
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and neuropathological changes induced by chemotherapy. Fluoxetine treatment
improved the memory deficits caused by 5-FU chemotherapy in a spatial working
memory paradigm. The proliferation aspect of neurogenesis was quantified and it
revealed that fluoxetine treatment reversed the reduction in neurogenesis caused
by the chemotherapy 5-FU+LCV. Conversely 5-FU+LCV chemotherapy did not
change the level of BDNF protein in the hippocampus or frontal cortex compared
to the control group. However, co-treatment of fluoxetine with 5-FU+LCV
significantly altered the BDNF levels in the hippocampus from that of the 5-
FU+LCV treated group whereas there was a marginally significant difference in
the level of DCX protein in the hippocampus between all groups. Evaluating
frontal cortex BDNF, showed a marked significant difference between the saline
and the fluoxetine only-treated groups however there was a significant difference
in the DCX protein level in the same tissue between the 5-FU+LCV
chemotherapy and the combined 5-FU+LCV&fluoxetine treated groups. Also a
significant difference was found in frontal cortex DCX level between the 5-
FU+LCV chemotherapy and fluoxetine only-treated groups.
4.4.1. Fluoxetine and 5-FU reduced weight gain
Fluoxetine and 5-FU+LCV displayed a significant reduction in weight gain over
the chronic treatment period (Fig 4.2). The effect of 5-FU+LCV chemotherapy
on weight gain is a consistent one (Chapter 2 and 3) and it is largely associated
with reduced ability of gastrointestinal tract to absorb nutrients due to cytotoxic
damage to the proliferating cells lining the intestinal wall (Huang, Kemp et al.
2002). Fluoxetine also significantly reduced the body weight gain compared to
those saline-treated as found in previous studies (Mancini and Halpern 2006). It
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is possible that absorption of fluoxetine could have been affected by 5-FU+LCV
treatment. Rats that had received both 5-FU+LCV chemotherapy and fluoxetine
gained the least weight out of all four groups indicating that combining both drug
treatments resulted in a compound effect on weight gain of the animals.
4.4.2. Fluoxetine and fluoxetine with 5-FU reduced water intake
Water bottles of animals were measured on a daily basis (Fig.4.3). The amount of
daily water intake was calculated. There was a significant decrease in amount of
water intake in (fluoxetine) and combined (fluoxetine&5-FU+LCV)-treated
groups compared to the saline-treated animals following fluoxetine
administration (Fig 4.3). It has been shown that fluoxetine reduces the amount of
water intake by Sprage-Dawley rats (Lee, Lee et al. 2000; Rezvani, Overstreet et
al. 2000). It seems that the reduction IN the amount of water intake in the 5-
FU+LCV&fluoxetine-treated group was due to the effect of fluoxetine not 5-
FU+LCV chemotherapy as there was no significant difference in the water intake
between 5-FU+LCV-only treated animals and the saline-treated ones.
4.4.3. Fluoxetine improved the memory and neurogenic deficits caused by 5-
FU chemotherapy
We have used the OLR test of hippocampal function as a means of assessing the
cognitive effects of a therapeutically relevant dose of the commonly used
chemotherapy agent 5-FU. This task has been shown to require an intact
hippocampal dentate gyrus (Mumby, Gaskin et al. 2002). Confirming our
previous results (Mustafa, Walker et al. 2008), these results show that 5-
FU+LCV treatment caused deficits in this task. Control animals were readily able
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to discriminate between the novel and familiar locations of objects and spent
significantly more time on the objects in the novel location. In contrast 5-
FU+LCV treated animals showed no significant difference in the time spent on
the two objects and in fact spent more time on the object in the familiar location.
The total distance moved (cm) and the mean velocity (cm/sec) performed by
animals during the test were not different between all groups after treatment
(Fig.4.4 [A, B]).
Animals receiving both i.v injections of 5-FU+LCV and fluoxetine in their
drinking water, although showing an improvement in their discrimination
between familiar and novel object locations, still did not significantly
discriminate between these positions (Fig. 4.5). However calculation of the
preference index, a measure of percentage of the combined exploration time of
both novel and familiar locations of an object (Bruel-Jungerman, Laroche et al.
2005) showed a significant improvement in selecting the object in the novel
location over the 5-FU+LCV treated animals (Fig. 4.6).
Regarding the effect of 5-FU chemotherapy on memory, one possible cause could
be disruption of adult hippocampal neurogenesis. The production of new
neurons in the SGZ for incorporation into the dentate gyrus, is a well-
characterized phenomenon in all mammals including humans (Eriksson,
Perfilieva et al. 1998; Imayoshi, Sakamoto et al. 2009). Reductions in cell
proliferation in the SGZ by pharmacological, environmental or genetic means are
associated with deficits in memory (Bruel-Jungerman, Laroche et al. 2005; Zhao,
Deng et al. 2008; Jessberger, Clark et al. 2009). In the present study, we showed
that 5-FU+LCV chemotherapy significantly decreased the number of
proliferating cells in the SGZ of the dentate gyrus using immunohistochemistry
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for the proliferative marker Ki67. Animals were put down four weeks after the
start of drug treatment. Other studies have suggested that this period is long
enough for changes in neurogenesis to affect behaviour (Abrous, Koehl et al.
2005; Lee, Kim et al. 2006).
In line with previous investigations on changes in neurogenesis this was
associated with a decline in the performance of memory specific tasks.
Understanding the effects of chemotherapy on patients is complicated by other
aspects of the disease and treatment and cancer patients can exhibit cognitive
impairments prior to treatment (Wefel, Lenzi et al. 2004). The present study
shows that 5-FU can produce cognitive decline in the OLR behavioural test and
that this is associated with a decrease in proliferation in the neurogenic region of
the hippocampus. These results are in line with animal studies of other
chemotherapy agents which have shown cognitive declines after treatment
(Winocur, Vardy et al. 2006; Foley, Raffa et al. 2008; Gandal, Ehrlichman et al.
2008; Han, Yang et al. 2008; Konat, Kraszpulski et al. 2008; Mustafa, Walker et
al. 2008; Seigers, Schagen et al. 2008). Our previous investigation showed that 5-
FU+LCV produced a non-significant reduction in cell proliferation in the SGZ
(Mustafa, Walker et al. 2008). The present investigation increased the number of
injections which was sufficient to significantly reduce cell proliferation. Further,
because our study was based on the whole dentate gyrus, future studies will have
to investigate functional specificity of different regions of the dentate gyrus in
controlling neurogenesis, such as ventral vs. dorsal areas of the hippocampus
(Moser, Moser et al. 1993). Most reports have found that antidepressants
increase proliferation of cells in the SGZ (Kodama, Fujioka et al. 2004) but
recently there have been reports which have failed to find this effect (Cowen,
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Takase et al. 2008; Holick, Lee et al. 2008). Our results show that co-treatment
of fluoxetine with 5-FU+LCV abolished the reduction in cell proliferation in the
SGZ caused by 5-FU+LCV and improved performance in the OLR test.
Fluoxetine on its own had no effect on proliferation or behaviour. It is unlikely
that the effects of fluoxetine are limited to neurogenesis in the hippocampus as
several studies have shown positive effects on other brain regions associated with
cognition notably frontal, cingulate and temporal lobes (Mayberg, Brannan et al.
2000; Brody, Saxena et al. 2001; Smith, Reynolds et al. 2002; Saxena, Brody et
al. 2003). The action of fluoxetine on these regions as well as the hippocampus
may therefore underlie its effects on cognition.
4.4.4. Co-treatment (fluoxetine&5-FU+LCV) elevated hippocampal BDNF
Western immunoblotting showed that 5-FU+LCV chemotherapy did not
significantly change BDNF protein levels in the hippocampus compared to saline
treatment (Fig.4.10 [A]). This effect is similar to that reported in the previous
experiment (Chapter 3) and strengthens the hypothesis that the deteriorated
cognition of the animals treated with 5-FU+LCV chemotherapy was mainly due
to 5-FU-induced reduction of hippocampal neurogenesis as shown in the results
(Chapters 3 and 4). However, fluoxetine co-treatment with 5-FU+LCV elevated
hippocampal BDNF level from that of 5-FU+LCV only treated group.
Surprisingly, fluoxetine on its own did not produce the same effect. It has been
reported that chronic fluoxetine treatment up-regulates cellular BDNF expression
in rats (Molteni, Calabrese et al. 2006). These effects are also consistent with the
reports that fluoxetine has been shown to increase BDNF levels in the
hippocampus of female mice (Engesser-Cesar, Anderson et al. 2007).
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It could be that 5-FU+LCV chemotherapy non-significantly reduced the
hippocampal BDNF levels from that of saline treatment and that co-treatment of
fluoxetine with 5-FU could reverse this condition. This experiment showed that
there was a marked significant increase in frontal cortex BDNF level compared to
saline treated BDNF level. In line with this finding, it was found that frontal
cortex BDNF level in female mice chronically treated with fluoxetine was
significantly more than the same protein level in the frontal cortex of the controls
(Mannari, Origlia et al. 2008). These findings suggest that 5-FU- induced
behavioural changes were mainly due to the reduction in dentate gyrus
neurogenesis caused by the chemotherapy drug while the improvement in
cognition noticed in rats after co-treatment with fluoxetine could be attributed to
two reasons. One of these is an increase of hippocampal neurogenesis and or
alternatively an up-regulation of hippocampal BDNF level which is mainly linked
to the improvement in both differentiation and survival aspects noticed after
chronic antidepressants treatment.
4.4.5. Fluoxetine elevated hippocampal and Frontal cortex DCX
The results in the present experiment showed a significant difference in the
DCX protein level in the frontal cortex tissue between the 5-FU+LCV
chemotherapy and the combined 5-FU+LCV&fluoxetine-treated groups. Also
a significant difference was found in frontal cortex DCX level between the 5-
FU+LCV chemotherapy and fluoxetine only-treated groups. Moreover,
hippocampal level of DCX protein was up-regulated by fluoxetine compared to
both 5-FU+LCV and co-treatment (5-FU+LCV&fluoxetine)-treated groups.
Considering that DCX is a transiently expressed protein which is found during
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early mitosis and continues until 30 days of maturation (Marcussen, Flagstad et
al. 2008), fluoxetine could have affected the protein level in hippocampal or
frontal cortex dividing cells at early or late stages of 5-FU treatment (2 weeks).
The same cause could be attributed to the significant increase in hippocampal
or frontal cortex protein level in the combined treatment group compared to the
5-FU+LCV chemotherapy treated group. In agreement with these findings, it
was found that fluoxetine treatment for 28 days increased levels of
hippocampal neurogenesis as well as hippocampal DCX level in Wister rats
(Marcussen, Flagstad et al. 2008). Similar findings were also observed by
(Wang, David et al. 2008). Furthermore, (Namestkova, Simonova et al. 2005)
found that fluoxetine reversed the reduced neurogenesis after testing rats for
their response in water maze task. This was indicated by the increased number
of DCX protein marker positive cells. Also there is evidence that chronic
fluoxetine treatment targets early dividing cells in the dentate gyrus of the
hippocampus as measured by increased cellular immuno-reactivity for the
DCX marker (Encinas, Vaahtokari et al. 2006). In addition, it was not
unexpected that fluoxetine up-regulates DCX (as an early proliferation marker
protein) in frontal cortex tissue as there is evidence that cerebral cortex
neuronal cells are positive expressers for DCX protein in animals (Xiong, Luo
et al. 2008) as well as in humans (Varea, Castillo-Gomez et al. 2007).
Previously, it has been demonstrated that fluoxetine treatment increases
cellular proliferation in both hippocampus and frontal cortex (Kodama,
Fujioka et al. 2004) as well as increases in hippocampus and frontal cortex
reactivity to plasticity marker proteins in rats such as polysialylated nerve cell
adhesion molecule (PSA-NCAM), phosphorylated cyclic-AMP response
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element binding protein (pCREB) and growth-associated protein 43 (GAP-43)
(Sairanen, O'Leary et al. 2007). Added to this, the fluoxetine-induced
improvement in cellular proliferation in the co-treatment group in the dentate
gyrus of the hippocampus compared to 5-FU+LCV only-treated group as
measured by increased cellular immunoreactivity for the proliferative marker
Ki67, these finding collectively support the observed increase in DCX protein
(as an immature proliferative marker) in both hippocampus and frontal cortex
as a result of chronic fluoxetine treatment.
4.5. CONCLUSION
In conclusion, our results show that 5-FU treatment caused cognitive deficits
which were associated with a reduction in cell proliferation in the SGZ of the
dentate gyrus. These deficits were reduced when fluoxetine was administered
throughout the 5-FU+LCV treatment period. However, it is unclear how and
when 5-FU chemotherapy exerts its effect on neurogenesis. For this reason, a
new experiment (Chapter 5) was carried out in which the long term effects of
5-FU on cell proliferation and survival were quantified by combining BrdU
tracking of cells born at the start of drug treatment with Ki67 quantification of
cell proliferation at different time points after drug treatment.
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Chapter 5
Effect of 5-Fluoruracil on survival and proliferation of the
hippocampal rat brain dividing cells
5.1. INTRODUCTION
A substantial proportion of patients undergoing chemotherapy, for a variety of
cancers, have reported problems with their memory, attention, and cognition
which affected their daily lives profoundly (Rugo and Ahles 2003; Bower 2008).
One of the puzzling features of the cognitive decline experienced by patients after
chemotherapy is that many patient studies have shown that this condition can
persist for up to several years after the completion of drug treatment (Castellon,
Silverman et al. 2005; Falleti, Sanfilippo et al. 2005; Fan, Houede-Tchen et al.
2005; Scherwath, Mehnert et al. 2006; Bower 2008; Correa and Ahles 2008).
Although all sufferers seem to ultimately make a full recovery, cancer survivors
resume their educational, social and familiar roles suffering from a long-term
side effect of their cancer treatment, which can have resounding effects on their
lives (Ahles and Saykin 2002). This is especially prevalent in young survivors
who still contribute socially and vocationally in their society and, as such, these
patients are of particular interest, in terms of the prevalence of neurological and
neuropsychological side effects (Anderson-Hanley, Sherman et al. 2003). There
are some similarities to the long term pattern of symptoms found after
chemotherapy with those found after cranial irradiation where cognitive
symptoms can also persist and, in fact, increase after treatment and full remission
from the original cancer (Soussain, Ricard et al. 2009). These treatment
162
strategies, chemotherapy and irradiation, designed to target cancer cells, are
commonly associated with harmful effects on multiple organ systems, including
the central nervous system (CNS).
Cancer patients may experience a wide range of neurotoxic adverse symptoms,
including vascular complications, seizures, mood disorders, and cognitive
dysfunction (Dietrich, Monje et al. 2008; Minisini, Pauletto et al. 2008).
Recent studies have stressed the biological basis of chemotherapy and radiation-
associated CNS toxicity. The most vulnerable cell populations susceptible to
these treatments are self – renewing neural precursor cells (NPCs), which are the
direct ancestors of all differentiated cell types of the CNS, but which are
particularly important in the neurogenic regions (SVZ and SGZ) and
oligodendrocytes (myelin forming cells) precursors which are required for the
maintenance of white matter tracts. Additionally non-dividing mature
oligodendrocytes also appear to be susceptible and demyelination has been
reported with both irradiation and chemotherapy (Dietrich, Han et al. 2006;
Soussain, Ricard et al. 2009). In contrast, mature astrocytes and neurons are
significantly less vulnerable at comparable doses of drugs or irradiation. In vitro
studies have similarly shown that application of chemotherapy agents is
associated with increased cell death of oligodendrocytes and NPCs (Doetsch,
Caille et al. 1999; Dietrich, Han et al. 2006; Han, Yang et al. 2008).
It has been shown that the initial reduction in cell proliferation and increased cell
death following a single dose of chemotherapy is followed by a marked rebound
in cell proliferation. However, repetitive drug exposure resulted in long–term
suppression of cell division and prolonged cell death in the subventricular zone,
the hippocampus, and the white matter tracts (Dietrich, Monje et al. 2008).
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We and others have shown that 5-FU treatment of rats, causes a reduction in
neurogenesis in the dentate gyrus of rat brain hippocampus (Han, Yang et al.
2008; ElBeltagy, Mustafa et al. 2010) and that this is associated with cognitive
decline (Mustafa, Walker et al. 2008; ElBeltagy, Mustafa et al. 2010).
However, it is still not clear how the decrease in neurogenesis occurs or what its
duration is. One possibility is that a reduction in the numbers of stem or
progenitor cells in the SGZ during chemotherapy causes a prolonged reduction in
the number of proliferating cells in this region (Eisch and Mandyam 2007).
Similarly increased death of dividing cells may also contribute to the overall
reduction in the number of these cells in the SGZ of the dentate gyrus (Arguello,
Harburg et al. 2008).
In this part of the investigation into the effects of 5-FU on hippocampal
neurogenesis, it was decided to look at the longer term (up to six weeks) effects
of treatment and in addition to look at the survival of cells dividing at the start of
chemotherapy treatment. A reduction in hippocampal neurogenesis due to
decreased proliferation or survival of NPCs is a possible causative mechanism by
which 5-FU could induce long term and progressive cognitive deteriorations in
cancer patients.
To investigate this, 2 successive intra peritoneal injections of the exogenous S
phase proliferative marker bromodeoxyuridine (BrdU) were given over two days
immediately prior to 5-FU+LCV treatment. This was designed to mark cells
dividing (specifically those in S phase) at the start of 5-FU+LCV administration.
Comparison with the numbers of BrdU positive cells in control animals, given
saline injections, at different time intervals after 5-FU+LCV treatment will
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quantify the survival of this population proliferating cells. Animals were killed
24 hours, 2 weeks or 6 weeks after treatment with 5-FU+LCV.
Sections of hippocampus were stained for BrdU and the endogenous cell cycle
marker Ki67. Comparison of Ki67 positive cell number with controls could
indicate changes in cell proliferation at the different time intervals after treatment.
The results demonstrate that the longer term rate of cell division and the survival
of neurogenic cells are both highly sensitive to the effect of 5-FU, and this
provides a novel insight into long term effects of 5-FU on neurogenesis in the rat
brain. The causes of the long term effects of chemotherapy or radiotherapy are
currently unknown (Soussain, Ricard et al. 2009). One suggestion is that these
treatments induce an inflammatory response in the brain which persists after
treatment has finished. It is known that inflammation reduces hippocampal
neurogenesis (Ekdahl, Claasen et al. 2003; Monje, Toda et al. 2003; Bastos,
Moriya et al. 2008) and is associated with cognitive impairment (Hein and
O'Banion 2009).
The evidence for inflammation having a role in the inhibition of hippocampal
neurogenesis is particularly strong after cranial irradiation where not only is there
a significant increase in activated microglia, but treatment with a non steroidal
anti inflammatory drug, partially prevents the reduction in cell proliferation in the
SGZ after treatment (Monje, Toda et al. 2003; Monje, Vogel et al. 2007).
Chemotherapy is not associated with particularly high levels of inflammation but
5-FU treatment has been reported to induce inflammation in peripheral tissues in
animal models of chemotherapy (Logan, Stringer et al. 2008; Lopes, Plapler et al.
2009). This suggests that it could have a similar direct effect on the brain or that
proinflammatory cytokines produced peripherally, could cross the blood brain
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barrier and induce inflammatory changes indirectly. However two groups have
recently published reports which failed to find evidence for inflammation in the
brain after either 5-FU (Han, Yang et al. 2008) or MTX (Seigers, Timmermans et
al. 2010) chemotherapy treatment. Han et al. used a marker for activated glia
while Seigers et al. measured cytokine levels in plasma and brain. Although
Seigers et al. found no significant changes in inflammatory cytokine levels, they
did report changes in microglial morphology.
It was decided to look at a different inflammatory marker to these studies to see
if treatment affected other aspects of the inflammatory response. As 5-FU has
been reported to increase expression of the inducible prostaglandin producing
enzyme cyclooxygenase 2 (COX-2) in peripheral tissues (Lopes, Plapler et al.
2009), it was decided to look at the effect of chemotherapy on the number of cells
expressing this marker in the brain. COX-2 synthesises prostaglandins from
arachidonic acid and is constitutively expressed at low levels in microglia and
neurons in the intact brain but expression is strongly increased after infection or
damage (Bastos, Moriya et al. 2008; Ahmad, Zhang et al. 2009). Interestingly
COX-2 expressing microglia appear to be closely associated with dividing cells
in the neurogenic regions of the brain and inhibition of COX-2, with specific
inhibitors, under non-inflammatory conditions, strongly reduces neurogenesis
(Goncalves, Williams et al. 2010). These results suggest that prostaglandin
synthesis by COX-2 is required for neurogenesis in non-inflammatory conditions
but that increased COX-2 expression during inflammation is associated with
decreased neurogenesis (Ekdahl, Kokaia et al. 2009). As part of the
investigations into the longer term effects of 5-FU treatment, it was decided to
quantify the number of COX-2 expressing cells in both the dentate gyrus itself
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and the hilus of the dentate gyrus by immunohistochemistry at different time
points after drug treatment.
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5.2. MATERIALS AND METHODS
5.2.1. Animals and drug administration.
All experiments and animal care were in accordance with UK Animals (Scientific
procedures) Act 1986. All experiments were on male Lister hooded (LH) rats
(Charles River UK) of 150-170gms at the start of experiments and animals were
weighed daily. Animals were allowed to habituate to the animal house for 2
weeks before treatment and housed in groups of 4 under standard conditions of
12-h light – 12-h dark cycle (light from 8.30am to 8.30 pm) with free access to
food and water. Doses given of 5-FU are within the range which reduces tumour
load in rats (Au, Walker et al. 1983; Watson, Michael et al. 1998), and are the
standard doses used to investigate the effects of 5-FU which are within the human
dose range (Reagan, Nihal et al. 2008).
48 L.H male rats were randomly divided equally into 2 main groups:
Group (A) Controls received 6 intravenous (i.v) injections of (0.9% normal)
saline under isoflurane anaesthesia every other day over two weeks.
Group (B) received 6 intravenous (i.v) bolus injections of 5-FU 20mg/kg
(MAYNE Pharma PLC) together with leucovorin, 20mg/kg (TEVA UK LTD.
into the tail vein under isoflurane anaesthesia. All animals were injected
intraperitoneally (i.p) with 2 successive BrdU (Sigma, St. Louis; in 0.9% saline)
150mg/kg each. one day before treatment started. On the last day of treatment,
all animals were subdivided into 6 subgroups as follows:
168
Group A1 and B1: 1
st
controls and 5-FU+LCV respectively (8 animals each)
were killed one day after treatment
Group A2 and B2: 2
nd
controls and 5-FU+LCV respectively (8 animals each)
were killed two weeks after treatment
Group A3 and B3: 3
rd
controls and 5-FU respectively (8 animals each) were put
down 6 weeks after treatment.
Figure 5.1, a protocol line of the study is presented above. Rats received
2 intraperitoneal injections of BrdU 24 hours before injecting them with
sterile normal saline or 5-FU+LCV (6 intravenous injections over 2
weeks in a dose of 20 mg/kg). Groups of animals were killed one day, two
weeks and 6 weeks after treatment as indicated on the figure.
Habituation (days 1-14)
2 BrdU injections
(days 14 and 15)
5-FU+LCV or Saline injections
(Day 31) A1&B1
Sacrifice
(Day 44)
A2&B2 sacrifice
(Day 72) A3&B3
Sacrifice
24h
2W 4W
2W
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5.2.2. Brain tissue preparation
Rats were killed by rapid stunning followed by decapitation. 40 brains were
randomly chosen for immnohistochemistry. These brains were divided sagittally;
one half was cryoprotected in a 30% sucrose solution for 3 hours at 4°C. Before
embedding in OCT (VWR International Ltd, Lutterworth, UK), embedding
medium for frozen tissue specimens and stored at -80°C. Frozen brains were
serially sectioned (20-Pm) in the coronal plane from Bregma point-2.12 to -6.08
mm(Paxinos and Watson 1997) to include the entire hippocampus using a Leica
CM 100 cryostat (Leica Microsystems, Knowlhill, UK). Sections were mounted
onto 3-aminopropyl-methoxysilane (APES) - coated slides and stored at -80 for
immunohistochemistry which was done according to the manufacture’s protocols.
The other half of brains were frozen at -80ºc for Western blotting.
5.2.3. Immunohistochemistry
A systemic random sampling technique (Mayhew and Burton 1988) was used to
choose every 21
st
section throughout the length of the dentate gyrus (overall 10
sections).
For Ki67 staining, sections were rinsed in PBS followed by fixing with 0.5%
paraformaldehyde (PFA) for 3 minutes, before incubation with monoclonal
mouse anti-Ki67 (1:100); Vector Laboratories, Orton Southgate, UK) for 1 h,
followed by 1h incubation with Alexa 566 (Invitrogen/molecular Probes, UK)
goat anti-mouse secondary antibody (1:300).
For BrdU staining, sections were washed three times in PBS and then fixed with
4% PFA for 3 minutes. Sections then were incubated in 2M HCL containing
0.3% Triton X100 for 20 min at room temperature (r.m.) then with 5M HCL for
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10 minutes to open the DNA structure of the labelled cells. Immediately after
acid washes, borate buffer (0.1M; pH 8.5) was added to neutralise the acid for 12
mins at r.t. Sections were then blocked in 0.1M PBS (Ph 7.4) + 1% TritonX100
+ 5% normal goat serum (1h) prior to incubating with sheep anti-BrdU
(Abcam,UK 1:100 in the blocking solution ) for 1hr. Samples are then incubated
with anti-sheep secondary (Vector labs. UK 1:300) for 1h at r.t. Washing in-
between steps was done with 0.1M borate solution (3x5 mins).
For COX-2 staining, sections were rinsed in PBS and fixed in 2% PFA, washed
in PBS and incubated with polyclonal anti-COX-2 AB(Abcam 15191-500)
diluted 1:100 in PBS for 1hr. After washing, sections were incubated in
secondary antibody, goat, anti-rabbit AB (Alexa fluro 546) diluted 1:300 in PBS
for 1hr.
For Ki67, BrdU and COX-2 staining, diaminobenzidine (DAPI) nuclear stain
(Vector shield, mounting medium in glycerol) was used as a counterstain and
sections were viewed at 40x magnification on a Nikon EFD-3 fluorescence
microscope. Ki67/BrdU-positive cells were counted within the SGZ, defined as
within 3 cell diameters of the inner edge of the dentate gyrus (Mustafa, Walker et
al. 2008). COX 2-positive cells were counted in both the blades and the hilus of
the DG. Counts from all sections of one dentate gyrus were averaged to provide
the number of positive cells per section (Mustafa, Walker et al. 2008; ElBeltagy,
Mustafa et al. 2010).
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5.2.4. Statistical analysis
All statistical parameters were calculated using Graph pad Prism 4.0 software,
USA. Unpaired student t- tests (two-tailed) was used to compare the number of
immunohistochemically positive cells between controls and 5-FU+LCV-treated
groups for each time interval. One and two- way ANOVAs with Bonferroni
post-hoc tests were used to analyse data of the proliferating and survival cell
count. Repeated measures two way ANOVA with Bonferroni post-hoc tests
were used to analyse the weights of the animals. A probability level of P<0.05
was considered statistically significant.
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5.3. RESULTS
5.3.1. Effect of treatment on weight of animals:
As shown in Fig 5.2, animals on 5-FU+LCV showed a loss in body weight during
the drug administration period as shown previously in studies in Chapters (2-4).
This effect is a well known side effect of 5-FU attributed to effects on the
gastrointestinal tract lining (Huang, Kemp et al. 2002) and although they showed
improved weight gain after the end of drug treatment (data not shown); they were
still significantly below control weights.
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Figure 5.2, Body weight of rats during the treatment period of the
experiment (Mean±S.E.M; n=24 each group). There was a significant
difference in weights between the two groups throughout the whole time
(p***<0.0001; repeated measures two- way ANOVA with Bonferroni post
test). 5-FU+LCV treatment significantly reduced body weight gain
throughout the treatment period (p**=0.003; repeated measures two- way
ANOVA with Bonferroni post test). Also the interaction between both time
and treatment was significant [p***<0.0001; repeated measures two- way
ANOVA with Bonferroni post-hoc test). The injections are indicated on the
graph by arrows and on X axis by numbers.
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5.3.2. Effect of 5-FU treatment on the rate of proliferation of the rat brain
dividing cells:
Ki67 positive cells were found in the SGZ of the dentate gyrus (Fig 5.3). As
shown in the figure, control animals showed no variation in the number of
dividing cells between post-mortem time points. 5-FU+LCV treated animals
showed no difference in the mean Ki67 positive cell counts in the SGZ of the
dentate gyrus of the hippocampus from the controls one day post-treatment
(P=0.3). However 2 weeks after treatment, there was a marked and significant
reduction in these numbers (P**=0.008). This reduction still persisted even 6
weeks post treatment but at a lower significance level (P*=0.02). There was a
tendency for a progressive reduction in the mean number of Ki67 positive cell
counts in the 5-FU+LCV treated groups with time; however, this was not
significant (P>0.05).
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Figure 5.3, Ki67 positive cell count (Mean ± SEM; n=6-9). Control animals
showed no significant difference in the numbers of dividing (Ki67-positive)
cells over time. There was no difference in the mean Ki67 number between
controls and 5-FU+LCV treated one day after treatment (P=0.3). In contrast
there was a marked and significant difference in the number of Ki67 positive
cells two weeks after treatment (p**=0.008) and 6 weeks after the end of
treatment (p*=0.02). One way ANOVA with the Bonferroni post-hoc test
was used to compare between all groups and unpaired t-test (two-tailed) was
used to compare the counts between controls and 5-FU+LCV-treated groups
of each time point separately.
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5.3.3. Effect of 5-FU treatment on the survival of cells dividing at the start of
treatment:
BrdU had been injected prior to the start of 5-FU+LCV treatment and BrdU
positive cells were detected at all ages in the inner edge of the blades of the
dentate gyrus. As shown in Fig 5.5, control animals showed no significant
change in the number of BrdU positive cells with time although the numbers at 6
weeks showed a non-significant decline. 5-FU+LCV-treated animals, unlike the
results, from Ki67 quantification, showed a significant reduction in the mean
BrdU positive cell counts in the SGZ of the dentate gyrus of the hippocampus
compared with controls one day after the end of treatment (P*=0.01) . Moreover,
after 2 weeks from treatment, there was still a marked significant reduction in
these numbers (P***=0.0003). This marked reduction persisted even 6 weeks
after treatment (P***=0.0002).
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Figure 5.4, Representative images of rat dentate gyrus by fluorescence
microscope. (A) Proliferating cells (circled) within the dentate gyrus are
immunostained using BrdU (green) or Ki67 (red) (B). DAPI nuclear
staining of the dentate gyrus is observed under the ultra-violet light filter
of the fluorescence microscope in both A and B.
A
B
10µm
10 µm
50 µm
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Figure 5.5, BrdU positive cell counts in all groups (Mean ± SEM; n=6-9).
BrdU positive cells in control groups, show no significant variation during
the period of investigation. There was asignificant reduction in the mean
number of BrdU positive cells in 5-FU+LCV treated animals compared with
the controls one day after treatment (p*=0.01), Also there was a marked and
significant reduction in the number of BrdU positive cells two weeks after
treatment between controls and 5-FU+LCV treated groups (p***=0.0003).
After 6 weeks from treatment there was still a marked significant reduction
between control and 5-FU+LCV treated groups in the mean numbers of
BrdU positive cell counts (p***=0.0002). One way ANOVA with Bonferroni
post-hoc test was used to compare between all groups and unpaired t-test
(two-tailed) was use to compare the counts between controls and 5-
FU+LCV- treated groups of each time point separately.
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5.3.4. Effect of 5-FU on the rate of both survival and proliferation of the rat
dentate gyrus dividing cells (Fig 5.6 and 5.7):
Comparing the effect of 5-FU+LCV treatment on both the survival and
proliferation of cells in the SGZ of the dentate gyrus between all groups, there
was a highly significant difference in the mean numbers of both Ki67- and
BrdU- positive cell counts between all controls and all 5-FU+LCV-treated groups
(P***<0.0001). Also the effect of time was significant (P*=0.04) indicating that
the numbers of positive cells were significantly lower in the animals killed two
weeks after treatment compared with those killed after one day and the same
numbers were significantly much lower in the animals killed 6 weeks after
treatment from those killed 2 weeks after treatment. However, the effect of 5-
FU+LCV treatment on survival (BrdU) of the dentate gyrus dividing cells was
not found to be different from its effect on proliferation (Ki67) as indicated from
the mean Ki67/BrdU positive cell counts (P>0.05). The analysis was done by
using two-way ANOVA with Bonferroni post-hoc tests to compare between all
groups.
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Figure (5.6) and (5.7) Ki67 and BrdU positive cell counts between all groups
during the three different time intervals (Mean ± SEM; n=6-9). (A) There
was a significant difference in the mean numbers of either Ki67 or BrdU
positive cell counts between all controls and all 5-FU+LCV treated groups
except for the Ki67 cell count between A1 and B1 which was not significant
(P***<0.0001; One-way ANOVA with Bonferroni post-hoc test. (B)The
effect of 5-FU+LCV treatment on survival (BrdU) of the dentate gyrus
dividing cells was not different from its effect on proliferation (Ki67) as
indicated from the mean Ki67/BrdU positive cell. The effect of time on
either Ki67 or BrdU cell counts was significant (P*=0.04). The interaction
Fig 5.6
Fig 5.7
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between time and treatment was not significant; Two-way ANOVA with
Bonferroni post-hoc test was used to compare between all groups.
5.3.5. Effect of 5-FU treatment on the number of COX2-labelled cells
COX-2 positive cells were found in both the blades of the dentate gyrus and the
region of the hilus between the blades (Fig 5.8 and 5.9). The number of cells per
section was counted, averaged from all sections and results are shown in Fig 5.10.
One day after the end of treatment the number of COX-2 positive cells was
significantly greater in the blades of the treated animals compared to controls.
No difference was found at other ages or for counts of COX-2 positive cell
numbers in the hilus.
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A B C
Fig 5.8, Representative images from the dentate gyrus of a control rat 24
hours after completion of 5-FU treatment. A. DAPI staining showing all
nuclei in the dentate gyrus and hilus. B. COX-2 immunostaining. C. Merged
image of A and B.
A B C
Fig 5.9, Representative images from the dentate gyrus of a 5-FU treated rat
24 hours after completion of 5-FU+LCV treatment. A. DAPI staining
showing all nuclei in the dentate gyrus and hilus. B. Cox-2 immunostaining.
C. Merged image of A and B.
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Fig 5.10 A, B and C. Numbers of Cox-2 positive cells per section in control
and 5FU+LCV treated animals at different time points after the end of
treatment (Mean ± SEM; n=6-9). At 24 hrs the number of COX-2 positive
cells was significantly higher in the dentate gyrus blades of treated animals
compared to the same number in the dentate gyrus blades of control animals
(P***<0.0001; One-way ANOVA with Bonferroni post test). No difference
was found at other ages or in the counts for cells in the hilum.
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5.4. DISCUSSION
It is now well established that new neurons are produced in discrete regions of the
adult brain throughout life. It has been shown that although some neurons die
in the dentate gyrus, the total number of granule cells increases during adulthood
(Imayoshi, Sakamoto et al. 2009). Therefore, it has been suggested that
neurogenesis is the cause of this increase in the number of neurons in the dentate
gyrus of the hippocampus (Bayer, Yackel et al. 1982; Boss, Peterson et al. 1985;
Dayer, Ford et al. 2003; Kempermann, Gast et al. 2003). The rate of adult
neurogenesis can be up or down-regulated by many factors (Kempermann 2006).
In our previous investigation we showed that, 5-fluorouracil, a well known
chemotherapeutic agent caused a reduction in cell proliferation in the SGZ of the
adult rat brain and that this was accompanied by cognitive deteriorations which
manifested as an inability of the rats to perform hippocampal-specific behavioural
tasks (Mustafa, Walker et al. 2008; ElBeltagy, Mustafa et al. 2010). Numerous
neurogenesis studies have demonstrated that SGZ cells of the dentate gyrus in
different stages of progenitor cell maturation are sensitive to physiological and
pharmacological stimuli (Kronenberg, Reuter et al. 2003; Encinas, Vaahtokari et
al. 2006; Mandyam, Crawford et al. 2008; Mandyam, Wee et al. 2008). Although
the effects of stimuli such as running, antidepressants, and environmental
enrichment on the maturation of progenitor cells have been well established
(Ming and Song 2005; Plumpe, Ehninger et al. 2006; Wang, David et al. 2008),
the effect of 5-FU on proliferation and or survival had not been assessed. In the
present work, we aimed to examine the effect of 5-FU on the survival and
proliferation of the rat brain dentate gyrus dividing cells at different time intervals
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using the two markers, Ki67 and BrdU. Ki67-positive cell numbers indicated the
rate of cell proliferation at different time points while BrdU-positive cell numbers
indicate the survival of cells which were dividing at the start of 5-FU treatment.
We found that 2 weeks of 5-FU+LCV treatment did not significantly reduce the
number of SGZ proliferating cells one day after treatment had finished. However,
proliferating cell number was significantly reduced, compared to controls two
weeks after the end of treatment. This significant reduction was still present even
6 weeks after treatment. This result is surprising as it suggests that 2 weeks of 5-
FU+LCV treatment does not have an immediate effect on the rate of cell
proliferation in the SGZ but rather has a delayed effect such that cell proliferation
is only significantly reduced two weeks after treatment. This result is in line
with our previous investigation which showed that the number of Ki67-positive
cells in the SGZ was significantly reduced 2 weeks after 5-FU+LCV treatment
compared to controls (ElBeltagy, Mustafa et al. 2010). Other groups have
reported similar findings after systemic application of thiotepa (Mignonea and
Weberb 2006) methotrexate (Seigers, Schagen et al. 2008) and 5-FU (Han, Yang
et al. 2008). Systemic application of these drugs was associated with a dose-
dependent inhibition of hippocampal cell proliferation in vivo. In addition,
methotrexate has been shown to impair cognitive performance in animal models
(Winocur, Vardy et al. 2006; Seigers, Schagen et al. 2008). In breast cancer
patients, CMF chemotherapy is associated with cognitive deteriorations (which
likely reflect an inhibition of neurogenesis) that are mostly noticed from 1 month
to several years after treatment (Wieneke and Dienst 1995; Schagen, van Dam et
al. 1999; Kreukels, Schagen et al. 2005). The BrdU results showed that the
survival of cells dividing immediately prior to 5-FU+LCV treatment was reduced
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at the earliest time point studied (one day after 5-FU treatment). However, the
degree of this effect was more obvious with time (2-6 weeks from treatment) as
indicated from the BrdU-positive cell counts. These results show that 5-FU has
the ability to increase the level of neurogenic cell death inside the hippocampus
early during treatment and that the level of cell death increases with time even
after cessation of treatment.
Taken together, the Ki67 and BrdU results indicate that 5-FU+LCV treatment
decreases the survival of newly born cells both during treatment and for some
time afterwards while its effects on cell proliferation appear to be delayed and,
becoming significant several weeks after the end of treatment.
The delayed and continuing effects of chemotherapy treatment found in the
present study may provide an explanation for the patient reports of prolonged
cognitive impairment. The mechanism behind these effects remains unclear but it
has previously been reported that 5-FU exposure induces G1/S phases arrest and
apoptosis by a P53-dependent molecular pathway, in HPV 18 positive cells
(Didelot , Mirjolet et al. 2003). Moreover, Dietrich et al. found that three
intraperitoneal injections of the alkalylating agent in chemotherapy, carmustine
(BCNU) significantly increased cell death for up to 10 days after treatment in the
corpus callosum and the hippocampal dentate gyrus, and up to 6 weeks in the
sub-ventricular zone. Similar effects were noticed after 3 intraperitoneal
injections of cisplatin (Dietrich, Han et al. 2006; Seigers, Schagen et al. 2008).
In this chapter a marker for inflammation, COX-2, was quantified over the 6
week period after 5-FU+LCV treatment. Although there was a significant
difference between COX-2 cell numbers in treated and control groups, one day
after treatment (Fig 10 A), this is due to a reduction in the number of COX-2
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positive cells in the control group at this age compared to other ages. There
appears to be no change in COX-2 positive cell number across the three ages
studied in the treated animals and there is no significant difference between
controls and treated groups at 2 and 6 weeks. It is possible that the low numbers
of COX-2 cells in the controls at one day are due to stress as a similar effect , in
this case a reduction in cytokine levels, was found by Seigers et al. in controls
immediately after treatment, but further work will be need to prove this (Seigers,
Timmermans et al. 2010). Overall it does not seem that 5-FU+LCV treatment
has increased COX-2 positive cell numbers compared to controls. This would
suggest that prolonged inflammation is not the cause of the long term depression
in cell proliferation and survival found in this chapter. As noted in the
introduction, several other groups have also looked for inflammation within the
brain after chemotherapy treatment and in agreement with the results found here,
have failed to demonstrate that this is occurring.
Another possible mechanism by which survival of the dentate gyrus dividing
cells could be affected is the possible alteration of the dentate gyrus BDNF levels.
It has been demonstrated that incubation with BDNF increases the differentiation
of progenitor cells into neurons but it does not directly influence the division of
progenitor cells (Palmer, Takahashi et al. 1997). Moreover, increased apoptosis
among hippocampal progenitor cells and excessive neuronal cell death were
reported in BDNF knockout mice (Linnarsson, Willson et al. 2000), indicating
that BDNF is essential for the survival of neurons especially those which
continuously regenerated in the brain (Lee, Kim et al. 2006). Furthermore, one of
our studies has shown that rat brains hippocampal BDNF levels were reduced by
2 weeks of 5-FU treatment which were not associated with an immediate
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reduction in the number of SGZ proliferating cells (Mustafa, Walker et al. 2008).
Indeed, both mechanisms (reduced hippocampal neurogenesis and hippocampal
BDNF levels) could be included in 5-FU effect on the survival of dentate gyrus
dividing cells and further investigations on the dentate gyrus BDNF levels should
be done to establish this effect.
The continued loss of cells which had been marked with BrdU at the start of 5-
FU+LCV treatment indicates that cells dividing at the start of treatment had a
lower survival after treatment compared to controls. Treatment of dividing cells
with 5-FU has a number of effects the most important of which is thought to be
the inhibition of the enzyme thymidylate synthase however in addition, it has
been shown that 5-FU causes the incorporation of the RNA base uracil into
genomic DNA during S phase of cell division. Failure to repair this has been
suggested as a cause of subsequent cell death if the cell attempts to re enter
mitosis (Wyatt and Wilson 2009). This mechanism could explain the continued
loss of cells marked at the start of drug treatment.
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5.5. CONCLUSION
Overall, this chapter shows that 5-FU+LCV treatment causes prolonged effects
on neurogenesis in the hippocampus. Further work on whether behaviour is also
affected over this time scale will need to be done but, if shown, will indicate a
possible mechanism for the long term effects of chemotherapy on cognition.
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CHAPTER 6
GENERAL DISCUSSION
The studies presented in this thesis are a continuation of a project which aims to
investigate the possible effect of chemotherapy on memory and neurogenesis by
developing and applying an animal model. The process of adult hippocampal
neurogenesis is now well established and studies using animal models have
shown that it is involved in an increasing number of normal and pathological
processes and that modulation of adult neurogenesis may open new doors to
therapeutic treatments (DeCarolis and Eisch 2010). Cancer patients, especially
young patients, often complain of cognitive problems, especially those related to
memory, attention and concentration which produce adverse effects on their lives.
This has led to many clinical investigations focusing on the underlying causative
mechanisms for this cognitive deterioration. Clinical cancer studies have ascribed
these cognitive deteriorations to the disease itself, the possible side effects caused
by drug combinations or to the metastasis of the original cancer into the CNS (see
references in the introduction to Chapter 4). However the most accepted theory
is that the chemotherapy itself is the most likely cause of these cognitive
symptoms. One of the drugs frequently associated with these CNS symptoms is
5-fluorouracil (5-FU), used throughout the present thesis. This drug has been
consistently associated with descriptions of cognitive impairment by cancer
patients, especially breast cancer survivors. 5-FU can be used either alone or in
combination with other chemotherapeutic drugs especially cyclophosphamide
and methotrexate in CMF combination therapy.
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Previous studies by the Nottingham group have provided an indication that 5-FU
chemotherapy affects spatial working memory and the formation of newborn
neurons in the adult rat hippocampus (Mustafa, Walker et al. 2008). The present
thesis extends these studies and further work is continuing to investigate the
cytotoxic effects of this drug on cell proliferation, differentiation and survival
during adult neurogenesis.
Quantification of hippocampal-specific memory was undertaken using the object
location recognition test (OLR) which measures spatial working memory and the
conditioned emotional response test (CER) which measures contextual fear
conditioning to unpleasant stimuli. Both of these two memory tests have been
shown to require input from the hippocampus (Mumby, Gaskin et al. 2002;
Resstel, Joca et al. 2006; Mustafa, Walker et al. 2008). Adult neurogenesis is
affected by a number of external or internal modulators. One of the most widely
studied classes of pharmacological modulators of neurogenesis is the SSRI
antidepressants such as fluoxetine. For this reason, we examined the effect of
fluoxetine, which has been shown to improve both neurogenesis and memory in
both clinical and animal studies. In particular it is important to know when and
how both 5-FU and fluoxetine exert their effects on neurogenesis and memory
which in turn will help to improve future animal models and aid in establishing
the potential role of antidepressants as a cognitive enhancer in clinical
chemotherapy studies. In order to do this, we followed cell survival using BrdU
marking of dividing cells to determine how and when they are affected by
chemotherapy.
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6.1 SUMMARY OF RESULTS (table 6.1)
The preliminary experiments, testing the effect of 5-FU on memory using
OLR and CER behavioural tests are detailed in the pilot studies (Chapter 2
Experiment1). The OLR test did not show a novel response even in the control
group while CER test showed a subtle deficit in the 5-FU treated group. Because
of the inability of control animals to perform the OLR task, it was necessary to
design a separate experiment in which optimization of these two tasks was done
before continuing to use them in the following studies in this animal model. This
was achieved in chapter 2, Experiment 1 where control animals were able to
successfully undertake both the OLR and the CER tasks taking into consideration
the methodological problems discussed in chapter 2. Animals spent significantly
more time exploring the new location of the object more than the old location.
Furthermore, the shocked animals measured freezing time was significantly more
than the freezing time of non-shocked animals. The choice and use of these
cognitive tests are discussed in section 6.2 below. The results in chapter 2 led us
to rely on these tests as measures of hippocampal specific function in latter
studies. In chapter 3, a further experiment with larger numbers of animals was
performed to investigate the effect of 5-FU on memory and neurogenesis within
the adult male hippocampus. Moreover, immunohistochemistry for the marker
(Ki67) was used successfully to measure changes in the number of dentate gyrus
dividing cells between saline and 5-FUtreated groups.
The levels of hippocampal neurotrophic factor (BDNF) and the immature
proliferative marker (DCX) were also compared between saline and 5-FU treated
animals by doing Western blot analysis. The level of these two proteins was also
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measured in the frontal cortex to provide information about their regional
specificity. The results obtained in this study from the OLR confirmed that 5-FU
impaired memory in both spatial and contextual fear conditioning. The number
of Ki67 immunoreactive cells in the 5-FU treated group was significantly lower
than the number in the control group. Although there was a trend towards
reduction in hippocampal BDNF levels, this was not significant. Similarly there
was no difference in hippocampal DCX levels between 5-FU and saline treated
group. In contrast, frontal cortex BDNF levels were significantly reduced by 5-
FU treatment compared to controls while frontal cortex DCX levels were
unchanged comparing saline and 5-FU treated groups. In chapter 4, the effect of
a major modulator of neurogenesis, the SSRI antidepressant fluoxetine, on
memory and neurogenesis of the adult male hippocampus was examined using
the methods outlined in the previous chapter. As shown previously the results
obtained from the OLR test showed a reduction in the performance of this test in
5-FU treated animals but this effect was prevented by co-treatment with
fluoxetine. Furthermore, the neurogenesis of 5-FU treated animals in the dentate
gyrus was reduced compared to the controls as shown by quantifying the Ki67
immunoreactive cells. This significant reduction was abolished following co-
treatment with fluoxetine suggesting an improvement in either cell proliferation
or survival or both.
The hippocampal BDNF levels were significantly increased by the co-treatment
(5-FU+LCV&fluoxetine) compared to 5-FU+LCV treatment alone while DCX
levels in the same tissue also showed a marginally significant enhanced effect.
On the other hand, the frontal cortex BDNF levels were increased by fluoxetine
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treatment compared to controls. Moreover, fluoxetine significantly increased
frontal cortex DCX levels compared to 5-FU+LCV and the co-treatment group.
The final study of this thesis was designed to gain insight into how and when 5-
FU was exerting its effect on neurogenesis. In this study we used the method of
birth dating and tracking of cells using BrdU which was administered by
intraperitoneal injection prior to 5-FU+LCV treatment. This was followed by
assessing the dividing cell survival, one, two weeks and six weeks after 5-
FU+LCV treatment by quantifying immuno-positive BrdU cells as well as
examining changes in proliferation by using immunohistochemistry for the
proliferative cell marker (Ki67). Our results suggested that 5-FU was maximally
affecting cellular proliferation two weeks after treatment and that this persisted
for at least 6 weeks. In contrast the effect of 5-FU on the survival of the dividing
cells in the dentate gyrus is early in onset (being significant one day after 5-FU
treatment) and continued over the course of the experiment. A summary of these
finding is presented in the following table (Table 6.1).
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Table 1.6
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6.2. Effect of Chemotherapy on memory of the adult hippocampus
Clinical studies of chemobrain reviewed in (Chapter 1) have provided strong
evidence that chemotherapy induces cognitive problems mainly in memory,
attention and concentration. These studies have linked these cognitive symptoms
to many types of chemotherapeutic drugs rather than ascribing them to a single
chemotherapy agent (Falleti, Sanfilippo et al. 2005; Bender 2006; Jenkins,
Shilling et al. 2006; Ahles, Saykin et al. 2008; Castellon and Ganz 2009; Collins,
Mackenzie et al. 2009; Schilder, Eggens et al. 2009). Application of animal
models in chemobrain studies provides a better clarification of the mechanism of
action of these chemotherapeutics and throws light on the possible anatomical
locations affected by chemotherapy within the brain. A large number of these
studies have investigated the effect of chemotherapy, either as a single agent or
combined drugs (commonly used in therapy), on the hippocampus especially the
dentate gyrus, because this is the gateway to memory in the brain (Dietrich, Han
et al. 2006; Mignonea and Weberb 2006; Macleod, DeLeo et al. 2007; Mustafa,
Walker et al. 2008; Seigers, Schagen et al. 2008). Because of the difficulties in
interpretation the effects of combined drug action, in the present thesis, the effect
of a single chemotherapy agent; 5-FU+LCV, on hippocampal memory has been
investigated using two hippocampal specific cognitive tasks. These tests have
been shown previously to require hippocampal input to spatial and contextual
fear conditioning memories respectively. The object location recognition task has
been used successfully previously in our lab (Mustafa, Walker et al. 2008).
However, this thesis is the first report to use the conditioned emotional response
test as a test for hippocampal memory after chemotherapy. The following section
will discuss each of these two tasks.
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6.2.1. Effect of chemotherapy on hippocampal spatial memory
The OLR test is a reliable test for the spatial working memory in rats as normal
animals tend to explore the new location of an object more than the old location
(Ennaceur and Delacour 1988). A wide range of animal models of chemobrain
have used this task to test for the hippocampal spatial memory orientation (Bruel-
Jungerman, Laroche et al. 2005; Mustafa, Walker et al. 2008). Another
behavioural task which has been shown by a number of studies to be a good test
for modelling this hippocampal specific memory is the Morris water maze (Shors,
Townsend et al. 2002; Lee, Kim et al. 2006; Winocur, Vardy et al. 2006; Seigers,
Schagen et al. 2008). Although, it is a specific task for measuring the spatial
memory orientation of rats, the water maze test requires a long training duration
for the animals which obviates the chronic testing with chemotherapy drugs. For
this reason, it was decided to choose the object location recognition task to test
for the effect of chemotherapy on hippocampal spatial working memory of rats in
a protocol modified from (Mustafa, Walker et al. 2008). The preliminary results
in the present studies (see table 6.1) have shown that even control rats were not
able to perform this task (Chapter 2, experiment1). This was possibly due to the
small sample number (n=5) used in this study. It was shown that the larger the
sample size the more significance was gained in the preference index for the new
location in the object location recognition task between animal groups (Ennaceur,
Michalikova et al. 2008).
This observation was confirmed by the present studies where the OLR test was
more successful modelling the hippocampal spatial memory and the results
obtained from this task confirmed the effect of 5-FU-induced cognitive deficits
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compared to control rats (Chapter 3 and 4. table 6.1) as reported previously
(Mustafa, Walker et al. 2008).
Studies in the present thesis (see chapter 4) showed the effect of 5-FU included
disruption of hippocampal spatial memory as measured using object location
recognition task and analysed using preference index statistical analysis
(ElBeltagy, Mustafa et al. 2010).
6.2.2 Effect of chemotherapy on contextual conditioning of rats
It has been shown that contextual conditioning to stimuli is a part of hippocampal
function (Rudy, Barrientos et al. 2002; Huff and Rudy 2004). However, the
hippocampus is not the only brain region responsible for the integration of this
test since an intact amygdala and the anterior cingulated gyrus are required for
performance in this task (McGaugh 2004; Ponnusamy, Poulos et al. 2007). For
this reason it was of interest to look at the effect of chemotherapy on this task. In
a protocol modified from (Resstel, Joca et al. 2006), we tested Lister hooded rats
for their conditioning to electric shocks as unpleasant stimuli. Initially no
difference was found in the measured freezing time between the saline and the 5-
FU treated rats (Chapter 2, experiment 1). This again was likely due to the small
sample size (n=5). In (Chapter 3) when the sample size was increased to 10 per
group, significantly less freezing time was shown by the 5-FU treated group
compared to the saline treated group (table 6.1). This result strengthens our
hypothesis that 5-FU chemotherapy impairs memories which are not only
hippocampal specific. Previously, it has been shown that chemotherapy impairs
contextual fear conditioning, a task requiring an intact hippocampus, but did not
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affect cued fear conditioning which is less hippocampal dependent (Macleod,
DeLeo et al. 2007).
Moreover, it has been recently shown that 5-FU alone or combined with
methotrexate impairs conditioning to a tone stimulus and this happens one day
after treatment (Foley, Raffa et al. 2008). However, it has been argued by some
authors that this is a stressful test as indicated from the measurement of elevated
corticosteroid levels (Davis 1997; Korte 2001). There is good evidence that
stress modulates neurogenesis by either producing an increase (Lee, Kim et al.
2006) or a decrease (Heine, Zareno et al. 2005), therefore, it was decided to avoid
using such a stressful test (CER) for rat hippocampal memory testing in
subsequent studies.
6.3. Effect of chemotherapy on adult hippocampal neurogenesis
Adult hippocampal neurogenesis is now a well characterized phenomenon
(Imayoshi, Sakamoto et al. 2009). Hippocampal neurogenesis is subject to
influence by both external and internal manipulations as described in general
introduction (Chapter 1). The use of animal models has enabled measures of both
neurogenesis and cognition to be carried out after chemotherapy. Many studies,
using animal models of chemotherapy or other anti mitotic drugs have reported a
reduction in all aspects of hippocampal neurogenesis (Bruel-Jungerman, Laroche
et al. 2005; Dietrich, Han et al. 2006; Han, Yang et al. 2008; Seigers, Schagen et
al. 2008; Ko, Jang et al. 2009). In order to study the effect of 5-FU chemotherapy
on the cell division required for hippocampal neurogenesis, we measured the
endogenous proliferation marker Ki67, which is only expressed in proliferating
cells (Kee, Sivalingam et al. 2002).
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In order to characterize the type of cell proliferation taking place in hippocampal
neurogenesis, the immature neuronal marker DCX was used to measure neural
cell changes. Furthermore, changes in hippocampal levels of the neurotrophic
factor BDNF after 5-FU chemotherapy treatment was examined to determine
possible trorhic factor changes associated with cell proliferation. In addition,
one study of this thesis investigated the possible effect of 5-FU chemotherapy-
induced changes on the survival of cells produced during neurogenesis by
quantifying BrdU immuno-reactive cells (Chapter 5).
6.3.1. Effect of chemotherapy on cell proliferation aspect of neurogenesis
Previous animal studies on the effects of chemotherapy on cell proliferation have
reported a negative effect by counting dentate gyrus Ki67 immuno-reactive cells
(Seigers, Schagen et al. 2008; Bessa, Ferreira et al. 2009). In the present study
(Chapter 5) the results obtained from Ki67-positive cell counts showed that 5-FU
is exerting its effect on proliferation at least two weeks after the end of treatment
and this effect persists for at least 6 weeks. The reasons for this are unclear, as the
effect of 5-FU on the survival of cells dividing at the start of treatment is apparent
at the end of treatment and continues throughout the experiment.
A possible mechanism by which 5-FU could exert prolonged affects on the
proliferation of cells during neurogenesis is by altering the levels of a brain
cyclooxygenase (COX-2), a prostaglandin-synthesizing enzyme up regulated in
inflammatory processes (Goncalves, Williams et al. 2010; Menter, Schilsky et al.
2010). Previously, it has been shown that while basal levels of COX-2 are
required for cell proliferation during neurogenesis in the dentate gyrus of the
hippocampus (Sasaki, Kitagawa et al. 2003; Goncalves, Williams et al. 2010) up-
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regulation of COX-2 during inflammation reduces the production and survival of
new cells in adult neurogenesis (Bastos, Moriya et al. 2008). It was thought that
5-FU chemotherapy might induce inflammation and increase COX-2 expression
which in turn could reduce hippocampal neurogenesis. However, as COX-2
levels do not appear to change after chemotherapy this seems unlikely.
6.3.2. Effect of chemotherapy on the survival aspect of proliferating cells
Neurogenic studies on animals highlighted the priority of the BrdU tracking
method over positive Ki67 counting method for detecting changes in the survival
of early dividing cells (Kee, Sivalingam et al. 2002; Kempermann 2006; Lee,
Longo et al. 2006). Several animal studies have shown that chemotherapy-
induced changes in the survival of proliferating cells using the BrdU protocol
(Shors, Townsend et al. 2002; Mignonea and Weberb 2006; Zhou, Hu et al. 2007;
Han, Yang et al. 2008; Bessa, Ferreira et al. 2009; Li, Cai et al. 2009). In this
thesis, the BrdU protocol was used to test the effect of 5-FU chemotherapy on the
survival of the dentate gyrus dividing cells (Chapter 5). The result demonstrated
that there was a significant reduction of the survival of dividing cells one day
after treatment. This reduction was more obvious 2 and 6 weeks after treatment
which highlighted that the onset of the 5-FU induced action on the survived
dividing cells was very early (one day) after treatment and this action remained
and even increased with time (2 and 6 weeks after treatment). 5-FU targets
dividing cells during S-phase of the cell cycle (Pinedo and Peters 1988).
Moreover, BrdU is marking cells by incorporation into their DNA during the S-
phase of the cell cycle (Kempermann 2006). For this reason, it was not surprising
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that 5-FU reduced the survival of dividing cells in the SGZ by the end of
treatment (one day after treatment) because it is assumed that 5-FU had killed
cells during the chronic period of treatment (2 weeks). In a recent study (Han,
Yang et al. 2008) it was found that 3 intraperitoneal injections of 5-FU every
other day reduced the BrdU positive cell counts only after 14 days whereas
increased TUNNEL expression, a marker for apoptotic cells, was found after 1
day. In addition, they reported that 5-FU chemotherapy produced destruction of
the white matter tract of CNS. Moreover one drawback with the BrdU cell
tracking method is that inclusion of apoptotic cells and fragmented DNA
generated during the cell cycle (Kee, Sivalingam et al. 2002; Kempermann 2006).
Considering that chemotherapy increases apoptosis in neuronal cell cultures and
within the dentate gyrus in vivo (Rzeski, Pruskil et al. 2004) and neuronal
precursors (Dietrich, Han et al. 2006) besides that 5-FU chemotherapy and its
metabolites have been shown to alter the Krebs cycle resulting in increased
apoptosis (Pinedo and Peters 1988; Yamashita, Yada et al. 2004) thus it is
inaccurate to say that the 5-FU induced reduction in dentate gyrus dividing cell
survival is the sole mechanism responsible for the reduction in the number of
BrdU dentate gyrus positive cells. However, at present the BrdU method is the
most reliable available method for detecting changes in the proliferating cell
survival.
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6.3.3 Effect of Chemotherapy on the differentiation aspect of neurogenesis
The effect of chemotherapy on the differentiation aspect of neurogenesis was
measured in (Chapters 3 and 4) by using Western blot techniques to identify the
immature proliferative marker (DCX) and the brain derived neurotrophic factor
(BDNF) in both hippocampus and frontal cortex tissues. The results obtained
suggested that 25mg/kg of 5-FU for two weeks did not alter DCX levels in either
hippocampus or frontal cortex tissues compared to controls. In contrast, BDNF
levels in the hippocampus were marginally reduced by this treatment regime
compared to controls. In addition, frontal cortex BDNF level was significantly
reduced by the same dose compared to controls. From the above it could be
concluded that 5-FU intravenous injections in a dose of 25mg/kg reduced both
hippocampal and frontal cortex BDNF levels while sparing DCX protein in same
tissues.
Also using 6 intravenous injections of (20mg/kg) of 5-FU did not change either
hippocampal or DCX levels between controls and 5-FU treated groups (Chapter
4, see table 6.1). These results suggest that levels of DCX protein are not
affected by 5-FU chemotherapy while the neurotorphic factor BDNF could be
affected. BDNF has been shown to potentiate differentiation and survival of
dividing cells in the brain (Zigova, Pencea et al. 1998).
Observing the effect of 5-FU chemotherapy on the proliferation of cells in the
dentate gyrus using the proliferative marker Ki67 in the same studies showed, a
significant reduction in the mean numbers of Ki67 positive cells in the 5-FU
compared to the saline treated group. This was correlated with the reduction in 5-
FU treated animals memory compared with controls as measured by OLR and
CER test in (Chapter 3) and OLR only in (Chapter 4, see table 6.1). This
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indicates that proliferating cells in the dentate gyrus were indeed affected by 5-
FU chemotherapy by mechanisms which spared the hippocampal DCX protein.
Taking into consideration that DCX protein is transiently expressed as
progenitors start to differentiate (Couillard-Despres, Winner et al. 2005;
Kempermann 2006) , those cells which were targeted by 5-FU could be at a
different stage of maturation to those expressing DCX or 5-FU could be
affecting those cells after they had stopped expressing DCX. This problem could
be solved by injecting BrdU at the start of experiment and detecting cells double
labelled for BrdU and DCX by immunohistochemistry but this was outside the
scope of the present experiments and will have to be considered in future studies.
Previous results from our lab have highlighted the possibility that 5-FU
chemotherapy could alter hippocampal BDNF levels without affecting
proliferation. This also was accompanied by a reduction in hippocampal specific
memory as measured by OLR task (Mustafa, Walker et al. 2008). These results
suggest that there could be several different mechanisms affecting hippocampal
cognition and memory namely a reduction of hippocampal neurogenesis or a
reduction in hippocampal BDNF. Previously it has been reported that dentate
gyrus neurogenesis could be affected by chronic mild stress without affecting
proliferation. This study has also given evidence that the survival of dentate
gyrus dividing cells could be changed without altering the hippocampal BDNF
levels (Lee, Kim et al. 2006). Moreover, it was shown that the cognitive
functions of the brain could be disrupted by alteration in hippocampal BDNF
levels alone as BDNF is required for the process of long term potentiation in the
hippocampus (Korte, Carroll et al. 1995; Lee, Duan et al. 2002). Furthermore, it
should be noted that not only BDNF acts as a neurotrophic factor responsible
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for aspects of neurogenesis but also other intrinsic factors influence
neurogenesis, such as vascular endothelial growth factor (VEGF), which has
been shown to have a positive effect on neuronal differentiation as well as
improving the performance of animals undertaking the Morris water maze task
(Cao, Jiao et al. 2004). From the above, it is clear that several factors could be
participating in 5-FU chemotherapy-induced changes in neurogenesis in the
hippocampus and future studies are needed to understand the mechanisms behind
this.
6.4. Correlation between chemotherapy induced memory impairments and
hippocampal neurogenesis
This thesis provides evidence from a rat model of chemotherapy that whenever
memory impairment was present, proliferation of neural progenitors in the
dentate gyrus of the hippocampus was reduced (Chapter 3 and 4). However, the
differentiation aspect of hippocampal neurogenesis was not affected as indicated
from the unchanged level of DCX protein between the saline and 5-FU-treated
groups in the hippocampus (Chapter 3 and 4). Moreover, in one study, BDNF
level in the hippocampus showed a marginal reduction in the 5-FU+LCV treated
group compared to controls (Chapter 3). These findings suggest a positive
correlation between cognitive impairment the reduction of proliferation of
hippocampal neurogenesis. In a review of adult hippocampal neurogenesis,
(Abrous, Koehl et al. 2005) it has been suggested that the differentiation and
survival parts of rat hippocampal neurogenesis increase during the early stages of
Morris water maze learning paradigm. However, in late stages of this task, there
is a transient increase in cell death which is followed by increased proliferation.
In addition, a more recent study (Dupret, Fabre et al. 2007) supported the idea
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that both cellular proliferation and apoptosis are required for spatial learning and
memory mediated by the hippocampus. Taking into consideration the later
findings in this thesis (Chapter 5), it appears that proliferation is a target of
chemotherapy at least two weeks from the end of treatment and lasts up to 6
weeks after treatment whereas survival of dividing cells is affected early (one
day) after treatment and this effect lasts up to (2-6) weeks after treatment. One
possibility is that the survival and proliferation of neural precursor cells in the
dentate gyrus are controlled by two distinct mechanisms both of which could
affect the process of hippocampal learning and memory independently. Using the
present animal model of chemotherapy, it should be possible to observe the
changes at different stages of hippocampal neurogenesis while hippocampal
learning is talking place. This will give a better understanding of the correlation
between hippocampal neurogenesis and the chemotherapy-induced cognitive
symptoms.
6.5. Effect of chemotherapy and antidepressants on memory and
neurogenesis of the hippocampus
The effect of antidepressants, namely the selective serotonin reuptake inhibitor
fluoxetine, on memory and neurogenesis in a rat model of chemotherapy was
tested in Chapter 4. Our results show that fluoxetine improved the memory
deteriorations caused by 5-FU chemotherapy. This was determined using the
OLR test analysed using the preference index (PI). Fluoxetine also increased the
number of dividing cells in the SGZ which were reduced by 5-FU chemotherapy.
Moreover, measuring hippocampal BDNF levels showed that there was a
significant up-regulation in this neurotrophic factor in the co-treated group
(fluoxetine+5-FU+LCV) compared to the 5-FU only-treated group, see table 6.1.
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Although not significant, there was also a marginal increase of the hippocampal
DCX level in the co-treated group compared to 5-FU+LCV only treated group. It
was concluded that fluoxetine improved memory in a rat model of chemotherapy
and this cognitive enhancement was mediated by an increase in neurogenesis and
or the up-regulation of hippocampal BDNF levels. Previous studies on the effect
of fluoxetine on neurogenesis and cognition in animal models have shown an
improvement in these parameters (Kodama, Fujioka et al. 2004; Perera, Coplan et
al. 2007; Valluzzi and Chan 2007; Li, Cai et al. 2009). In addition there is
clinical evidence that fluoxetine increases hippocampal progenitor cells (Boldrini,
Underwood et al. 2009). It has also been suggested that chronic treatment with
fluoxetine can improve the cognition of Alzheimer’s patients (Mowla,
Mosavinasab et al. 2007). In the study of (Santarelli, Saxe et al. 2003), it was
shown that hippocampal neurogenesis was important in the action of
antidepressants including fluoxetine. The other mechanism through which
antidepressants are suggested to exert their effect on hippocampal memory is the
up-regulation of hippocampal BDNF levels which was a positive finding in the
present thesis (Chapter 4, see table 6.1). Previous reports, (Sairanen, Lucas et al.
2005), have found that treatment with antidepressants (imipramine and
fluoxetine) increased hippocampal BDNF levels as well as enhancing the
proliferation of precursor cells in the dentate gyrus of mice and that BDNF
promotes the survival of these cells. Added to this, it was found that rats treated
with imipramine had increased expression of three proteins associated with neural
plasticity, PSA-NCAM, pCREB, and GAP-43 in their hippocampi and frontal
cortices (Sairanen, O'Leary et al. 2007). This also could account for the elevated
frontal cortex BDNF level in the co-treated group compared to the group treated
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with 5-FU chemotherapy in the present study. The use of antidepressants to treat
chemotherapy impaired memory has not been fully assessed but the improvement
in memory as a result of chronic antidepressant treatment seems to be a positive
finding although, the mechanism of the effect is not fully understood.
According to the work of the present thesis and work of other colleagues in the
group, alteration of neurogenesis is one of the likely mechanisms behind this but
further work is needed to establish the exact mechanism through which
antidepressants exert their behavioural improving effect in animal models of
chemotherapy.
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6.6 Future work
6.6.1. Future consideration in chemobrain modelling
6.6.1.1. The use of leucovorin (LCV)
The 5-FU chemotherapy method used in this thesis was accompanied by co
treatment with LCV. The latter is a folate derivative that is used to potentiate the
cytotoxic effect of 5-FU chemotherapy. LCV has a chemical structure which is
similar to vitamin B9 and when metabolized it enhances the process of DNA
synthesis. The effect of LCV on animal cognition however has not been
assessed. However, in their study,(Phillips, Thaler et al. 1989) have provided
evidence that leucovorin eliminated the methotrexate-induced neurotoxicity in a
rat model of chemotherapy. In a more recent study, (Seigers, Schagen et al. 2008)
also supported this finding. In addition, clinically, it has been found that
leucovorin reverses toxic brain encephalopathy resulting from Methotrexate
(Jaksic, Veljkovic et al. 2004). Observing its mechanism of action, methotrexate
inhibits dihydrofolate reductase which results in depletion of the endogenous
folate so that when combined with LCV, the later reverses the chemotherapeutic
action while in the case of 5-FU chemotherapy LCV potentiates the drug-
induced cytotoxicity by increasing the conjunction between the drug and the
enzyme thymidylate synthetase which is essential for DNA synthesis (Herrmann,
Reuter et al. 1988). Moreover, the promoting role of folinic acid in DNA
synthesis has been previously established (Nixon 1979). It is clear that in future
chemobrain models, the effect of leucovorin alone on memory and neurogenesis
needs to be determined.
211
6.6.1.2. The use of single agent vs. combined chemotherapy
The animal model of chemotherapy developed in this thesis aimed to continue
earlier investigations on the effect of single agent chemotherapy (5-FU), on
memory and adult neurogenesis. Clinical reviews of chemobrain (table 1.1) have
highlighted the observation that chemotherapy involving several agents has a
greater effect on cognition than treatments composed of only a single agent (van
Dam, Schagen et al. 1998; Ahles, Saykin et al. 2002; Schagen, Muller et al.
2002). Some animal models have supported this finding, for example Wincour et
al (2006a) and Foley et al (2008). have reported greater impairments in
performance in tasks including the Morris water maze and the delayed non
matching sample tasks after combined 5-FU and methotrexate treatment
compared to either drug on its own (Winocur, Vardy et al. 2006; Foley, Raffa et
al. 2008). These results suggest that the combination of methotrexate and 5-FU
produce a more potent deleterious effect on memory and learning in mice than
either drug on its own. Future work should consider combined chemotherapy
regimes, as two or more mechanisms of action of chemotherapeutic drugs could
be more powerful than one mechanism. Future animal models on chemobrain
therefore, should investigate the effect of combined chemotherapy on memory
and neurogenesis in the adult rat hippocampus.
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6.6.1.3. Chemobrain in female rats
Most clinical reviews dealing with chemobrain have investigated the cognitive
symptoms found after breast cancer treatment. This has involved female cancer
survivors who may respond differently to the male rats commonly used in animal
tests of cognition. One feature of this is that female breast cancer patients are
often treated with the oestrogen receptor antagonist tamoxifen or other hormonal
therapies along with chemotherapy. Some reported a worsening effect of
tamoxifen on cognition (Paganini-Hill and Clark 2000; Shilling, Jenkins et al.
2003; Jenkins, Shilling et al. 2004; Bender, Sereika et al. 2006; Palmer, Trotter et
al. 2008) while other studies found no effect (Schagen, van Dam et al. 1999).
Most studies, including the present one, use male animals to avoid the possible
confounding variables caused by the oestrous cycle however as it appears that the
oestrous cycle can affect cognitive behaviour in rats and humans a study using
female animals is possibly more relevant to the study of chemobrain in breast
cancer (Sutcliffe, Marshall et al. 2007; Galea, Uban et al. 2008; Spencer, Waters
et al. 2008; Maki and Sundermann 2009). Interestingly one of the few studies
using female ovariectomised rats found that cyclophosphamide enhanced their
performance in the Morris water maze task (Lee, Longo et al. 2006). Animal
studies of the effects of hormonal treatment have found that while tamoxifen
alone impaired hippocampal specific spatial memory as modelled by the water
maze task (Chen, Wu et al. 2002) oestrogen enhances hippocampal neurogenesis
in female rats (Tanapat, Hastings et al. 1999). This may open up further avenues
of research into the combined effects of tamoxifen or oestrogen with
chemotherapy in future animal studies of chemotherapy.
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6.6.2. Future consideration in studying the cellular effects of chemotherapy
6.6.2.1. Regional specificity of chemotherapy
The effect of chemotherapy on hippocampal neurogenesis was investigated in this
thesis by counting the number of positive Ki67cells throughout the whole length
of the hippocampus to obtain an average number for each brain regardless of the
region e.g. (ventral vs. dorsal portions of the hippocampus). However, as shown
in Chapter 4, the effect of the antidepressant, fluoxetine, on different sub-regions
of the hippocampus was quantified but no difference in the mean numbers of
positive Ki67 cells between the ventral and the dorsal portions of the
hippocampus was found in any of the animal groups (data not shown). This does
not exclude the possibility that chemotherapy could affect different brain regions
independently. Observing the results obtained from determining BDNF protein
levels in both frontal cortex and the hippocampus, after saline or chemotherapy
treatment (Chapter 3), we found that while the protein level was marginally
decreased in the hippocampus there was a significant reduction in the same
protein levels in the frontal cortex tissue due to 5-FU+LCV chemotherapy
treatment. This adds further evidence suggesting a regional specificity of the
effect of chemotherapy on different parts of the brain. Moreover, it has been
found that induction of seizures affects proliferation and differentiation in ventral
and dorsal portions of the hippocampus independently (Ferland, Gross et al.
2002). Future animal models should take this regional specificity into
consideration as this may help in better understanding of the different roles of
these sub regions in controlling memory mediated by the hippocampus.
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6.6.2.2. The value of double-labelling
The current animal model depended mainly on single immunolabelling of dentate
gyrus dividing cells to detect changes in hippocampal neurogenesis after 5-FU
chemotherapy. Either the endogenous proliferative marker (Ki67) or the
exogenous marker (BrdU) was used to investigate the chemotherapy induced
changes in proliferation or survival of cells respectively during hippocampal
neurogenesis. However, the exact fate regarding either neuronal or glial cells and
which was affected by 5-FU chemotherapy, remains unclear. Previously it has
been reported that cranial irradiation particularly affects dividing cells which
would mature into neurons (Monje, Mizumatsu et al. 2002; Monje, Toda et al.
2003).
It would be interesting to look at cells double labelled for proliferation and
differentiation markers to see the effect of chemotherapy on different cell types
(Couillard-Despres, Winner et al. 2005). Co-labelling of markers for
proliferation such as DCX, a marker of developing neurons; NeuN; a marker for
mature neurons; or GFAP, a marker of astrocytes, along with the BrdU would
help to clarify the picture of chemotherapy induced changes in hippocampal
neurogenesis.
6.6.2.3. Apoptosis and neurogenesis
The work of Abrous and her group (Abrous, Koehl et al. 2005) has highlighted
the importance of apoptosis as a process occurring in both neurogenesis and
learning. As chemotherapy agents, including 5-FU, are designed to induce
apoptosis and cell death, it will be important to observe how increased cell death
(detected by TUNNEL staining) in the dentate gyrus as a result of chemotherapy
interacts with or differs from the normally occurring cell death in untreated
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animals. This will also shed light on the underlying mechanism by which
chemotherapy produces the observed behavioural changes.
6.6.2.4. VEGF and differentiation
Vascular endothelial growth factor has also been claimed to increase neuronal
differentiation and to improve the performance of rats in the Morris water maze
(Cao, Jiao et al. 2004). Moreover, VEGF has been shown to promote
proliferation in neural stem cells (Xiao, Kong et al. 2007). Studying the effect of
chemotherapy on VEGF will be essential to determine its role in modulating the
chemotherapy induced cognitive changes as well as hippocampal neurogenesis
and the possible links between both.
6.6.2.5. Stress and neurogenesis
As indicated previously, the effect of stress can alter neurogenesis in either
directions. Thus, future studies are needed to determine the effect of stress
induced by chemotherapy by examining possible changes in the stress hormone,
corticosterone.
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6.6.3. Future considerations regarding the use of antidepressants in animal
model s of chemotherapy
The study in Chapter 5 was designed to investigate the long term effect of 5-FU
chemotherapy on dividing cells in the dentate gyrus and the survival of new cells
by looking at different time points after treatment. This will not only help in
understanding how and when 5-FU chemotherapy exerts its effect on
hippocampal neurogenesis but also will provide information about the most
effective time point for antidepressant therapy to counteract the effects of
chemotherapy. Clinically, although antidepressants are sometimes given to
cancer patients for depression, there is no systematic use nor are they given
specifically to prevent the cognitive effects of chemotherapy. As noted
previously, fluoxetine improves cognition in patients with traumatic brain injury
(Horsfield, Rosse et al. 2002) and depression (Cassano, Puca et al. 2002;
Levkovitz, Caftori et al. 2002) and this is backed up by animal studies showing
that this drug improves their behavioural performance (Holick, Lee et al. 2008)
and neurogenesis (Kodama, Fujioka et al. 2004; Marcussen, Flagstad et al. 2008).
However the exact mechanism by which antidepressants improve cognition after
chemotherapy is unknown and needs further study.
The results presented in Chapter 4 suggest that the 5-FU chemotherapy reduces
hippocampal neurogenesis and that this is responsible for the cognitive changes.
However, these behavioural changes could also be due to the reduced levels of
the neurotrophic factor (BDNF) in the hippocampus and this will need further
investigation. For example, chemotherapy induced changes in the levels of the
transcription factor, cAMP response element binding protein (CREB) could
subsequently affect BDNF levels (Nibuya, Nestler et al. 1996). Antidepressant
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treatment for longer periods up-regulate the levels of plasticity associated
proteins within the hippocampus (Sairanen, O'Leary et al. 2007) thus
investigating the effect of chemotherapy on these proteins as well as BDNF will
be essential in order to reach a better understanding about the mechanism by
which antidepressants improve chemobrain symptoms.
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6.7. Conclusion
The findings obtained from the present animal model of chemotherapy have
demonstrated the possible association between 5-FU chemotherapy and memory
impairments. Treatment was associated with a reduction in neural progenitor
proliferation in the SGZ of the hippocampus which suggests that a reduction in
neurogenesis may provide a possible mechanism by which 5-FU is exerting its
behavioural effects. Interestingly the reduction in neurogenesis continues for at
least 6 weeks after treatment providing an explanation for the long term effects of
chemotherapy described by patients. However, it is possible that the impairment
of hippocampal neurogenesis is not the sole mechanism by which 5-FU
chemotherapy causes the symptoms of “chemobrain” as results presented here
also suggest that other factors could be implicated such as alteration in the level
of the neurotrophic factor BDNF or stress hormones. The project also
demonstrated that the SSRI antidepressant, fluoxetine can prevent the memory
and neurogenesis impairments caused by chemotherapy. Although, we provide
evidence that an antidepressant improved neurogenesis in this animal model, the
exact mechanism by which it acts on the brain needs more clarification. Indeed,
investigating the effect of 5-FU chemotherapy on different aspects of
hippocampal neurogenesis could answer the question of how and when the drug
targets the brain and also could give a better understanding about how to
incorporate antidepressants in the overall treatment of cancer with chemotherapy.
Taking into consideration the information discussed in the section on future work,
these studies will be of great value in establishing the causes and treatment of the
effects of chemotherapy on memory and neurogenesis of adult brain
hippocampus.
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Appendix I
WESTERN BLOTTING SOLUTIONS
(All materials are from Sigma, unless otherwise indicated)
Lysis Buffer: 20 mM Tris-hydroxymethylaminomethane (Tris), 1 mM ethylene
iycol tetra-acetic acid (EGTA), 320 mM sucrose, 0.1% Triton Xl 00, 1mM NaF,
10 mM f3-glycerophosphate dissolved in 500 ml distilled water at pH 7.6.
1 tablet of ethylenediamine tetra-acetic acid (EDTA)-free protease inhibitor
cocktail ‘Roche Diagnostics, Germany) is added to 10 ml of lysis buffer solution
just before .use.
x2 Solubilisation Buffer: 2.5 ml of 0.5 M Tris, 2 ml of glycerol, 2 ml of 10 %
sodium dodecyl sulfate (SDS) solution, 2.5 ml of distilled water, 1ml of ȕ-
mercaptomethanol, and 40 µl of 2.5 % bromophenol blue.
Lowry Solution: 20 ml of Solution A (2g of NaOH, 1g of SDS and l0g of
NaCO3 dissolved in 500 ml of distilled water) and prior to Lowry assay, solution
A is mixed with Solution B (2% NaK tartrate and 1 % CuSO4).
Electrophoresis Buffer (x10): 30.3g of Tris, 144g of Glycine, and 10g of SDS
dissolved in 1 litre of distilled water.
Transfer buffer: 30.3g Tris and 144g glycine dissolved in 8 litres of distilled
water and 2 litres of methanol added (kept at 4°C).
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Tris-buffered saline-Tween 20 (TBST): 25 mM Tris and 125 mM NaC1
dissolved in distilled water and adjusted to pH 7.6 (using concentrated
hydrochloric acid). Tween 20 is then added to make a final concentration of 0.1
%.
One SDS gel is comprised of the following:
1- 4% stacker sodium dodecyl sulphate (SDS)-polyacrylamide gel: 3.12
ml of 30% acrylamide (Protogel, Geneflow), 6 ml of 0.5 M Tris-HCL,
0.24 ml of 10% SDS, 0.12 ml of 10% ammonium-perisulfate (APS) and
0.024 ml of tetramethylenenediamine (TEMED) dissolved in 14.6ml of
distilled water.
2- Resolving sodium dodecyl sulphate (SDS)-polyacrylamide gel: 30%
acrylamide (protogel, Geneflow), 1.5 M Tris-HCL, 10% SDS and 10%
APS dissolved in TEMED and distilled water. Quantities of these
solutions are altered according to achieve the required percentages (e.g.
15%) SDS gel.
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Appendix II
Throughout all studies treatment and care of animals was in accordance with
Home Office guidelines on the use of animals in scientific research in the United
Kingdom.
All procedures were carried out under the project licence 40-3283KF and
personal licence 40/8761.
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